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ABSTRACT 
 
Targeting Cdc7, a kinase essential for DNA replication initiation, results in potent 
cancer cell killing. Cancer cells in which CDC7 is silenced by RNAi enter an abortive 
S phase followed by apoptosis due to loss of a functioning DNA replication origin 
activation checkpoint. This checkpoint prevents normal cells from entering S phase 
(reversible G1 arrest) if the DNA replication initiation machinery is perturbed. The 
pre-clinical anti-cancer effects of CDC7 silencing have highlighted this kinase as an 
important target for new drug development. Expanding on published reports, I 
performed further target validation using molecular tools generated in the work of this 
thesis, including an affinity-purified antibody to the Cdc7 regulator ASK and 
functional recombinant Cdc7/ASK kinase complex. Making use of fibroblast and 
HL60 tissue culture model systems, I show that Cdc7 and ASK are amongst a group 
of essential replication initiation factors that are tightly downregulated to suppress 
proliferative capacity during exit from cycle into quiescent and differentiated states. 
This finding is further supported by low expression levels in normal liver and oral 
squamous epithelium and the lack of Mcm2 phosphorylation at serine 53, a well 
known Cdc7 target. In liver carcinoma and oral squamous cell carcinoma, on the 
contrary, the majority of cancer cells are expressing Cdc7 and ASK and show Mcm2 
phosphorylation at Ser-53. Thus it can be postulated that Cdc7 inhibitors should 
selectively kill cancer cells, while normal proliferating cells are reversibly arresting in 
G1 and quiescent and differentiated cell populations are not affected due to 
downregulation of the target protein. To screen for compounds that selectively inhibit 
Cdc7, I developed a sensitive in vitro kinase assay and contributed to the successful 
transfer of this assay to a high-throughput screening platform and the generation of a 
structural model of the Cdc7 kinase domain allowing in silico predictions of the most 
potent inhibitors. On completion of the work for this thesis, the HTS assay and 
structural model fromed the core of an ongoing drug discovery programme run by 
Cancer Research Technology. Two series of novel, selective small molecule inhibitors 
which exhibit low nM activity against Cdc7 and cellular efficacy (apoptosis) have 
been developed and are currently being tested in mouse xenograft models. The work 
presented in this thesis provides a strong rationale for targeting the DNA replication 
initiation pathway, and in particular Cdc7. Future intend to treat clinical trials will 
establish the potential of pharmacological Cdc7 inhibitors for selective cancer cell 
killing in patients.  
 
 
 
 
 
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   4 
TABLE OF CONTENTS 
 
Dedication              1 
Acknowledgements             2 
Abstract              3         
Table of contents             4 
Table of figures             9 
Table of tables           11 
Abbreviations           12 
 
Chapter One: Introduction                 15        
1.1.  Conventional cancer chemotherapy        16     
1.2.  Targeted therapy                     24   
1.3.  Development of Cyclin-dependent kinase inhibitor      27 
1.4.      The anti-cancer drug discovery and development process     31 
1.5. The DNA replication initiation machinery as a potential anti-cancer  
Targets                                                                                                              34 
1.5.1.  The DNA replication initiation pathway in eukaryotic cell                           35 
1.5.1.1.Origins of replication                                                                                       35 
1.5.1.2.DNA replication initiation pathway                                                               36 
1.6. Dbf4-dependent kinase Cdc7                                                                           43 
1.6.1. Cell cycle control of Cdc7 kinase activity       43 
1.6.2. Role of Cdc7 kinase complex                                                                           45 
1.7.      Inhibition of the DNA replication initiation pathway                                      51 
1.8.      Summary and aims of thesis                                                                            56 
 
Chapter Two: Materials and Methods        58 
2.1.   General              58 
2.1.1.  Chemicals and reagents         58 
2.1.2.  Buffers and solutions          58 
2.1.3.  Culture media           62 
2.2.  Molecular biology techniques        63 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   5 
2.2.1. Bacterial strains          63 
2.2.2. Transformation of E. coli         64 
2.2.3. Plasmid isolation          64 
2.2.4. Restriction endonuclease digestion        65 
2.2.5. Dephosphorylation of linearised vector DNA      65 
2.2.6. Ligation of DNA          65 
2.2.7.   Polymerase chain reaction         65 
2.2.8. Site-directed mutagenesis         66 
2.2.9. Agarose gel electrophoresis         67 
2.2.10. Recovery of DNA from agarose gels        67 
2.2.11. DNA sequencing          67 
2.3. Recombinant baculovirus methods        68 
2.3.1. Cell lines and viruses          68 
2.3.2. Viral DNA isolation              68 
2.3.3. Generation of recombinant baculovirus                                                      68  
2.3.4. Plaque Assay                                                                                     69 
2.3.5. Virus titeration                                                                      69 
2.4.    Protein chemistry methods         69 
2.4.1. Protein expression constructs         69 
2.4.2. Expression of recombinant human Cdc7, ASK and mutant Cdc7  
in Sf9 insect cell           70 
2.4.3.  Expression of recombinant human Cdc7/ASK kinase complex  
in Sf9 insect cells                                                                                        70 
2.4.4.   Purification of baculoviral-expressed human Cdc7, ASK, mutant Cdc7  
and Cdc7/ASK kinase complex                                                                       71 
2.4.5.   Expression of recombinant ASK (271-674) fragment in E. coli                     71 
2.4.6.   Purification of bacterial-expressed ASK (271-674) fragment   72 
2.4.7.   Expression of recombinant human Mcm2 (1-154) fragment in E. coli           73 
2.4.8.   Purification of bacterial-expressed human Mcm2 (1-154) fragment              74 
2.4.9.   SDS-polyacrylamide gel electrophoresis                                                        74 
2.4.10. Coomassie Blue staining of SDS-PAGE gels                                                 74 
2.5. Immunological thechniques                              75 
2.5.1. Antibodies                                           75 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   6 
2.5.2. Preparation of whole cell extracts                 75 
2.5.3. Immunoblotting                              76 
2.5.4. Immunoprecipitation                   76 
2.5.5.  Immunohistochemistry                  77 
2.6. Cell biology thechniques                  77 
2.6.1. Cell culture and synchronisation                            77 
2.6.2.  Bivariate flow cytometric analysis                 78 
2.6.3.  Monitoring differentiation                                                                         79  
2.6.4.  Assaying for apoptosis                  79 
2.6.5.   Tissue specimens                                                                                            80 
2.7.  Kinase Assay Development                  80 
2.7.1. In vitro kinase assay                                         80 
2.7.2. Antibody-based Kinase assay (96-well format)                                             80 
2.7.3. High-Throughput Screen for Cdc7 inhibitors (384-well format)                   81 
2.8.      Computing                                                                                                      82 
2.8.1. Bioinformatic and database resources                                                            82 
 
Chapter Three: Purification of active, recombinant Cdc7/ASK complex and 
generation of rabbit polyclonal antibodies to Cdc7 and ASK                   84 
3.1. Introduction          84 
3.2. Materials and Methods        88 
3.3. Results          89 
3.3.1. Generation of CDC and ASK recombinant baculoviruses               89 
3.3.2. Expression and purification of Cdc7, ASK and active Cdc7/ASK kinase 
complex in insect cells                                                                                    90 
3.3.3. Generation of Cdc7 and ASK antibodies                                                  98 
3.4. Discussion and Conclusions                  102 
 
Chapter Four: Cell cycle dependent regulation of Cdc7/ASK kinase  
comples in proliferating cells and out-of-cycle states              106 
4.1. Introduction                   106 
4.2.      Materials and Methods                 110 
4.3.      Results                   110 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   7 
4.3.1. Expression dynamics and regulation of Cdc7/ASK kinase in cycling cells 111 
4.3.2. Expression dynamics and regulation of Cdc7/ASK kinase during exit into  
G0 and re-entry into the cell cycle                                                             117 
4.3.3. Expression dynamics and regulation of Cdc7/ASK kinase in terminally 
differentiated cells                                                                                     122  
4.3.4. Cdc7 and Mcm2 protein expression and Cdc7-dependent phosphorylation of 
Mcm2 on serine 53 profile analysis in human tissues              127  
4.4.      Discussion and Conclusions       135 
 
Chapter Five: Development of a Cdc7 kinase assay               142 
5.1.  Introduction         142 
5.2.      Materials and methods        146 
5.3.      Results         147 
5.3.1. Development of an antibody-based Cdc7 kinase assay   147 
5.3.2. Optimisation of antibody-based kinase assay for primary screening  149 
5.3.3. Cdc7 homology modelling and structural analysis of Cdc7 active site 153 
5.3.4. Biochemical analysis of wild-type and mutant Cdc7 kinase activity  157 
5.4.      Discussion and Conclusions       159 
 
Chapter Six: Compound screening and characterization of small molecule Cdc7
 inhibitors                                                                                                             166 
6.1.      Introduction         166 
6.2.  Materials and Methods                  168 
6.2.1. HTS automation epuipment                                                                           168 
6.2.2. HTS reagents and supplies                                                                             169 
6.2.3. Antibody-based assay protocol for HTS                                                        169 
6.3.      Results         171 
6.3.1. Optimization of automated HTS                            171 
6.3.2. HTS assay reproducibility                                        172 
6.3.3. Cdc7 primary screen of the Biomol kinase inhibitor plate and hit 
characterization                                                                                     173  
6.3.4. CRT DL main library screening and Hit analysis                                     175  
6.3.5. Three dimensional modelling of the Cdc7 active site                         180 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   8 
6.3.6. Development of a cell-based assay for Cdc7 inhibitors              183  
6.4.      Discussion and Conclusions       187 
 
Chapter Seven: Conclusions and Implications     193 
 
Chapter Eight: Reference list       201 
 
Appendix A: Summary of data from antibody-based Cdc7/ASK kinase assay 
agents (1)-(5)                                                                 252 
 
Appendix B: Synthesis of CRT100115 compound                           257 
 
Appendix C: Raw data of Cdc7 screening                                                             259 
C.1. Kinase list of the Biomol kinase inhibitor plate                                     259 
C.2. Raw data of CRT DL main library screening                                                 262 
 
Appendix D: Kulkarni et al., 2009. Cdc7 kinase is a predictor of survivial and a novel 
therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res. 15:2417-2425. 
 
Appendix E: Okorokov et al., 2007. Hexameric ring structure of human MCM10 
DNA replication factor. EMBO Rep. 8: 925-930. 
 
Appendix F: Barkley et al., 2007. Cdc6 is a rate-limiting factor proliferative capacity 
during HL60 cell differentiation. Exp Cell Res. 15:3789-3799. 
 
 
 
 
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   9 
TABLE OF FIGURES 
 
Figure 1.1. Chronology for the development of some of the anti-cancer  
drugs commonly in use today                                                               17 
Figure 1.2. Schematic diagram of the drug discovery and development process   33  
Figure 1.3. The eukaryotic DNA replication initiation pathway     38 
Figure 1.4. Schematic overview of checkpoint pathways and role of Cdc7/Dbf4  
 kinase in the intra-S checkpoint                                                           47 
Figure 1.5. Differential response of cells to DNA replication inhibitor                  53 
Figure 3.1. Schematic drawing and comparison of Cdc7 and Dbf4-related  
subunits from H. sapiens, S. cerevisiae and S. pombe                          85 
Figure 3.2. Generation of Cdc7 and ASK recombinant baculoviruses                    91 
Figure 3.3. Optimisation of recombinant Cdc7 and ASK expression     93 
Figure 3.4. Expression and purification of His-tagged human Cdc7                       95 
Figure 3.5. Expression and purification of His-tagged human ASK                       96 
Figure 3.6. Expression and purification of His-tagged human Cdc7/ASK               
kinase complex                                                                                      97 
Figure 3.7. Generation of Cdc7 and ASK antibodies                                              99 
Figure 3.8. Generation of ASK antibody                                                   101 
Figure 3.9. Characterisation of ASK antibody (SK3681)                                      103 
Figure 4.1. (A) Cell cycle regulation of Cdc7, ASK and Drf1 protein levels       107 
(B) Diagrammatic representation of the mitotic cell division cycle  
Figure 4.2. Flow cytometric DNA profiles of cycling HeLa cells              113 
Figure 4.3. Expression dynamics and regulation of DNA replication  
initiation factors during the cell cycle                                                 115 
Figure 4.4. Flow cytometric DNA profiles during exit into quiescence  
and re-entry into the cell cycle                                                            119 
Figure 4.5. Expression dynamics and regulation initiation factors during exit  
into G0 and re-entry into cycle                                                            121 
Figure 4.6. Expression of the monocyte/macrophage differentiation  
markers CD11b and CD14 in HL60 cells after addition  
of 1,25 Vit D3                                                                                      124 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   10 
Figure 4.7. Flow cytometric DNA profiles of HL60 cells  
undergoing differentiation                                                                  126 
Figure 4.8. Expression dynamics and regulation of replication initiation  
factors during 1,25 Vit D3 induced differentiation in HL60 cells      128 
Figure 4.9. Detection of Mcm2, Cdc7 and phosphor Mcm2  
in oral squamous epithelium and oral squamous cell  
carcinoma (OSCC)                                                                              130 
Figure 4.10. Detection of Mcm2, Cdc7 and phosphor Mcm2 in human liver  
and hepatocellular carcinoma (HCC)                           131 
Figure 5.1. Kinase assay with purified human Cdc7/ASK kinase complex  
and Mcm2 fragment                                                                            148 
Figure 5.2. Optimisation of antibody-based kinase assay for Cdc7/ASK kinase 
activity                                                                                                 151 
Figure 5.3. Optimisation of antibody-based kinase assay for Cdc7/ASK kinase 
activity                                                                                                 152 
Figure 5.4. Optimisation of antibody-based kinase assay for Cdc7/ASK kinase 
activity                                                                                                 154 
Figure 5.5. High-degree of conservation at molecular level between Cdk2,  
Erk and Cdc7 demonstrated by comparison of kinase structures        156 
Figure 5.6. Modelling of the Cdc7 ATP-binding pocket                                       158 
Figure 5.7. Kinase activity analysis of wild-type and Cdc7 mutants                    160 
Figure 6.1. HTS automation equipment                                                  170 
Figure 6.2. Z factor distribution for the CRT main library screen of  
384-well microplates                                                                           174 
Figure 6.3. Cdc7/ASK primary screen of the Biomol Kinase Inhibitor Plate       176 
Figure 6.4. Cdc7/ASK primary screen of CRT DL main library                          178 
Figure 6.5. Three dimensional model of the Cdc7 active site                               182 
Figure 6.6. Cellular effects of CRT100115 on SK-OV3 and BT549 cells           184 
Figure 6.7. Flow cytometric DNA profile of SK-OV3 and BT549 cells  
treated with CRT100115                                                                     186 
Figure 6.8. Cellular effects of CRT100115 on SK-OV3 and BT549 cells            188 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   11 
TABLE OF TABLES 
 
Table 2.1. Bacterial strains                                        64 
Table 2.2. Cycling parameters for QuikChnage Site-Directed Mutagenesis   66 
Table 2.3. Oligonucleotides for Cdc7 kinase negative mutants     67 
Table 2.4. Protein expression constructs         70 
Table 3.1. Cdc7/ASK related kinase complexes       85 
Table 4.1. Mcm2, Cdc7 and phosphor Mcm2 expression profile in  
oral squamous epithelium and liver tissue                                          133 
Table 6.1. HTS protocol                                          174 
Table 6.2.  Screening results of Biomol Kinase Inhibitor Plates against  
Cdc7/ASK kinase                                                                                176 
Table 6.3.  Screening results of CRT DL main library against  
Cdc7/ASK kinase                                                                                178 
Table 6.4. Selectivity profile of hit compounds against kinases panel                179 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   12 
ABBREVIATIONS 
 
1,25 Vti D3 1,25 dihydroxyvitamin D3 
3D  Three-dimensional 
6-MP  6-mercaptopurine 
ACS  Autonomously replicating sequence consensus sequence 
ADME Absorption, distribution, metabolism and excretion 
APC  Anaphase-promoting complex 
ARS  Autonomously replicating sequence 
ASK  Activator for S-phase kinase 
ATM  Ataxia telangiectasia mutated 
ATR  Ataxia telangiectasia related protein 
BrdU  Bromodeoxyuridine 
C  Confluent 
CDK  Cyclin dependent kinase 
CDKI  Cyclin dependent kinase inhibitor 
CRT  Cancer research technology 
CIN  Cervical intraepithelial neoplasia 
CLL  Chronic lymphocytic leukaemia 
DAB  3’3’-diaminobenzidine tetrahydrochloride 
DAPI  4’, 6’-diamidino-2-phenylindole 
DC  Differentiated compartment 
DMF  N,N,dimethylformamide 
DHFR  Dihydrofolate reductase 
DSB  Double-strand breaks 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   13 
E  Elution fraction 
EGFR  Epidermal growth factor receptor 
EM  Electron microscopy 
FITC  Fluorescein isothiocyanate 
G0  Quiescence/quiescent 
HER-2  Human epidermal growth factor receptor-2 
HNSCC Head and neck squamous cell carcinoma 
IMZ  Imidazole 
MCM  Minichromosome maintenance 
MDR  Multi-drug resistance 
MOI  Multiplicity of infection 
MTX  Methotrexate 
NSCLC Non-small cell lung carcinoma 
NLS   Nuclear localisation sequence 
ORC  Origin recognition complex 
ORF  Open reading frame 
pASK  phosphorylated ASK 
Pgp  P-glycoprotein 
PI  Propidium iodide 
pRb  Retinoblastoma protein 
Pre-IC  Pre-initiation complex 
Pre-RC Pre-replicative complex 
PP  - phosphatise 
RLF  Replication licensing factor 
RPA  Replication protein A 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   14 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
TdT  Terminal deoxynucleotidyl transferase 
TPMT  Thiopurine methyltransferase 
WCE  Whole cell extract 
VCA  Vincristine mitotic accumulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   15 
CHAPTER ONE 
Introduction 
The eukaryotic cell cycle consists of four phases - G1, S, G2 and M (Murray & Hunt 
1993). Critical events in the cell cycle are the DNA synthesis phase (S), in which 
DNA replication takes place and mitosis (M), in which the replicated genome is 
subsequently segregated as sister chromatids into the two daughter cells. Preparation 
for S phase takes place in the preceding G1 phase and, similarly, the cell prepares for 
mitosis in the second gap phase, G2. Dependent on environmental and developmental 
signals, cells in G1 phase can reversibly leave the cell cycle and enter a quiescent 
state, known as G0, wherein cells are metabolically active but not embarking upon 
cell division (Pardee 1989). Alternatively, cells can withdraw irreversibly from the 
cell cycle through the processes of terminal differentiation and replicative senescence 
(Myster & Duronio 2000; Hayflick & Moorhead 1961; Campisi 1996). 
 
DNA replication can be regarded as a final and critical step in growth control that lies 
downstream of growth signalling pathways and therefore is of potential importance in 
tumourigenesis. Indeed, cancers are characterised by uncontrolled cell proliferation 
which results from aberration in the complex growth signalling pathways that control 
cell cycle phase transitions, DNA synthesis and mitosis. A topical issue in drug 
discovery and development is to identify how cancer cells differ from normal cells, 
and how those differences can be exploited therapeutically. Several studies of the G1 
events involved in the DNA replication initiation pathway suggest that inhibition of 
DNA replication initiation may provoke a differential response in normal and cancer 
cells (Shreeram et al. 2002; Feng et al. 2003; Montagnoli et al. 2004). This suggests 
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that various points in the DNA replication initiation pathway may be considered as 
potential targets for drug discovery, and in particular for cancer therapy.  
 
In the work of this thesis, I studied the cell cycle dependent regulation of the 
Cdc7/ASK kinase complex in human cells with the aim of exploiting this essential 
kinase which is required for G1-S transition and S phase progression as a potential 
therapeutic target. In the following sections, the literature relevant to this work is 
reviewed, focussing in the first part on conventional chemotherapy and cyclin-
dependent kinase inhibitors as an example for current anti-cancer drug discovery 
programmes. In the second part the DNA replication initiation pathway and its 
potential as a therapeutic target is reviewed.   
 
1.1. Conventional cancer chemotherapy 
Before 1950, cancer therapy largely depended on surgery which is the longest 
established treatment for most solid tumours. Radiotherapy became an effective 
treatment for the control of local and regional tumours after 1960 (reviewed in 
Chabner & Roberts Jr 2005). Despite the success of surgery and radiotherapy in 
controlling local tumours, they cannot cure metastatic cancer. Chemotherapy is a 
systemic treatment which can be used to kill cancer cells in every organ in the body. 
Therefore, it became an essential mode of treatment for metastatic cancer, and the 
focus for current anti-cancer drug development programmes. Conventional 
chemotherapeutic agents, which revolutionized the treatment of many types of cancer 
during the last 50 years, are shown in Figure 1.1 (Baguley 2002; Chabner & Roberts  
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Figure 1.1: Chronology for the development of some of the anti-cancer drugs commonly in use today. 
The modern era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and anti-folate 
drugs. Anti-cancer drug development since then has been dominated by the development of genotoxic 
(cytotoxic) drugs which act by targeting DNA synthesis or function. For example, nitrogen mustards and other 
alkylating agents covalently interact with DNA and induce DNA damage. Other agents which inhibit tumour 
growth by interfering with DNA synthesis or function include anti-metabolites, anti-tumour antibiotics, 
topoisomerase inhibitors and platinum compounds. Further strategies for inhibiting tumour growth were 
developed in the form of microtuble inhibitors and immunotherapies. Recent anti-cancer drug development 
has focused on targeted therapy that specifically inhibits and/or modifies tumour specific molecular biological 
targets including growth factors, signalling molecules, cell-cycle proteins, modulators of apoptosis and 
molecules that promote angiogenesis (Baguley 2002). 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                                                              HK Hong   
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Jr 2005). In general, these agents can be classified by their mode of action. For 
example, the anti-cancer activity of nitrogen mustards and other derivatives, including 
melphalan and cyclophosphamide, is coupled to the ability of these compounds to 
covalently interact with DNA. Other agents which inhibit tumor growth by disrupting 
DNA synthesis incude anti-folate compounds, anti-tumor antibiotics, topoisomerase 
inhibitors and platinum compounds. In addition, further agents for inhitbiting tumor 
growth were developed in the form of microtubule inhibitors and immunotherapies. 
 
Alkylating agents 
The beginning of the modern era of chemotherapy is linked to the discovery of 
nitrogen mustard as an effective treatment for cancer in 1942 (Gilman 1963). Nitrogen 
mustard is a prototype for alkylating agents, which are selectively interacting with 
DNA and induce DNA damage (Papac & Wood 1962; Roberts et al. 1968; Thomas et 
al. 1978; Erikson et al. 1980; Garcia et al. 1988). The effects of nitrogen mustard were 
first noted in autopsy findings from soldiers dying of exposure to sulphur mustard gas 
during the First World War (Krumbhaar 1919), and the first clinical trial began to 
treat a patient with non-Hodgkin’s lymphoma (Gilman 1963). The response of the 
patient indicated that its therapeutic value is the induction of temporary regression in 
certain malignant diseases, and that the drug could be administered systemically to 
induce tumour regression. Thus, the work of Alfred Gilman with nitrogen mustard led 
to clinical use of the first chemotherapeutic alkylating agent and eventually to the 
production of a range of compounds with similar modes of action. Other improved 
alkylating agents, including cyclophosphamide and chlorambucil were chemically 
stabilized and became standard components of regimens used to treat patients with 
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lymphomas, leukaemias and some solid tumours (Gale and Foon 1985; Black and 
Livingston 1990). However, it has been noted that tumours quickly became resistant 
to these drugs (Behrens et al. 1987), and that these drugs are extremely toxic to 
rapidly proliferating normal tissues, invoking a number of side effects including 
nausea, vomiting, bone marrow depression and alopecia (Smith 1989).  
 
Anti-folate compounds (Methotrexate) 
A second approach to chemotherapy began shortly after the Second World War when 
the effects of folic acid on patients with leukaemia were investigated by Sydney 
Farber (Farber et al. 1948). Folic acid is needed to synthesize the DNA base for DNA 
replication and is important during periods of rapid cell division and growth (Mitchell 
et al.1941). Folic acid was identified as the factor that is deficient in patients with 
megaloblastic anaemia (Wills & Evans 1937), and it seemed to stimulate proliferation 
of acute lymphoblastic leukaemia (ALL) cells when administered to children with this 
cancer. This led to the synthesis of folate analogues, which block the function of 
folate-requiring enzymes and became the first drugs to successfully induce remission 
in children with ALL by suppressing proliferation of malignant cells (Farber et al. 
1948; Bertino 1979). One of the first anti-folate compounds to be developed for 
clinical trial was methotrexate (4-amino-10-methyl-folic acid, MTX) which proved to 
have anti-tumour activity in breast cancer, osteogenic sarcoma and leukaemias 
(Jonsson & Kamen 1991; Stoller et al. 1977). The action of methotrexate depends on 
active transport into cells through the reduced-folate transporter 1 (RFT-1), its 
conversion to a long-lived intracellular polyglutamate, and its binding to dihydrofolate 
reductase (DHFR), which leads to inhibition of the synthesis of thymidylate and 
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purines and the induction of apoptosis (Jolivet et al. 1983; Allegra et al. 1990; 
Schweitzer et al. 1990). Mutation of RFT-1, amplification or mutation of DHFR, loss 
of polyglutamation, and defects in the apoptotic pathway have been shown to reduce 
efficacy leading to drug resistance (Bertino et al. 1996). Methotrexate was also the 
first drug that is used to monitor drug clearance (Stoller et al. 1977), and is still 
primarily used to treat patients with ALL, as well as those with certain lymphomas, 
osteosarcoma and choriocarcinoma (reviewed in Chabner & Roberts Jr 2005).  
 
Platinum compounds 
Cisplatin, a platinum based compound that was discovered by Barnett Rosenberg 
(Rosenberg et al. 1965), was approved for clinical use by the FDA in 1978 (reviewed 
in Desoize & Madoulet 2002). Cisplatin interacts with DNA producing inter- and 
intrastrand cross-links, which induce apoptosis through the inhibition of DNA 
replication and transcription (Pil & Lippard 1992). Cisplatin showed anti-cancer 
activity both in testicular cancer and in ovarian cancer in early phase I trials, however, 
further trials were stopped because of renal toxicity. This renal toxicity was reduced 
by combining cisplatin with high-volume fluid hydration (Lebwohl & Canetta 1998; 
Lokich & Anderson 1998; O’Dwyer et al. 2000). Cisplatin is now an important drug 
which is used to treat cancers including sarcoma, small cell lung cancer, germ cell 
tumours, lymphoma and ovarian cancer (O’Dwyer et al 2000; Desoize & Madoulet 
2002), and is frequently given as part of a combination chemotherapy regimen with 
other drugs (Parmar et al. 2003; Stordal et al. 2007; reviewed in Muggia 2009). 
Subsequently, cisplatin derivatives, carboplatin and oxaliplatin were also developed 
and showed broad anti-tumour activity and comparatively less nephrotoxicity 
(reviewed in Rabik & Dolan 2007). In addition, fludarabine phosphate, a purine 
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analogue that inhibits DNA synthesis by interfering DNA polymerase, has been 
developed and has become a mainstay in the treatment of patients with chronic 
lymphocytic leukaemia (Rai et al. 2000).  
 
Toposiomerase inhibitors 
The discovery of taxanes (Wani et al. 1971) and camptothecins (Wall et al. 1966) 
generated interest in natural products as anti-cancer agents. Paclitaxel (Taxol) is the 
first of a novel class of microtubule stabilizing agents that lead to cell cycle arrest at 
G2/M followed by apoptosis (Schiff et al. 1979; Horwitz 1992; Jordan et al. 1996;  
Blagosklonny & Fojo 1999; Wang et al. 2000). In early preclinical studies, paclitaxel 
showed strong in vivo anti-tumour activity in the P1534 leukemia model and human 
tumour xenografts in nude mice (Fuchs & Johnson 1978; Suffness 1993). This moved 
Taxol into further preclinical studies and clinical trials, and it showed consistent 
efficacy in the treatment of patients with ovarian cancer, breast cancer, colon cancer, 
non-small cell lung cancer (NSCLC), head and neck cancer, and AIDS-related 
Kaposi’s sarcoma (Horwitz 1992; Spencer & Faulds 1994; Rowinsky & Donehower 
1995; Alshowaier & Nicholls 1997). Camptothecin, derived from a Chinese 
ornamental tree, inhibits topoisomerase I that allows DNA unwinding and strand 
passage (Hsiang et al. 1985). Camptothecin displayed in vitro cytotoxicity against 
human oral epidermoid carcinoma (9KB cell line) and in vivo anti-tumour activity 
(Wall et al. 1976). Despite showing their promise in preclinical studies, both classes 
of drug encountered significant problems in drug development. Paclitaxel proved 
difficult to synthesize and could only be obtained from the bark of the Pacific Yew 
tree. Furthermore, it was virtually insoluble and had to be formulated in a lipid 
emulsion that caused hypersensitivity reactions in some patients. To resolve these 
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problems, various approaches were employed including water-soluble prodrugs (Vyas 
et al.1995; Burt et al. 1995), non-prodrug water-soluble analogues (Uoto et al. 1998) 
and orally active analogues (Malingre et al. 2001). Some of them have been shown to 
improve solubility and finally underwent clinical evaluation (Singer et al. 2003; 
Sparreboom & Verweij 2003). Currently, paclitaxel and its semi-synthetic analog 
docetaxel are used to treat patients with various cancers and have become one of the 
most important anti-cancer agents presently used in cancer therapy (reviewed in 
Ganesh 2007). In the case of camptothecin, the drug had little anti-tumour activity in 
early clinical trials and was toxic to kidneys due to instability of its lactone ring at 
neutral pH, causing renal tubular damage. First generation analogues of camptothecin, 
topotecan (Hycamtin) and irinotecan (Camptosar), which are water-soluble and more 
stable derivatives of camptothecin, were discovered and passed Food and Drug 
Administration (FDA) approval for the treatment of colon cancer and are also used to 
treat lung and ovarian cancers (Saltz 1999; Noda et al. 2002; Bodurka et al. 2003).  
 
Other effective drugs include anthracyclines and epipodophyllotoxins, both of which 
inhibit the action of topoisomerase II which is crucial for DNA replication, 
transcription and repair (Minocha & Long 1984; reviewed in Deweese & Osheroff 
2009). However, despite rapid and continuous advances in anti-cancer drug 
development, these drugs are compromised by their lack of specificity with the 
resulting death and damage to normal tissue. Moreover, cancer cells can rapidly 
acquire resistance to anti-cancer drugs due to their inherent genetic instability 
(Gottesman et al. 2002; Luqmani 2005; Broxterman et al. 2009; Liu 2009). 
Furthermore, there are additional problems related to their acute and long-term 
toxicities. Although the toxic side effects of conventional anti-cancer drugs can 
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potentially be managed by lowering the dosage of the drug that is used for treatment, 
the ability of cancer cells to become resistant to different drugs remains a significant 
impediment to successful chemotherapy. It has become apparent that resistance 
develops against every effective drug, even the newest (Gottesman et al. 2002).  
 
Drug resistance 
Drug resistance can be either intrinsic to a subpopulation of heterogeneous cancer 
cells or acquired as a cellular response to drug exposure. In general, acquired drug 
resistance is the main cause of treatment failure in cancer patients following an initial 
good response (Kim and Tannock 2005). Multidurg resistanse (MDR) is a well 
recognised phenomenon of acquired resistance to chemotherapeutic drugs (reviewed 
in Liu 2009). There are two classes of transporter proteins at the cellular surface 
which are responsible for MDR genes in cancer cells. One is the ATP-binding cassette 
(ABC) transporter superfamily which fuctions as an ATP-dependent efflux pump for 
the drugs. The other is the solute carrier transporter superfamily which mediates the 
cellular uptake of chemotherapeutic drugs (Huang 2007). Resistance to 
chemotherapeutic drugs may occur either by increased levels of efflux transporters or 
by decreased activity of uptake transporters.  
 
P-glycoprotein (P-gp; MDR1/ABCB1), the first identified ABC transporter, is 
encoded by human MDR1/ABCB1 gene (Sarkadi 2006). P-gp is expressed in primarily 
in variety of cell types in the liver, pancreas, kindney, colon and jejunum (Thiebaut et 
al. 1987). Overexpression of P-gp results in increased drug efflux, thereby lowering 
the intracellular concentration of the drug and reducing sensitivity to treatment 
(Gottesman & Pastan 1996). Cancers derived from tissues which normally show low 
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expression of P-gp can acquire increased levels of the protein following treatment 
(Kohno et al. 1989), particularly when treatment involves anti-tumor antibiotics 
(Diddens et al. 1987), topoisomerase inhibitors (Rasheed & Rubin 2003) and 
microtubule inhibitors (Geney et al. 2002). Resistance to platinum compound is 
associated with increased expression of the copper efflux transporter, ATP7A 
(Samimi et al. 2004). Different types of drug resistance mechanism occur with anti-
metabolites. Resistance to methotrexate which is an anti-folate compound can occur 
by a variety of mechanisms, including impaired transport of drug into the cell via the 
RFC, an increase in DHFR due to gene amplification or increased transcription, and 
diminished interacellular retention secondary to decreased polyglutamylation (Bertino 
et al. 1996).  In addition to the mechanisms of resistance described above, reduced 
sensitivity to drug can be occur in variety of ways, including alterations in the activity 
or level of target enzyme (Pommier et al. 1986; Sullivan et al. 1989), decresed drug 
activation due to conjugation with increased glutathione (Behrens et al. 1987), 
enhanced DNA repair (Rixe et al. 1996), and failure to apoptosis pathway as a result 
of mutated cell cycle protein such as p53 (Selivanova 2001).  
 
1.2. Targeted therapy  
Over time understanding of cell biology and the development of new technologies has 
vastly increased and uncovered new signalling transduction pathways which regulate 
cellular activities such as cell proliferation and survival. This has led to a refinement 
of the concept for the ideal cancer target, allowing the establishment of rational drug 
discovery programmes. Notably, many key factors which are involved in the multiple 
steps of growth signalling pathways have been found to be frequently altered in 
cancer cells, and have therefore become the focus of target-based drug discovery 
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programmes (Sherr 2000; Sausville et al. 2000; Monga & Sausville 2002). The new 
targets include growth factors, signalling molecules, cell-cycle proteins, modulators of 
apoptosis and molecules that promote angiogenesis (Hanahan & Weinberg 2000; 
Yarden & Sliwkowski 2001; reviewed in Goldblatt & Lee 2010). Target-based drugs 
can be classified into small molecules that have specific molecular weights and 
structural formulas, and macromolecules that include monoclonal antibodies 
(reviewed in Saijo et al. 2003; Hait & Hambley 2009). 
 
Antibodies aside, the majority of recently developed target-based drugs are small 
molecules that specifically inhibit and/or modify cancer-specific biological changes. 
Innovations in technology and combinatorial chemistry are providing thousands of 
unique structures for in vitro screening, increasing the success rate in the 
identification of targeted small molecule inhibitors of specific targets. The first 
example of targeted therapy is the development of imatinib mesylate (also known as 
Glivec, Gleevec and ST1571) (Druker et al. 1996; Druker & Lydon 2000; Zang et al. 
2003). Imatinib is a small molecule inhibitor of the Bcr-Abl fusion kinase in chronic 
myeloid leukaemia (CML). It also inhibits the KIT tyrosine kinase and platelet 
derived growth factor receptor- (PDGFR-) tyrosine kinase, extending its treatment 
potential to gastrointestinal stromal tumours and hypereosinophilic syndromes 
(Chabner & Roberts Jr 2005). However, in the acute leukaemia phase of CML, 
imatinib showed only brief remissions with treatment leading to a rapid outgrowth of 
drug-resistant cells displaying mutations in the catalytic kinase domain of Abl (Gorre 
et al. 2001; Shah & Sawyers 2003; Apperley 2007). Some patients with advanced 
gastrointestinal stromal tumors acquired resistance through the emergence of 
imatinib-insensitive c-KIT kinase variants (Sleijfer et al. 2007). 
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A second example of a targeted inhibitor is gefitinib (Iressa), a small molecular 
weight synthetic anilinoquinazaline, targeting the ATP binding pocket of the tyrosine 
kinase domain of the epidermal growth factor receptor (EGFR), which blocks 
signaling pathways involved in the proliferation and survival of tumour cells (Herbst 
et al. 2004). Gefitinib showed partial remission in 10-15% of patients with non-small-
cell lung cancer (NSCLC), but does not outperform conventional chemotherapies in 
the number of tumour responses (Herbst et al. 2002; Ranson et al. 2002; Kris et al. 
2003; Giaccone 2004). Sequence analysis of the EGFR in primary NSCLC tumors 
identified mutations within the tyrosine kinase domain that correlated with sensitivity 
to gefitinib (Lynch et al. 2004; Paez et al 2004). These mutations include in-frame 
deletions in amino acids 747-750 and point mutations at position 858 (L858R) (Irmer 
et al. 2007) or position 790 (T790M) (Kobayashi et al. 2005), which may accout for 
the differential response in patients.  
 
Further targeted therapies have been developed, including Herceptin (trastuzamab). 
Herceptin is a recombinant monoclonal antibody targeted against human epidermal 
growth factor receptor-2 (HER-2), which is overexpressed in 20-30% of breast 
cancers (Slamon et al. 2001; Emens & Davidson 2004; Hudelist et al. 2004; Emens 
2005; Neyt et al. 2005). Binding of Herceptin to the extracellular domain of HER-2 
results in downregulation of HER-2 by inducing receptor internalisation, inhibition of 
cell cycle progression and stimulation of antibody-dependent cellular cytotoxicity 
(reviewed in Harries & Smith 2002). Results from several clinical trials showed that 
Herceptin is effective as a single agent in previously treated and untreated patients 
with metastatic breast cancer (Cobleigh et al. 1999; Vogel et al. 2002). Moreover, 
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combination of chemotherapy and Herceptin revealed a prolonged survival of patients 
with HER-2 positive metastatic breast cancer compared with chemotherapy alone 
(Slamon et al. 2001). However, the cardiac dysfunction was seen in some patients 
who received an anthracycline-cyclophosphamide regimen together with Herceptin, 
and prospective monitoring of cardiac function is an integral part of current Heceptin 
combination studies (reviewed in Harries & Smith 2002). 
 
1.3. Development of Cyclin-dependent kinase inhibitors 
Although many kinases have emerged as key regulators of most signalling pathways 
in cancer cells, the cyclin-dependent kinases (CDKs) have attracted special attention 
as drug targets because of their direct relevance to cell proliferation in cancer 
development (Malumbres & Barbacid 2001; Shapiro 2006). CDKs are 
serine/threonine kinases that are activated by association with a regulatory subunit, 
the cyclin. The activity of CDKs is negatively regulated by direct interaction with 
CDK inhibitors (CDKIs) which are divided into two major families: the INK4 
(inhibitor of CDK4) family, including p16, p15, p18 and p19, which inhibit cyclin D 
associated kinases; and the Cip/Kip (kinase inhibitor protein) family, including p21, 
p27 and p57, which inhibit most CDKs (Sherr & Roberts 1999; Grana & Reddy 1995; 
Morgan 1997; Pines 1995). Accumulated evidence has shown that dysregulation of 
molecules controlling cell cycle progression plays an important role in tumour 
pathogenesis. For example, alterations in the pathway involving CDK4, CDK6, cyclin 
D, INK4, pRb and E2F have been observed in more than 80% of human cancers 
(Sherr & McComick 2002; Morgan 2007). Furthermore, genetic abnormalities of 
other CDKs (CDK1, 2 and 7), cyclins (A and E) and CDKIs (p21 and p27) have also 
been reported in many human cancers (Bardelli et al. 2003; Greenman et al. 2007).  
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There are several strategies to inhibit CDK activity for therapeutic intervention, and 
these strategies can be divided into efforts to directly target the catalytic CDK subunit 
or to manipulate CDK activity indirectly by targeting the regulatory pathways. The 
direct CDK inhibitors are ATP competitive compounds which are designed to interact 
specifically with the ATP-binding site of the catalytic domain of CDK (De Azevedo 
et al. 1997; Meijer & Kim 1997; Senderowiz et al. 2000; Senderowicz & Sauville 
2000). Flavopiridol (Flavo), one of the most characterized CDK inhibitors, showed 
consistent anti-tumour activity in preclinical animal models and subsequently 
underwent several clinical trials as a single agent and in combination with other 
chemotherapeutic agents (Senderowicz & Sausville 2000; Innocenti et al. 2000; 
Stadler et al. 2000; Shapiro et al. 2001; Senderowicz 2003; Schwartz et al. 2005). 
Flavopiridol inhibits most CDKs; CDK1/cyclin B, CDK2/cyclin A and E, 
CDK4/cyclin D and CDK6/cyclin D and CDK7/cyclin H (Carlson et al. 1996; 
Losiewicz et al. 1994; Senderowicz 1999; Worland et al. 1993; Sedlacek 2001). 
Crystallographic studies have indicated that flavopiridol inhibits the activity of most 
CDKs by directly occupying the ATP-binding site (Hardcastle et al. 2002). 
Flavopiridol has been reported to repress the expression of cyclin D1 and D3, leading 
to loss of CDK4 activity in a breast cancer cell line (Carlson et al. 1999) and also the 
expression of VEGF (vascular endothelial growth factor) in human monocytes 
(Melillo et al. 1999). Flavopiridol also inhibits P-TEF (positive transcription 
elongation factor, also known as CDK9/cyclinT) which is critical for the function of 
RNA polymerase II, suggesting that transcriptional regulation of cyclin D and VEGF 
by flavopiridol may be a consequence of P-TEF related process (Chao & Price 2001). 
The inhibition of CDKs by flavopiridol leads to cell-cycle arrest and apoptosis in a 
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range of different tumour cell lines (Kaur et al. 1992; Drees et al. 1997; Byrd et al. 
1998; Arguello et al. 1998; Parker et al. 1998; Senderowicz 1999; Sedlacek 2001). 
p53-independent apoptosis was observed in squamous head and neck cell lines with 
flavopiridol treatment (Patel et al. 1998). In addition, flavopiridol-induced apoptosis 
in leukaemia cell lines is associated with early activation of the MAPK kinase family 
(MEK, p38 and JNK), and this activation may lead to activation of caspases (Lahusen 
et al. 2000). Kitada et al. reported that the apoptotic effects of flavopiridol are 
associated with down-regulation of the anti-apoptosis proteins XIAP, Mcl-1 and 
BAG-1 in B cell chronic lymphocytic leukaemia (BCLL) cell lines, suggesting that 
mechanisms other than inhibiting CDK activity may be involved in flavopiridol-
induced apoptosis (Kitada et al. 2000).  
 
Despite promising results from preclinical studies, however, their efficacy in clinical 
trials has been modest due to their lack of selectivity affecting cancer cells, problems 
related with their pharmacokinetic properties, and appropriate schedule of 
administration (Schwartz et al. 2001; Shapiro et al. 2001; Aklilu et al. 2003). 
Flavopiridol showed anti-cancer activity in some patients with renal cell carcinoma, 
colon carcinoma, non-Hodgkin lymphoma, gastric carcinoma and mantel cell 
lymphoma in phase I clinical trials (Senderowicz et al. 1998; Tan et al. 2002; Thomas 
et al. 2002; Senderowicz 2003; Sausville et al. 2003). However, the activity of this 
drug administered alone in phase II trials in several epithelial tumours has been less 
than that encountered in preclinical studies (Senderowicz et al. 2000; Shapiro et al. 
2001; Schwartz et al. 2001; Aklilu et al. 2003). Therefore, combination with standard 
chemotherapeutics such as paclitaxel and gemcitabine has been undertaken in 
preclinical and clinical trials and showed some synergistic effects in patients with 
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prostate, lung and oesophageal cancers (Schwartz et al. 2002; Cartee et al. 2002; 
Nahta et al. 2002).  
 
Other CDK inhibitors have been developed, and of these, several have been evaluated 
for anti-cancer activity in preclinical studies. Purine-based CDK inhibitors showed 
selectivity for CDKs 1, 2 and 5, but demonstrated no inhibitory activity to CDKs 4 
and 6. Some of these inhibitors have been reported to have potent anti-cancer activity, 
including olomoucine, purvalanols and CGP74514A (reviewed in Knights & Pestell 
2009). These inhibitors are widely used in academic laboratories, however, as yet 
none of these compounds appear to have advanced to clinical trials for cancer therapy. 
Other CDK inhibitors (e.g. UCN-01, CYC202, BMS-387032) are also reported to 
show potent and selective inhibition of CDK, and anti-cancer effects in xenograft 
models (reviewed in Knights & Pestell 2009). Clinical trials of these inhibitors have 
been conducted with patients in phase I and II trials, but have yet to yield an objective 
therapeutic response (Sausville et al. 1998, 2001; Fuse et al. 1998). In contrast UCN-
01 has been evaluated in combination with cisplatin, topotecan, fluorouracil, 
carboplatin and irinotecan (Lara et al. 2005; Kortmansky et al. 2005; Welch et al. 
2007; Edelman et al. 2007; Jimeno et al. 2008) for the treatment of leukemia and 
advanced solid tumours, with early clinical trials showing promising results (Deep & 
Agarwal 2008).  
 
A large number of novel chemotherapeutic strategies have been developed to reverse 
cancer progression, but there are still many limits in cancer treatment that have yet to 
be overcome. The drugs presented here represent some of the more successful and 
highly developed chemotherapeutic strategies at preclinical/clinical stages in drug 
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discovery and development and in clinical use. Many other chemotherapeutic 
strategies are currently undergoing investigation and evaluation, and new cancer 
targets are continually sought. 
 
1.4. The anti-cancer drug discovery and development process  
The drug discovery and development process is both complex and expensive, 
requiring many years and resources from an initial therapeutic concept to a new drug 
application. The process of drug discovery involves the identification and validation 
of targets, assay development, HTS (high-throughput screening), hit validation, lead 
generation/optimization and assessment of therapeutic efficacy. Once a compound has 
shown its value in this process, it will begin the process of drug development 
involving preclinical and clinical studies (phase I, phase II, phase III) prior to final 
registration as a drug (Figure 1.2) (Bleicher et al. 2003).  
 
Three interrelated elements are essential to the success of the targeted drug discovery 
and development process. First, there must be good reason to believe that a given 
target, a specific gene or protein against which a drug will be developed, has causal 
relevance to cancer. The relevant data must evaluate the effects of modulating the 
activity of a given target in available experimental models. The process of gathering 
such functional information about the target is called ‘target validation’. Second, the 
process of finding a new drug against a chosen target usually requires a well 
optimized biochemical assay which can be adapted to HTS, wherein large libraries of 
chemicals are tested for their ability to modify the target (Walters & Namchuk 2003). 
In parallel with the HTS process, in silico screening (or virtual high throughput 
screening), where screening is done using computer-generated models and attempting 
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to "dock" virtual libraries to a target, is also often used to improve the efficiency of 
HTS by enhancing the overall quality and minimizing the number of hits-to-leads. 
Third, once a lead compound has been established with sufficient target potency and 
selectivity, this lead compound must be clinically assessed in preclinical studies 
involving in vitro and in vivo (animal) studies and in clinical trials. Clinical trials, 
commonly classified into four phases, are used to test the efficacy and safety of a 
candidate drug. In phase I trials, the drug is administered to a small number (20-80) of 
healthy volunteers to test for toxicity and side effects and for correct dosage levels. In 
phase II trials which focus on determining the optimal dosing of the drug, the test is 
repeated in a large number (100-300) of appropriate cancer patients, followed by a 
pivotal phase III trial against a comparator product (Roberts et al. 2003; Molzon 
2003). If the drug successfully passes through phases I, II, and III, it will usually be 
approved by the national regulatory authority for use in the general population. Phase 
IV is ‘post-approval’ studies.  
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1.5. The DNA replication initiation machinery as a potential anti-
cancer target 
Despite advances in our understanding of cell biology and new technologies, drug 
discovery is still a long process with a low rate of novel therapeutic agents. The study 
of the molecular basis of cancer, as well as the availability of the complete sequence 
information of the human genome, has led to the expectation that the discovery and 
development of new cancer drugs might produce more predictable and efficient 
cancer therapies (Benson et al. 2006). Accordingly, a new strategy for cancer therapy 
has emerged in the form of targeted therapy which is the development of drugs that 
target the action or activity of a specific signalling pathway in cancer cells (Benson et 
al 2006). Although various target-based drugs have shown promising efficacy in early 
drug development programmes, their clinical use has been limited by the associated 
toxic side effects and the development of drug resistance (Deep & Agarwal 2008; Hait 
& Hambley 2009).   
 
The initiation of DNA replication is a crucial decision point in cell proliferation that 
lies at the convergence point of complex and potentially redundant oncogenic 
signalling and transduction pathways (Williams & Stoeber 1999). Unlike these 
numerous pathways, there appears to be only a single mechanism of DNA replication 
initiation, which is tightly controlled through the assembly and activation of the pre-
replication complex (pre-RC), and the basic components of this mechanism are 
conserved in all eukaryotic species studied (reviewed in Sclafani & Holzen 2007; also 
see  1.5.1.2. DNA replication initiation pathway). Importantly, the position of the 
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DNA replication initiation pathway at the final step of growth signal transduction 
pathways may provide a reductionist solution to the major challenge of developing 
effective therapeutic strategies, given the complexity of addressing multiple mutations 
that occur at all levels of signal transduction pathways for each tumour type and 
subtype. Moreover, inhibiting the initiation of DNA synthesis should minimize 
genomic damage and therefore circumvent the problems of infertility and further 
neoplastic transformation associated with the use of DNA damaging agents and drugs 
targeting elongation DNA synthesis. A further criterion which must be considered is 
the specificity of therapeutic agents targeting the DNA replication initiation pathway, 
especially since DNA replication is essential to all dividing cells and agents targeting 
elongation DNA synthesis are known to invoke severe toxic side effects in normal 
cells. Prior to addressing this issue, I will provide an overview of the DNA replication 
initiation pathway and our current understanding of a specific kinase - Cdc7 - in this 
pathway. 
 
1.5.1. The DNA replication initiation pathway in eukaryotic cells 
The DNA replication initiation pathway is a complex process involving multi-protein 
enzymatic reactions and the basic components of this pathway are conserved in all 
eukaryotes (reviewed in Sclafani & Holzen 2007). Consequently, findings based on 
genetics in yeast, biochemistry in Xenopus eggs and in tissue culture model systems 
using mammalian cells can be brought together to generate a molecular understanding 
of the DNA replication initiation pathway (reviewed in ven den Heuvel 2005).   
 
1.5.1.1. Origins of replication  
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Origins of replication are the places at which DNA replication starts (Jacob 1993). 
Generally, replication starts at an origin and proceeds bidirectionally to form a single 
replicon (reviewed in Sclafani & Holzen 2007). Many attempts to identify putative 
replication origins have relied on assaying the ability of DNA fragments to facilitate 
the so-called autonomous replication of plasmids in Saccharomyces cerevisiae 
(Stinchcomb et al. 1980). Using 2D-gel analysis, those Autonomously Replicating 
Sequence (ARS) were shown to be bona fide origins in yeast, both in plasmids and in 
chromosomal DNA (Brewer & Fangman 1987; Huberman et al. 1988). The consensus 
ARS is approximately 100 bp long and consists of a 17 bp A domain region with an 
ACS (ARS consensus sequence) and flanked by a less conserved B domain (Newlon 
1996). In Xenopus egg extracts, replication occurs at regular intervals of 
approximately 10 kb (Lucas et al. 2000; Blow et al. 2001). Studies of replication 
origins in mammalian cells have revealed that replication can occur at regions referred 
to as ‘zones’ that vary in size from 6 to 55 kb (Dijkwel & Hamlin 1995), and are 
dependent on chromatin and nuclear structure, sharing little sequence similarity 
except for the presence of AT-rich elements and DNA unwinding elements 
(DePamphilis 1999). 
 
1.5.1.2. DNA replication initiation pathway  
The mechanism of DNA replication initiation occurs in two steps; the first stage is 
started by the formation of the pre-replicative complex (pre-RC) which comprises six 
subunits of the origin recognition complex (ORC), the loading factors Cdc6 and Cdt1, 
and the putative DNA helicase Mcm2-7 at replication origins. This assembly process 
occurs during late mitosis and early G1 and results in the origin becoming ‘licensed’ 
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for DNA replication. In the second stage, the licensed origins are activated by S 
phase-specific cyclin-dependent kinases (CDKs) and the Dbf4-dependent kinase 
(DDK, Cdc7/ASK) (Figure 1.3; reviewed in Sclafani & Holzen 2007). 
 
Pre-RC assembly 
In our current understanding of eukaryotic DNA replication, the origin is marked by 
ORC which provides a “landing-pad” for other replication proteins (Diffely & Cocker 
1992; reviewed in Duncker et al. 2009). ORC is a six protein complex comprised of 
the Orc1-6 subunits that are structural and functional conserved in all eukaryotes 
(Quintana & Dutta 1999). ORC was first discovered by identification of proteins that 
bound to the ARS core sequence of the A-domain in Schizosaccharomyes cerevisiae 
origin (Bell & Stillman 1992). Human (Vashee et al. 2003), Xenopus (Gillespie & 
Blow 2001) and S. pombe (Chuang & Kelly 1999; Kong & DePamphilis 2001) ORCs 
prefer an A-T rich sequence, but no consensus sequence has been identified. Except 
for Orc6, most ORC subunits are in the superfamily of AAA+ ATPases (ATPases 
Associated with various cellular Activities) with conserved Walker A, B, C and D 
motifs (Koonin 1993; Bell & Dutta 2002). The ATP binding activity of human Orc1, 
Orc4 and Orc5 subunits is required for replication in the Xenopus cell free system 
(Giordano-Coltart et al. 2005). Orc1 ATPase is activated by Cdc6 binding, which is 
also an AAA+ ATPase, inducing a conformational change in the ORC-Cdc6-DNA 
complex which increases specificity (Speck et al. 2005; Speck & Stillman 2007). This 
suggests that ORC-Cdc6 might act as a clamp loader for the MCM complex, allowing 
the MCM complex to encircle double stranded DNA (Neuwald et al. 1999). 
6
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Figure 1.3: The eukaryotic DNA replication initiation pathway. After mitosis, pre-replicative 
complex (pre-RC) assembly begins with the loading of the origin recognition complex (ORC) onto 
chromatin at replication origins. ORC recruits Cdc6 and Cdt1, which in turn load the Mcm2-7 
complex to origins of DNA replication to form pre-RCs. Once Mcm2-7 complexes are loaded at 
origins, Cdc6 and Cdt1 are removed from the origin and the origin licensing repressor geminin 
inhibits pre-RC re-formation by interaction with Cdt1. Cdc7/ASK and CDKs become active and 
phosphorylate Mcm2-7 proteins triggering a conformational change in the Mcm2-7 complex that is 
required for unwinding of DNA. In late G1, Mcm10, Cdc45 and the replisome that contains DNA 
polymerase-a/primase are recuited. 
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 ORC is bound to origins throughout the cell cycle in S. cerevisiae (Liang & Stillman 
1997), however in mammalian cells, Orc2-Orc6 remain chromatin-bound at all stages 
of cell cycle, whereas Orc1 is released from chromatin during S phase and restored 
during the subsequent G1 phase (DePamphilis 2003).  
 
ORC recruits two more proteins, Cdc6 and Cdt1, to the origin. These proteins in 
conjunction with ORC are required for chromatin loading of the MCM complex, 
which is the putative DNA replicative helicase (Labib & Diffley 2001; Pacek & 
Walter 2004). In the presence of ATP, addition of Cdc6 to the ORC complex 
produces a ring-like structure around DNA that resembles the MCM complex in size 
and shape (Adachi et al. 1997; Fletcher et al. 2003; Gomez-Llorente et al. 2005; 
Kubota et al. 2003; Pape et al. 2003). Cdc6 has conserved Walker A and B motifs 
which are essential for ATP binding and hydrolysis. Mutations in these motifs 
abrogate Cdc6 functions regarding pre-RC assembly and/or recruitment of the MCM 
complex (Perkins & Diffley 1998). Cdt1 is also required to load the MCM complex 
during G1 phase and is negatively regulated by geminin which prevents re-replication 
to occur at already licensed origins (Maiorano et al. 2000; Nishitani et al. 2000; 
Wohlschlegel el al. 2000; Tada et al. 2001; Cook et al. 2004; Lee et al. 2004; 
Ferenbach et al. 2005). As Cdc6 ATPase is needed for Cdt1 binding to the origin in 
vitro, it has been proposed that a Cdt1-MCM complex is loaded onto the ORC-Cdc6-
DNA complex during initiation (Randell et al. 2006). Cdc6 and Cdt1 then dissociate 
and ATP hydrolysis by ORC completes the MCM loading reaction (Randell et al. 
2006; Speck et al. 2005; Speck & Stillman 2007).  
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MCM is a six subunit protein complex comprised of the Mcm2-7 subunits which are 
conserved in all eukaryotes (Kearsey & Labib 1998; Tye 1999; Tye & Sawyer 2000) 
and the six subunits generate a heterohexamer (Ishimi 1997; You et al. 1999; Fletcher 
et al. 2003; Pape et al. 2003). The identification of DNA helicase activity in an 
assembly of MCM proteins (Ishimi 1997), and the discovery that MCMs move along 
the DNA as the replication fork progresses (Aparicio et al. 1997; Labib et al. 2000) 
supported the notion that MCM acts as the replicative helicase at eukaryotic DNA 
replication forks. Human MCM subunits generate a subassembly including Mcm4-6-7, 
which was shown to have DNA-dependent ATP hydrolysis as well as weak helicase 
activity in vitro, although no such activities have been detected in the intact Mcm2-7 
complex (Ishimi 1997; You et al. 1999; Kelman et al. 1999; Chong et al. 2000; Lee & 
Hurwitz 2001). Mcm2-7 complexes from Xenopus and yeast have ATPase but not 
DNA-binding or helicase activity (Adachi et al. 1997). Several reports have shown 
that excess Mcm2-7 complexes are loaded at origins with approximately 40 MCM 
hexamers per origin in Xenopus (Edwards et al. 2002) and 10 in S. cerevisiae 
(Donovan et al. 1997), and are distributed at significant distances away from where 
ORC is bound (Ritzi et al. 1998; Edwards et al. 2002; Harvey & Newport 2003). 
Various suggestions have been made for the function of the excess Mcm2-7 
complexes, including roles in DNA pumping (Laskey & Madine 2003), checkpoint 
activation (Cortez et al. 2004; Tsao et al. 2004), transcriptional regulation (Yankulov 
et al. 1999; DaFonseca et al. 2001; Fitch et al. 2003), and chromatin remodelling 
(Burke et al. 2001; Dziak et al. 2003). Once the components of the pre-RC have been 
assembled, the next step is origin activation which involves Mcm2-7 helicase 
activation and recruitment of additional factors including Mcm10, Cdc45, Sld3, Sld2, 
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Dpb11 and the GINS complex (Takeda & Dutta 2005; reviewed in Sclafani & Holzen 
2007). 
 
In addition to the core pre-RC components, ORC, Cdc6, Cdt1 and Mcm2-7, a further 
MCM protein, Mcm10/cdc23 (S. cerevisiae/S. pombe) is also essential for DNA 
replication (Merchant et al. 1997; Aves et al. 1998; Homesley et al. 2000). Mcm10 is 
needed for the loading of the Cdc45 protein after pre-RC assembly and for stabilizing 
the replisome as shown in human cells (Izumi et al. 2000), Xenopus egg extract 
(Wohlschegel et al. 2002) and S. cerevisiae (Ricke & Bielinsky 2004; Sawyer et al. 
2004). Mcm10 interacts with the Mcm2-7 complex (Merchant et al. 1997; Aves et al. 
1998; Homesley et al. 2000), as well as Orc2 and Cdc7/Dbf4, and has been suggested 
to stimulate Mcm2-7 phosphorylation by Cdc7/Dbf4 (Lee et al. 2003). Mutations in S. 
cerevisiae Mcm10 show defects in completion of S phase after origins have fired, 
suggesting an addition role in elongation (Merchant et al. 1997; Homesley et al. 2000; 
Kawasaki et al. 2000; Gregan et al. 2003). 
 
Further initiation factors involved in activation of the replication origin have been 
identified through genetic screening in S. cerevisiae, including Dpb11 (DNA 
polymerase B possible subunit) (Araki et al. 1995), its counterpart in S. pombe Cut5 
(Saka & Yanagida 1993; Araki et al. 1995; McFarlane et al. 1997), Sld2 and Sld3 
(Kamimura et al. 2001; Masumoto et al. 2002; Noguchi et al. 2002; Nakajima & 
Masukata 2002) and the GINS complex (composed of Sld5, Psf1, Psf2 and Psf3) 
(Kanemaki et al. 2003; Kubota et al. 2003; Takayama et al. 2003). Putative 
homologues of Dpb11 have been identified in higher eukaryotes including Mus101 in 
Drosophila (Yamamoto et al. 2000), TopBP1 in mammals (Makiniemi et al. 2001) 
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and Cut5/Mus101 in Xenopus (Van Hatten et al. 2002; Hashimoto & Takisawa 2003), 
based on their conservation of repeating BRCT protein motifs and their involvement  
in both DNA replication and checkpoint activation. Although all these factors are 
essential for initiation of DNA replication, precise mechanisms of assembly of the 
individual factors or their functions in DNA replication, and functional homologues of 
these factors in higher eukaryotes remain to be elucidated.  
 
Origin activation   
S phase-specific cyclin-dependent kinases (CDKs, CDK2/cyclin A and E) and Cdc7 
kinase/Dbf4 (Dbf4-dependent kinase; DDK) are required for origin activation (Woo 
& Poon 2003). CDKs and Cdc7 kinase regulate different steps in activation of the 
replication origin. CDKs may function globally to initiate S phase, whilst Cdc7 has a 
more specific role in both G1-S transition and S phase progression and has been 
shown to phosphorylate various members of the Mcm2-7 complex in vivo and in vitro 
(Pasero et al. 1999; Murray 2004; Forsburg 2004; Ishimi et al., 2001; Tsuji et al., 
2006; Cortez et al. 2004; Yoo et al. 2004; Montagnoli et al. 2006; Charych et al. 2008; 
Swords et al. 2010). Phosphorylation of the Mcm2-7 complex by Cdc7 results in a 
conformational change in the structure of the Mcm2-7 complex, which enables it to 
promote DNA unwinding and leads to the loading of Cdc45 in mammalian cells 
(Masai et al. 2006), in Xenopus egg extracts (Jares & Blow 2000; Walter 2000), S. 
cerevisiae (Sclafani et al. 2002; Zou & Stillman 2000; Sheu & Stillman 2006; Devault 
et al. 2008), and in S. pombe (Yabuuchi et al. 2006). CDK is also required for tight 
association of Cdc45 with chromatin in S. cerevisiae (Zou & Stillman 2000) and 
Xenopus egg extracts (Mimura et al. 2000). CDK’s role in promoting origin activation 
has been recently determined. In the current model, the role of CDKs is to 
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phosphorylate Sld2 (Masuda et al. 2003) and Sld3 (Tanaka et al. 2007; Zegerman & 
Diffley 2007), enabling their binding to Dpb11, which then binds to the origin and 
recruits the replisome with Cdc45. Loading of the GINS complex, Cut5 and Cdc45 
requires both CDKs and Cdc7 kinase, suggesting that both CDKs and Cdc7 are 
involved in two parallel pathways that are required for replication initiation (Yabuuchi 
et al. 2006). Similar to findings reported in yeast, in human cells the interactions 
between Cdc45, Mcm2-7, and GINS complex also requires both CDKs and Cdc7 
kinase activity for the initiation of DNA replication (Im et al. 2009). The final step in 
replication initiation is the loading of the replicative polymerases, DNA polymerase , 
 and  (Waga & Stillman 1998; Kawasaki & Sugino 2001; Hubscher et al. 2002), 
which occurs after origin unwinding has been stimulated by Cdc45 and RPA binding 
(Mimura et al. 2000; Walter & Newport 2000).  
 
1.6. Dbf4-dependent kinase Cdc7 
As discussed in Section 1.5., the regulation of pre-RC assembly and its activation at 
replication origins is essential for eukaryotic chromosomal DNA replication, which is 
central to cell growth, development, and the generation of tissues and organs. Cdc7 is 
an essential kinase required for origin activation to promote DNA replication. In this 
section, the main focus will be on the current understanding of Cdc7 regulation in 
eukaryotic cells, and the roles of this kinase in eukaryotic DNA metabolism.  
 
1.6.1. Cell cycle control of Cdc7 kinase activity  
The Cdc7 kinase/Dbf4-dependent kinase (DDK) was originally identified in S. 
cerevisiae as a mutant which, under non-permissive conditions, arrests with a defect 
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in S phase initiation (Hartwell 1973; Sclafani & Jackson 1994). Kinases related to 
Cdc7 have been identified in other species including S. pombe (Masai et al. 1995), 
mouse (Kim et al. 1998), Xenopus and H. sapiens (Jiang et al. 1997; Sato et al. 1997; 
Hess et al. 1998), suggesting a conservation of regulatory mechanisms of DNA 
replication by this family of kinases. Cdc7 is activated by binding a regulatory subunit 
called ASK (Activator for S phase Kinase) in H. sapiens, also called Dbf4 in S. 
cerevisiae and Xenopus, and Dfp1/Him1 in S. pombe (Diffley et al. 1995; Hardy & 
Pautz 1996; Stillman 1996; Masai & Arai 2002; Sclafani et al. 2000). A second 
ASK/Dbf4-related molecule, named Drf1, has also been identified in H. sapiens, and 
its possible homologue in Xenopus (Montagonoli et al. 2002; Yanow et al. 2003). 
 
Cdc7 kinase activity was reported to be cell-cycle-regulated from yeast to mammals 
(Jackson et al. 1993; Kumagai et al. 1999; Takeda et al. 1999; Brown & Kelly 1998; 
Oshiro et al. 1999; Weinreich & Stillman 1999; Jiang et al. 1999; Ferreira et al. 2000; 
Yamada et al. 2002). Although Cdc7 protein levels are approximately constant 
throughout the cell cycle, its activity is dependent upon and regulated by interaction 
with ASK which is regulated in cell-cycle dependent manner in mammalian cells 
(Kumagai 1999; Jiang et al. 1999; Masai & Arai 2002; Sato et al. 2003).  In S. 
cerevisiae, Dbf4 is degraded in late mitosis and early G1 phase by the APC 
(anaphase-promoting complex) (Weinreich & Stillman 1999; Oshiro et al. 1999; 
Ferreira et al. 2000). 
 
Biochemical and genetic studies indicate that the Mcm2-7 complex is a target of Cdc7 
kinase (Ishimi et al., 2001; Tsuji et al., 2006; Montagnoli et al. 2006; Sheu & Stillman, 
2006; Masai et al., 2006; Charych et al. 2008). Cdc7 kinase directly phosphorylates 
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Mcm2 (Lei et al. 1997; Kumagai et al. 1999; Jiang et al. 1999; Sclafani 2000; Masai 
& Arai 2002; Tsuji et al. 2006; Cho et al. 2006; Charych et al. 2008), Mcm4 (Masai et 
al. 2006; Devault et al. 2008; Sheu & Stillman 2010) and Mcm6 (Masai et al. 2006; 
Sheu & Stillman 2006), activating the Mcm2-7 helicase and stimulating association of 
Cdc45 with the Mcm2-7 complex.  
 
S phase-specific cyclin-dependent kinases (CDKs, CDK2/cyclin A and E) and Cdc7 
are regulated independently of each other during the cell cycle but by similar 
mechanisms, i.e. both kinases require their regulatory subunits, cyclin and ASK/Dbf4, 
for kinase activity (Masai & Arai 2002; Morgan 2007; Sclafani 2000). Although the 
requirement of CDKs and Cdc7 kinase/DDK for DNA replication initiation is 
conserved in eukaryotes, the order of execution points is controversial and may differ 
among species. CDKs function has been shown to be required before Cdc7 kinase in S. 
cerevisiae (Nougarede et al. 2000), whereas Cdc7 kinase/DDK must execute its 
function before CDKs for replication in Xenopus egg extracts and S. pombe (Walter 
2000; Yabuuchi et al. 2006). 
 
1.6.2. Role of Cdc7 kinase complex   
Characterisation of cdc7 mutants indicated that Cdc7 kinase is involved in several 
aspects of DNA metabolism (Sclafani & Jackson 1994). Cdc7 kinase is required for 
the initiation of DNA replication, and involved in checkpoint pathways (reviewed in 
Sawa & Masai 2008; Swords et al. 2010). A recent study in Xenopus egg extracts 
showed that Cdc7 kinase is also required for chromosomal segregation in mitosis 
through loading of Scc2-Scc4 and cohesin onto chromatin (Takahashi et al. 2008). In 
the meiotic cell cycle, Cdc7 kinase promotes meiosis I segregation by the initiation of 
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DNA recombination and the recruitment of monopolin to kinetochores for 
monoorientation through phosphorylating meiosis-specific proteins (Wan et al. 2006, 
2008; Sasanuma et al. 2008; Matos et al. 2008; Marston 2008; Katis et al. 2010). 
   
The mechanisms that ensure precise DNA replication during each cell cycle are not 
clearly understood, but are in part linked to cell cycle checkpoint pathways (Zhou & 
Elledge 2000). At least two types of aberrant events are monitored during S phase, 
failure of ongoing replication forks and DNA damage which immediately lead to 
activation of S phase checkpoints (Jares et al. 2000; reviewed  in Segurado & Tercero 
2009) (Figure 1.4). Several protein kinases involved in checkpoint pathways include 
ATM, ATR (Xenopus and mammalian), Mec1 (S. cerevisiae )/Rad3 (S. pombe) and 
Rad53 (S. cerevisiae)/Cds1, Chk1 (S. pombe) (reviewed in Niida & Nakanishi 2006; 
Segurado & Tercero 2009). As a consequence of checkpoint activation in S phase, 
further replication origin initiation is suppressed (intra S checkpoint) and progression 
into mitosis is blocked (G2/M checkpoint). Checkpoint pathways are composed of 
three phases; the sensor phase that is involved in detecting the presence of damaged 
chromosomes, the mediator phase that is involved in activating checkpoint kinases, 
and the effector phase which is involved in executing the checkpoint responses (Niida 
& Nakanishi 2006). Beyond the role of Cdc7 kinase in the initiation of DNA 
replication, there is evidence that Cdc7 kinase plays important roles in the checkpoint 
pathways (reviewed in Sclafani 2000; Duncker & Brown 2003; Sawa & Masai 2008; 
Swords et al. 2010). 
Replication block DNA damage
ATM/ATR 
(Xenopus, mammalian)
or
Mec1
(S. cerevisiae)
or
Rad3
(S. pombe) 
Chk1/Chk2 
(Xenopus, mammalian)
or
Rad53
(S. cerevisiae)
or
Cds1/Chk1
(S. pombe) 
G1
S
G2 M
G1/S
checkpoint
G2/M
checkpoint
p53
p21
Cdk2
Cdc7/Dbf4
-Hyper-phosphorylation 
of Dbf4
-Dissociation of Dbf4 
from chromatin
Early 
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Figure 1.4: Schematic overview of checkpoint pathways and role of Cdc7/Dbf4 kinase in the 
intra-S checkpoint. Incomplete replication and DNA damage lead to activation of the checkpoint 
kinases; ATM/ATR or Mec1 or Rad3. Depending on where the cell happens to be in the cell cycle, 
this can cause cell cycle arrest via either the 'G1/S', the ' Intra-S' or the 'G2/M' checkpoint. As a 
consequence of Rad53/Cds1 activation, Cdc7/Dbf4 becomes hyper-phosphorylated and is 
displaced from chromatin which blocks further origins from initiating (reviewed in Jares et al. 2000). 
Activation of p53 induces p21 which blocks re-replication by inhibiting Cdk2, which is required for 
new origin firing.  
Intra-S
checkpoint
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 Cdc7 kinase interacts with and phosphorylates Claspin, a checkpoint mediator protein, 
and is required for the activation of the ATR-Chk1 checkpoint pathway in response to 
stalled replication forks in mammalian cells (Kim et al. 2008). Similarly, Hsk1 kinase 
(the fission yeast Cdc7 homologue) phosphorylates Mrc1, the yeast equivalent of 
Claspin, in response to replication fork arrest, and this phosphorylated Mrc1 is 
required for the activation of Cds1 which is a yeast checkpoint effector kinase 
(Takeda et al. 1999). It has also been reported in budding yeast that Cdc7 kinase is 
required for continuous activation of the Rad53 checkpoint kinase in response to 
hydroxyurea (Ogi et al. 2008), suggesting that Cdc7 kinase plays a important role in 
activating checkpoint pathways through regulation of checkpoint mediator proteins. 
On the other hand, the role of Cdc7 in the effector phase of checkpoint pathways was 
suggested from different studies. In yeast models, Dbf4 (S. cerevisiae)/Dfp1 (S. 
pombe) is phosphorylated in a Rad53 (S. cerevisiae)/Cds1 (S. pombe) dependent 
manner when cells are treated with hydroxyurea (Brown & Kelly 1998; Weinreich & 
Stillman 1999; Kihara et al. 2000), and this phosphorylation reduces Cdc7 kinase 
activity by dissociation of Dbf4 from chromatin (Weinreich & Stillman 1999).  
 
Cdc7 kinase is also inactivated in Xenopus egg extracts through the dissociation of the 
Cdc7/Dbf4 complex in response to etoposide, which activates the ATR-dependent 
checkpoint pathway (Costanzo et al. 2003), and the subsequent failure of chromatin 
binding of Cdc45 (Jares & Blow 2000). Furthermore, Cdc7 kinase is shown to be 
downregulated by etoposide in Bcr-Abl negative, ATR-proficient human leukemia 
cells (Dierov et al. 2004), suggesting that Cdc7 kinase  is an essential target which is 
inactivated by checkpoint pathways to inhibit the initiation of DNA replication. 
However, on the contrary, several studies demonstrated that Cdc7 kinase activity is 
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not affected by replication fork arrest in Xenopus and human cells, suggesting the 
possibility that Cdc7 kinase in higher eukaryotes is not an essential target of the S 
phase checkpoint (Takahashi & Walter 2005; Liu et al. 2006; Silva et al. 2006; 
Heffernan et al. 2007; Tenca et al. 2007; Tsuji et al. 2008). A recent study showed 
that addition of purified Cdc7 kinase complex to Xenopus egg extracts or 
overexpression of ASK in cancer cells downregulates ATR-Chk1 checkpoint pathway 
in response to DNA damaging agents, suggesting that Cdc7 kinase is involved in 
regulating the S phase checkpoint by abrogating checkpoint pathway and activating 
reinitiation of DNA replication during the checkpoint recovery, although the target(s) 
of Cdc7 kinase in this mechanism were not revealed (Tsuji et al. 2008). Notably, 
downregulation of Cdc7 by small interfering RNA causes defective S phase 
progression leading to p53-independent apoptotic cell death without a significant 
checkpoint response in a variety of cancer cell lines (Montagnoli et al. 2004; Tenca et 
al. 2007), suggesting that loss of Cdc7 kinase in cancer cells leads to S phase arrest 
which results in DNA damage and cell death in the case of defective checkpoint 
activation (reviewed in Swords et al. 2010).  
 
Takahashi et al. have reported the important role of Cdc7 kinase for chromosomal 
segregation in mitosis through the chromatin association of cohesion (Takahashi et al. 
2008). A protein complex called cohesion is required to establish and maintain sister-
chromatid cohesion which is essential for accurate segregation of chromosomes after 
DNA replication (Bailis et al. 2003; Nasmyth 2005). Cohesion is established by ring-
shaped structures that consists of a four subunit complex; two structural maintenance 
of chromosome (SMC) proteins, Smc1 and Smc3, Rad21/Scc1, an -kleisin subunit 
and SA/Scc3 (Losada 2007). Cohesion is loaded onto chromosomes to link replicated 
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sister chromatids, and a complex composed of Scc2 and Scc4 is required for this 
cohesion loading (Ciok et al. 2000; Gillespie & Hirano 2004; Seitan et al. 2006). A 
recent study in Xenopus egg extracts showed that Cdc7 kinase interacts with the 
Scc2/Scc4 complex, and it’s kinase activity is required for chromatin association of 
Scc2/Scc4 complex, which promotes the chromosomal recruitment of cohesion 
(Takahashi et al. 2008). It has also been suggested that binding of Scc2/Scc4 complex 
to Cdc7 kinase allows the use of Mcm2-7 as a platform enabling cohesion assembly 
onto chromatin prior to the initiation of DNA replication (Takahashi et al. 2008; 
reviewed in Swords et al. 2010).        
 
In addition to the important role of Cdc7 kinase in mitotic cell cycle, Cdc7 kinase has 
been identified as a key regulator in meiosis (reviewed in Marston 2009; Swords et al. 
2010). Meiosis is a specialized cell cycle that generates haploid gametes from diploid 
cells through having one round of DNA replication followed by two consecutive 
chromosome segregations, meiosis I and II (reviewed in Morgan 2007; Marston 2009). 
The segregation of homologous chromosomes during Meiosis I requires three key 
modifications; meiotic recombination and formation of chiasmata between 
homologous chromosomes, generation of sister kinetochore monoorientation, and 
protection of centromeric cohesion (Petronczki et al. 2003; reviewed in Marston 
2009). Several studies in budding yeast showed that inactivation of Cdc7 kinase in 
meiosis results in a delay in DNA replication and a prophase arrest with no meiotic 
recombination (Schild & Byers 1978; Valentin et al. 2005; Wan et al. 2006). Analysis 
using a temperature-sensitive (ts) mutant of hsk1also suggested that Hsk1 is essential 
for meiotic double strand break (DSB) formation during meiosis progression in fission 
yeast (Ogino et al. 2006). It was suggested that the initiation of meiotic recombination 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   51 
is regulated by Cdc7 kinase activation together with Cdc28/Clb5 (S phase Cyclin-
dependent kinase) via phosphorylation of Mer2 protein, one of the Spo11 
endonuclease accessory factors that promotes the formation of DSB (Murakami & 
Keeney 2008; Wan et al. 2008; Sasanuma et al. 2008). Furthermore, the requirement 
of Cdc7 kinase for sister kinetochore monoorientaion during meiosis I analyzed in 
bob1 cdc7 mutants showed that homolog segregation fails during meiosis I because 
cohesion at centromeres holds bioriented sister chromatids together (Lo et al. 2008; 
Matos et al. 2008). Cdc7 kinase regulates monopolin complex localization to 
kinetochores together with Cdc5/Spo13 kinase through phosphorylation of the 
monopolin subunit Lrs4, which is essential for monopolar attachment (Matos et al. 
2008). A recent study showed that Cdc7 kinase and casein kinase 1/ (CK1/) are 
required for cohesion’s -kleisin subunit (Rec8) cleavage and meiosis I nuclear 
division (Katis et al. 2010). The role of Cdc7 kinase in chromosomal segregation in 
mitosis and homolog segregation in meiosis has mainly been studied in Xenopus and 
yeast, and thus, it remains to be determined whether Cdc7 kinase plays a similar role 
in human cells. 
 
1.7. Inhibition of the DNA replication initiation pathway  
Cell cycle specific drugs targeting DNA synthesis have already been used in modern 
chemotherapy. However, these drugs often cause genomic damage which activates the 
ATR/ATM dependent S-phase checkpoint pathway and mediates cellular responses 
involving the activation of DNA repair, cell cycle control and survival (Zhou & 
Elledge 2000). Unlike the cellular responses to inhibition of DNA elongation, the 
inhibition of the DNA replication initiation should minimize collateral damage to 
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DNA. Furthermore, uncontrolled cell growth in cancer cells and dysregulation of the 
replication initiation pathway in tumourigenesis (Williams et al. 1998; Hess et al. 
1998; Freeman et al. 1999; Stoeber et al. 1999; Going et al. 2002; Stoeber et al. 2001; 
Stoeber et al. 2002; Karakaidos et al. 2004; Korkolopoulou et al. 2005; Bonte et al. 
2008; Clarke et al. 2009) suggests that agents targeting the DNA replication initiation 
pathway may have high efficacy as anti-cancer agents (reviewed in Blow & Gillespie 
2008).  
 
As discussed in section 1.5.1, the initiation of the DNA replication process involves 
two steps, pre-RC assembly and origin activation (reviewed in Sclafani & Holzen 
2007). In order to inhibit the replication initiation pathway for therapeutic intervention, 
several studies suggest that there are therapeutic opportunities to be gained by 
targeting either pre-RC assembly or origin activation (Shreeram et al. 2002; Feng et al. 
2003; Montagnoli et al. 2004; Machida et al. 2005). The potential exploitation of the 
DNA replication initiation pathway by inhibiting pre-RC assembly as an anti-cancer 
target was initially shown in a study by Shreeram et al., which suggested that 
inhibition of the licensing system may provoke a differential response in normal and 
transformed cells and cause cancer cell-specific killing (Shreeram et al. 2002) (Figure 
1.5). Inhibition of pre-RC assembly by overexpressing a non-degradable form of 
geminin in U2OS (p53+/Rb+) and Saos2 (p53-/Rb-) cells resulted in progression into 
S or G2 phase after which cells undergo apoptosis. In contrast, ectopic expression of 
geminin in IMR-90 primary fibroblasts resulted in G1 arrest and did not induce cell 
death, suggesting that primary cells could respond to the inhibition of replication 
initiation by blocking S phase progression (Shreeram et al. 2002; Shreeam & Blow 
2003; reviewed in Blow & Gillespie 2008).  
G2
M
G1
S
S arrest
G2/M arrest
Apoptosis
Saos2 (p53-/Rb-)
BT549 (p53-/Rb-)
U20S (p53+/Rb+)
Figure 1.5: Differential response of cells to DNA replication initiation inhibitor. DNA replication 
begins at replication origins in early G1 with the formation of pre-RCs, which involves sequential assembly 
of ORC, Cdc6, Cdt1 and Mcm2-7 complexes, as a prerequisite for origin firing and DNA replication 
initiation. (A) When replication initiation is blocked in untransformed cells, the initiation of DNA replication is 
impeded by activation of a putative 'origin activation checkpoint' and cells arrest in G1 phase. (B) 
Transformed cells do not arrest in G1 due to a defective 'origin activation checkpoint'. Instead DNA 
replication is initiated from a few licensed origins, ultimately resulting in DNA damage and apoptosis 
(Shreeram et al. 2002 and Montagnoli et al. 2004).
G2
M
G1
S
ORC
Cdt1
Cdc6Cdc7/ASK Mcm2-7
G1 arrest
IMR90
NHDF
A
B
Untransformed cells + DNA replication initiation inhibitor
Insufficient replication-competent origins
ORC
Cdt1
Cdc6Cdc7/ASK Mcm2-7
Triggering of 'origin activation checkpoint'
Transformed cells + DNA replication initiation inhibitor
Defective 'origin activation checkpoint'
DNA replication initiated 
at limited number of origins
Insufficient replication-competent origins
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Secondly, a similar difference between cancer and normal cells was also seen by 
inhibiting origin activation. Montagnoli et al. showed that inhibition of Cdc7 kinase 
by small interfering RNA in cancer cell lines caused an abortive S phase, leading to 
cell death by either p53-independent apoptosis or aberrant mitosis without eliciting a 
significant checkpoint response. However, in primary fibroblasts, a putative p53-
dependent pathway actively prevents progression through a lethal S phase in the 
absence of Cdc7 kinase (Montagnoli et al. 2004).  
 
The mechanisms of cancer cell specific death by inhibiting the replication initiation 
pathway are not clearly understood. In primary fibroblasts, inhibition of the 
replication initiation pathway which targets either pre-RC assembly or origin 
activation would cause replication fork arrest, but cells have a putative ‘origin 
activation checkpoint’ in G1 phase that monitors insufficient replication-competence 
and prevents lethal progression into S phase. By contrast, cancer cells with a deficient 
origin activation checkpoint response induce apoptosis after an abortive S phase 
(reviewed in Blow & Gillespie 2008; Swords et al. 2010). Because cancer cell-
specific killing appears to be a unique feature of the inhibition of replication initiation, 
small molecule inhibitors of the replication initiation pathway would be expected to 
induce cancer specific cell death. Since protein kinases are quite selective in their 
actions, they have become exploitable targets for small molecule inhibitors that 
directly interfere with catalytic activity through ATP-competitive ligands in the ATP-
binding site of the protein kinase (reviewed in Smyth & Collins 2009). As a member 
of the family of serine/threonine kinases, Cdc7 kinase contains conserved catalytic 
domains forming the ATP-binding site, which is a prime target for the design and 
development of selective inhibitors. 
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Furthermore, the available structural information for CDK2, including crystal 
structure data with incorporated small molecule inhibitors (Fabbro et al. 2002), may 
provide a good starting point for the development of small molecule inhibitors of 
Cdc7 kinase.  However, as shown recently, Cdc7 kinase is involved in several aspects 
of DNA metabolism, including DNA replication initiation, chromosomal segregation 
in mitosis and meiosis, and DNA damage response, suggesting that there is a 
possibility that Cdc7 inhibitors may affect somatic and germ line cell cycle 
progression and could cause toxic side effect to normal cells. Moreover, an important 
question which remains to be addressed is whether the G1 arrest observed in primary 
cells following inhibition of replication initiation is reversible. If primary cells were 
able to restart cell proliferation following removal of a replication initiation inhibitor, 
cytotoxicity would be significantly reduced. Our group has recently shown that G1 
arrest following Cdc7 knockdown in primary cells is rapidly reversible, even after 
holding cells in a G1 arrested state for days, with recovery and cell cycle progression 
occurring within hours (Rodriguez-Acebes et al, in press). These data suggest that 
normal cells are likely to arrest temporarily in G1 phase in response to Cdc7 small 
molecule inhibitor and that the arrest is reversible when the inhibitor is removed, 
which may reduce toxic side effects to normal cells. Taken together, these findings 
support the hypothesis that inhibitors of the replication initiation pathway could 
potentially provide effective anti-cancer agents for the treatment of a wide range of 
cancers. The importance of Cdc7 kinase for the viability of cancer cells and the 
reversibility of cell proliferation following removal of Cdc7 inhibition in normal cells 
suggest that Cdc7 kinase is a novel target for anti-cancer drug development 
programmes.  
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   56 
1.8. Summary and aims of thesis 
DNA replication is central to cell division, and understanding its fundamental 
mechanisms not only advances our understanding of cell proliferation, but also of 
more complicated processes such as development, differentiation and self-renewal of 
tissues (reviewed in Sclafani & Holzen 2007). The DNA replication initiation 
pathway has recently emerged as a potential target for a novel therapeutic anti-cancer 
regime. Among the factors involved in DNA replication initiation, Cdc7 has emerged 
as an exciting anti-cancer target because it is an essential kinase required for origin 
activation. Modern enzymatic assay screening platforms provide a powerful approach 
for the development of novel inhibitors. In the first part of this thesis, described in 
Chapter Three, I have focused on the generation of molecular tools, including affinity-
purified antibodies and functional Cdc7/ASK recombinant proteins that are essential 
for an investigation of the role of this kinase in the cell cycle dependent regulation of 
DNA replication in human cells. In Chapter Four, I describe a detailed expression 
analysis of the replication initiation machinery and characterize the regulation of 
Cdc7/ASK kinase activity in in vitro tissue culture model systems of cycling cells and 
in the out-of-cycle states of quiescence and differentiation. These studies were 
extrapolated into normal and cancerous human tissues to validate Cdc7/ASK kinase as 
a potential therapeutic target and to predict how normal human tissues may respond to 
an inhibitor targeting DNA replication initiation. In Chapter Five, I describe the 
development of a robust and sensitive assay for Cdc7 kinase activity and the 
generation of a homology model of the Cdc7 active site to identify specific small 
molecule inhibitors. Finally in Chapter Six, I discuss how this assay has been 
transferred into a 384-well format for automated HTS. Using HTS, Cdc7/ASK kinase 
has been screened against compound libraries for hit identification, which has been 
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taken further to hit selection/validation and a hit-to-lead development programme. 
The work presented in this thesis provides a strong rationale for targeting the DNA 
replication initiation pathway as a new therapeutic approach to cancer treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   58 
CHAPTER TWO 
Materials and methods 
2.1 General 
2.1.1.  Chemicals and reagents 
Unless otherwise indicated all chemicals were obtained from Sigma (St. Louis, MO, 
USA). All solutions were made using deionised water, except where stated, and 
sterilised either by autoclaving at 121°C or passage through a sterile filter (0.22 µm).  
All enzymes and buffers for DNA manipulation were obtained from New England 
Biolabs Inc. (Beverly, MA, USA) or the Promega Corporation (Madison, WI, USA). 
 
2.1.2.  Buffers and solutions 
4 X LAEMLLI SAMPLE BUFFER 
Tris-Cl pH 6.8    33 mM 
SDS     3.3% (w/v) 
Glycerol     30% (v/v) 
β-mercaptoethanol    17% (v/v) 
Bromophenol blue    0.02% (w/v) 
 
5 X TRIS-GLYCINE ELECTROPHORESIS BUFFER  
 Tris-base    125 mM 
 Glycine    1.25 M 
 SDS     0.5% (w/v) 
 
COOMASSIE BLUE R-250 STAINING SOLUTION 
 Methanol    50% (v/v) 
 Glacial acetic acid   10% (v/v) 
 Coomassie Blue R-250  0.25% (w/v) 
 
COOMASSIE GEL DESTAIN SOLUTION 
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 Methanol    10% (v/v) 
 Glacial acetic acid   10% (v/v) 
 
TRANSFER BUFFER 
Tris-base     0.3 M 
CAPS      10 mM 
SDS      0.02% (w/v) 
Methanol    10% (v/v) 
 
GEL LOADING BUFFER  
 Glycerol     10% (v/v) 
 Bromophenol blue   0.025% (w/v) 
 
TE BUFFER 
 Tris-HCl pH 8.0   10 mM 
 EDTA pH 8.0    1 mM 
 
DNA EXTRACTION BUFFER 
 Na2Co3                     100 mM 
NaCl       170 mM 
EDTA pH 10.9   10 mM 
 
RIPA BUFFER 
Tris-Cl pH 7.4    50 mM 
NaCl       150 mM 
NP40      1% (v/v) 
Sodium deoxycholate    1% (v/v) 
SDS      0.1% (w/v) 
EDTA      1 mM 
 
IMMUNOPRECIPITATION BUFFER 
Tris-Cl pH 8.0       50 mM 
NaCl       150 mM 
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EDTA      5 mM 
NP40      0.5% (v/v) 
 
LYSIS BUFFER FOR BACULOVIRAL-EXPRESSED RECOMBINANT PROTEIN 
Tris-Cl pH 9.0       25 mM 
KCl       250 mM 
NP40      0.5% (v/v) 
Glycerol     10% (v/v) 
MgCl2     10 mM 
 
WASH BUFFER FOR BACULOVIRAL-EXPRESSED RECOMBINANT PROTEIN  
Tris-Cl pH 9.0       25 mM 
KCl       250 mM 
NP40      0.5% (v/v) 
Glycerol     10% (v/v) 
MgCl2     10 mM 
Imidazole      5 mM  
 
ELUTION BUFFER FOR BACULOVIRAL-EXPRESSED RECOMBINANT PROTEIN  
Tris-Cl pH 9.0       25 mM 
KCl       250 mM 
NP40      0.5% (v/v) 
Glycerol     10% (v/v) 
MgCl2     10 mM 
Imidazole      250 mM  
 
LYSIS BUFFER FOR BACTERIAL-EXPRESSED RECOMBINANT PROTEIN 
Tris-Cl pH 7.5    25 mM 
NaCl       250 mM 
Glycerol     10% (v/v) 
 
DENATURE BUFFER FOR BACTERIAL-EXPRESSED ASK FRAGMENT 
Tris-Cl pH 7.5    25 mM 
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KCl       500 mM 
Triton X-100     2% (v/v) 
Urea                  6M 
 
RENATURE BUFFER FOR BACTERIAL-EXPRESSED ASK FRAGMENT 
Tris-Cl pH 7.5    25 mM 
NaCl       250 mM 
Glycerol     10% (v/v) 
Imidazole      20 mM 
 
WASH BUFFER FOR BACTERIAL-EXPRESSED RECOMBINANT PROTEIN 
Tris-Cl pH 7.5    25 mM 
NaCl       250 mM 
Glycerol     10% (v/v) 
Imidazole      5 mM 
 
ELUTION BUFFER FOR BACTERIAL-EXPRESSED RECOMBINANT PROTEIN  
Tris-Cl pH 7.5    25 mM 
NaCl       250 mM 
Glycerol     10% (v/v) 
Imidazole      250 mM 
 
IN VITRO KINASE ASSAY BUFFER 
Tris-Cl pH 7.5       50 mM 
MgCl2     10 mM 
Dithiothreitol    1 mM 
ATP      0.1 mM 
 
ANTIBODY-BASED KINASE REACTION BUFFER FOR 96-WELL FORMAT 
Tris-Cl pH 7.5       50 mM 
MgCl2     10 mM 
Dithiothreitol    1 mM 
ATP      0.1 mM 
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KINASE REACTION BUFFER FOR HTS 
Tris-Cl pH 8.5       50 mM 
MgCl2     10 mM 
Dithiothreitol    1 mM 
 
WASH BUFFER FOR HTS 
Tris-Cl pH 8        25 mM 
NaCl       150 mM 
Tween 20     0.05% (v/v) 
 
DEVELOPMENT BUFFER FOR HTS 
Diethanolamine pH 9.8      1M 
MgCl2     0.5 mM 
PNPP (p-Nitrophenyl Phosphate)       4.5 mM  
 
2.1.3.  Culture media 
All growth media were sterilised by autoclaving at 121ºC for 20 min, and media 
recipes are for 1 litre.  
 
LB BROTH [AGAR] 
 Tryptone    10 g  
 Yeast extract    5 g 
 NaCl     10 g 
 [Bacteriological (No1) agar]  15 g 
 pH 7.0 
 
2 X TY BROTH [AGAR] 
 Tryptone    16 g 
 Yeast extract    10 g 
 NaCl     5 g 
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 [Bacteriological (No1) agar]  15 g 
 pH 7.0 
 
NZY 
 N-Z-amine AS   10 g 
Yeast extract    5 g 
NaCl     5 g 
 
SOC MEDIUM 
 Tryptone    2% (w/v) 
 Yeast extract     0.5% (w/v) 
 NaCl     10 mM 
 KCl     2.5 mM 
 MgCl2.6H20    10 mM 
 MgSO4    10 mM 
 Glucose    20 mM 
 pH 7.4 
 
2.2.  Molecular biology techniques 
2.2.1.  Bacterial strains 
Genetic manipulations and expression of recombinant proteins were carried out in the 
following strains of Escherichia coli (Table 2.1.):  
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Table 2.1. Bacterial strains 
Bacterial 
Strain 
Antibiotic 
resistance 
Partial 
genotype 
Application Supplier
Top10 - F-recA1 endA1 DNA cloning Invitrogen 
XL1-Blue Tetracycline  F’proAB lac1q Z∆M15 
Tn10 (TetR) 
Site-directed mutagenesis Stratagene
Rosetta 
(DE3) 
pLysS 
Chloramphenicol F-ompTdcm lacY1 
(DE3) pLysS pRARE 
(CamR) 
Expression of His-
hsMcm2 (1-154) 
Stratagene
Rosetta2 
(DE3) 
pLysS 
Chloramphenicol F--ompT hsdSB(rB- mB-) 
gal dcm (DE3) 
pLysSRARE2 (CamR) 
Expression of His-ASK 
(271-674) 
Novagen  
DH10Bac Ampicillin F– mcrA Δ(mrr-
hsdRMS-mcrBC) 
Φ80lacZΔM15 
ΔlacX74 recA1 endA1 
araD139 Δ(ara leu) 
7697 galU galK λ– 
rpsL nupG/ 
pMON14272/pMON71
24 
Generation of Bacmid Invitrogen 
 
2.2.2.  Transformation of E. coli 
50 µl aliquots of chemically competent cells were thawed on ice. Purified plasmid 
DNA (1 – 100 ng) was added, mixed gently and incubated on ice for 5 min. Cells 
were heat-shocked in a pre-heated water bath at 42°C for 1 min and chilled on ice for 
2 min. Cells were resuspended in 250 µl of SOC medium, except for XL1-Blue cells 
where NZY+ broth was used, allowed to recover at 37°C for 1 h with gentle shaking 
and spread over LB agar plates containing the appropriate selection marker(s). Plates 
were incubated overnight at 37°C. 
 
2.2.3.  Plasmid isolation 
3-5 ml of LB medium was inoculated with a single bacterial colony and cultures 
grown overnight at 37°C with shaking at 200 r.p.m. Plasmid DNA was isolated using 
the QIAprep spin miniprep kit (Qiagen GmbH, Hilden, Germany) following the 
manufacturer’s protocol and stored in TE buffer at -20°C.  
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2.2.4.  Restriction endonuclease digestion 
Digestion of DNA was carried out according to the manufacturer’s protocol for the 
particular restriction endonuclease enzyme. Typically, 50 to 500 ng of DNA was 
digested in a reaction volume of 20 µl containing 10 U of restriction endonuclease for 
1 h at 37°C. 
 
2.2.5.  Dephosphorylation of linearised vector DNA 
Linearised vector DNA was incubated with calf intestinal phosphatase (0.5 U/µg 
vector DNA) for 30 min at 37°C for dephosphorylation of blunt, 3’- or 5’-
overhanging ends. 
 
2.2.6.  Ligation of DNA 
Ligation of insert DNA into plasmid was performed using T4 DNA ligase (Promega, 
Madison, WI, USA). Reactions containing a 3:1 molar excess of insert to vector, 10 U 
of T4 DNA ligase and 2 x rapid ligation buffer (Promega) in a final volume of 20 µl 
were incubated for 2 h at RT. 5 µl of the reaction mix was transformed into 
chemically competent E. coli. 
 
2.2.7.  Polymerase chain reaction 
For cloning PCR products, the 3’-5’ exonuclease proof-reading Pfu-ultra DNA 
polymerase (Stratagene, La Jolla, CA, USA) was used to amplify the template. 1-10 
ng of template DNA was mixed in a final reaction volume of 50 µl containing 180 
ng/µl of each oligonucleotide primer, 200 µM dNTPs, 10% 10x DNA polymerase 
buffer and 2.5 U DNA polymerase (2.5 U/µl). Thermocycling was initiated by 
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denaturation of the template at 95°C for 2 min, then 30 cycles of template 
denaturation at 95°C for 1 min, primer annealing at 55°C for 2 min and DNA 
extension at 72°C for 3 min. Cycling was completed by a final extension at 72°C for 7 
min. Blunt-end PCR products were cloned into a pGEM-T Easy vector (Invitrogen, 
Carlsbad, CA, USA), amplified, and subcloned into a pFastBac baculovirus 
expression vector (Invitrogen). Primer sequences for amplification of His-Cdc7 and 
His-ASK are 5’-GCTAGCATGGCAGATAATAAAGCTCCC-3’ (forward nhe1 
primer) and 3’-CAATTGTTACACAGACCACGGGTGG-5’ (reverse mfe1 primer).  
 
2.2.8.  Site-directed mutagenesis 
Site-directed mutagenesis was performed using the QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s protocol. Briefly, 
reactions were set up containing 5 µl 10x reaction buffer, 100 ng dsDNA template, 
125 ng of appropriate forward and reverse primers, 1 µl dNTP mix, 3 µl QuikSolution 
and DNase/RNase free dH20 to a final volume of 50 µl. One µl PfuTurbo DNA 
polymerase (2.5 U/µL) was added to each tube and the reactions cycled using the 
parameters outlined in Table 2.2. Following temperature cycling, the reactions were 
cooled on ice for 2 min and parental supercoiled dsDNA digested by incubation with 
1 µl Dpn I (10 U/µl) for 1 h at 37°C.  
Table 2.2. Cycling parameters for QuikChange Site-Directed Mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 1 min 
2 25 95°C 50 s 
60°C 55 s 
68°C 7 min 
3 1 68°C 7 min 
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To generate the Cdc7 kinase negative mutants, including pFastBac-D196A (Asp-196 
replaced by Ala), pFastBac- D177A (Asp-177 replaced by Ala) and pFastBac-K90A 
(Lys-90 replaced by Ala), mutagenesis was conducted on the Cdc7 sequences in the 
pFastBac vector. Oligonucleotides using the mutagenesis outlined in Table 2.3. 
Table 2.3. Oligonucleotides for Cdc7 kinase negative mutants 
template oligonucleotides 
pFastBac-D196A 5’-GAAAAAGTATGCCTTGGTAGCCTTTGGTTTGGCCCAAGG-3’ 
5’-CCTTGGGCCAAACCAAAGGCTACCAAGGCATACTTTTTC-3’ 
pFastBac-D177A 5’-GGTATTGTTCACCGTGCTGTTAAGCCCAGCAAT-3’ 
5’-ATTGCTGGGCTTAACAGCACGGTGAACAATACC-3’ 
pFastBac-K90A 5’-CCTGAAGAGAAAATTGCTCTAGCACACTTGATTCCAACAAGTC-3’ 
5’-GACTTGTTGGAATCAAGTGTGCTAGAGCAATTTTCTCTTCAGG-3’ 
 
 
2.2.9.  Agarose gel electrophoresis 
Horizontal gels were cast with agarose concentrations ranging from 0.8 to 1.0% (w/v). 
Solid agarose was mixed with 1 x TAE buffer and heated in a microwave until the 
agarose had fully dissolved. The solution was cooled to about 50ºC and 0.075% (v/v) 
gel star (Cambrex Bio Science Rockland Inc., Maine, ME, USA), was added. The gel 
was poured into a gel try, with combs inserted for casting wells, and allowed to set for 
30 min at RT. Samples were prepared for electrophoresis by mixing with 6 x gel 
loading buffer. Electrophoresis was carried out at 1 – 4 V/cm for 30 min. After 
electrophoresis DNA was visualised at 312 nm. 
 
2.2.10. Recovery of DNA from agarose gels 
DNA fragments were cut from agarose gels using a sterile scalpel. The DNA was 
recovered from the excised gel using the QiaEXII gel extraction kit (Qiagen GmbH) 
following the manufacturer’s protocol. 
 
2.2.11. DNA sequencing  
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DNA sequencing was carried out by the Wolfson Institute for Biomedical Research 
Scientific Support Services, UCL, London, UK (http://www.ucl.ac.uk/wibr/services/ 
dna/index.html). DNA was sequenced at a concentration of 500 ng/µl and purity of ≥ 
1.8 OD260/OD280 ratio on a Beckman Coulter CEG 8000 DNA Sequencer.  
 
2.3.  Recombinant baculovirus methods 
2.3.1.  Cell lines and viruses 
Sf9 insect cells (ATCC, Manassas, Va.) were maintained at 27ºC in serum-
supplemented TMN-FH medium (BD Biosciences, San Jose, CA, USA) containing 
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco-BRL, Invitrogen). Routine 
cell culture maintenance and virus infection procedures were carried out as described 
previously (Jarvis 2009). 
 
2.3.2.  Viral DNA isolation 
Viral DNA was isolated from supernatants of virus infected cells. 25ml of cell 
supernatants were centrifuged at 15000 r.p.m. for 5 min to pellet viral particles. 
Particles were resuspended in DNA extract buffer (0.1M Na2CO3, 0.17M NaCl, 
0.01M EDTA pH 10.9), and incubated overnight at 37°C with proteinase K and 1% 
SDS. DNA was isolated after a further extraction with phenol and chloroform: 
isoamyl alcohol and ethanol precipitation and stored in TE buffer at 4°C.  
 
2.3.3.  Generation of recombinant baculovirus  
Baculoviruses expressing Cdc7, ASK and mutant Cdc7 were generated according to 
the Bac-to-Bac system (Invitrogen). As described above the CDC7 and ASK coding 
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sequences were amplified and were separately cloned into the pFasbac vector 
following the manufacturer’s protocol (Invitrogen). Bacmids containing the CDC7 
and ASK open reading frames were generated in DH10Bac E. coli cells and 
transfected into Sf9 cells according to the manufacturer’s protocol (Invitrogen). After 
confirmation of high-level Cdc7 and ASK protein expression, the supernatant 
containing the recombinant virus was amplified over three rounds, and used for 
protein production.  
 
2.3.4.  Plaque Assay 
Plaque assay (Jarvis 2009) was used to visualize and purify the recombinant virus. 
Dilutions of virus containing supernatant were incubated with Sf9 cells (2 x 106) 
attached to a cell culture dish for an hour and replaced with medium containing 0.5% 
agarose (Invitrogen) that forms a semisolid overlay. After incubation for 5-7 days at 
27°C, the plates were examined for plaques under an inverted microscope.  
 
2.3.5.  Virus titeration 
Dilution of 10-5, 10-6, 10-7, 10-8 of the virus stock are infected with Sf9 cells seeded 
into a 96 well plate. After incubation for 5 days at 27°C, virus stocks were tittered by 
the number of infected and uninfected wells at all dilution. The titer was represented 
as plaque forming units (PFU) per millilitre.  
 
2.4. Protein chemistry methods 
2.4.1.  Protein expression constructs 
The following constructs were used for protein expression (Table 2.4): 
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Table 2.4. Protein expression constructs 
Protein Construct Insert 
Size 
Cloning 
fragment 
Expression 
system 
His-Cdc7 pFastBacB-Cdc7 1.7kbp Nco1-XhoI Baculoviral  
His-Cdc7(D196A) pFastBacB-Cdc7(D196A) 1.7kbp Nco1-XhoI Baculoviral  
His-Cdc7(D177A) pFastBacB-Cdc7(D177A) 1.7kbp Nco1-XhoI Baculoviral 
His-Cdc7(K90A) pFastBacB-Cdc7(K90A) 1.7kbp Nco1-XhoI  Baculoviral  
His-ASK pFastBacA-ASK 2.0kbp EcoRI – XhoI Baculoviral 
His-ASK (271-674) pProEX-HTa-ASK(271-674) 1.2kbp XhoI– EcoRI E. coli 
His-hsMcm2 (1-154) PProEX-HT2-Mcm2(1-154) 0.5kbp BamHI–HindIII  E. coli 
 
2.4.2.  Expression of recombinant human Cdc7, ASK and mutant Cdc7 in Sf9 
insect cells 
Sf9 insect cells were grown in 400 ml of serum-supplemented TMN-FH medium 
containing 100 U/ml penicillin and 100 µg/ml streptomycin in square dish (245 x 245 
x 25 mm, Corning Costar) at 27ºC up to a density of 1.5 x 106 cells/ml. cells were 
infected with the appropriate recombinant baculovirus at 5 M.O.I., and incubated for 
72 h at 27ºC. Insect cells were harvested by centrifugation at 5,000 g for 5 min at 4ºC, 
washed in PBS and stored at -80ºC. 
 
2.4.3.  Expression of recombinant human Cdc7/ASK kinase complex in Sf9 
insect cells 
Sf9 insect cells were grown in 400 ml of serum-supplemented TMN-FH medium 
containing 100 U/ml penicillin and 100 µg/ml streptomycin in square dish (245 x 245 
x 25 mm, Corning Costar) at 27ºC. Cells were co-infected with the Cdc7 and ASK 
recombinant baculoviruses at a multiplicity of infection of 5 and 10 for each 
recombinant baculovirus respectively and incubated for 72 h at 27ºC with gentle 
mixing. Infected cells were harvested by centrifugation at 5,000 g for 5 min at 4ºC, 
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washed in PBS and stored at -80ºC. 
 
2.4.4.  Purification of baculoviral-expressed human Cdc7, ASK, mutant Cdc7 
and Cdc7/ASK kinase complex 
Infected cells were harvested 72h post-infection, washed in PBS and lysed in lysis 
buffer (25 mM Tris-HCl pH 9, 250 mM KCl, 0.5% NP 40, 10% glycerol, 10 mM 
MgCl2 and 0.02 volumes of complete EDTA-free Protease inhibitor cocktail) on ice 
for 30 min. Lysates were cleared by spinning at 13,000rpm for 1h at 4°C and loaded 
on to a 5 ml HiTrap chelating HP column (Amersham Biosciences AB, Uppsala, 
Sweden). The column was washed with five column volumes of wash buffer (25 mM 
Tris-HCl pH 9, 250 mM KCl, 0.5% NP 40, 10% glycerol, 10 mM MgCl2 and 5 mM 
Imidazole) prior to elution. Recombinant proteins were eluted with a step gradient of 
10%, 20%, 40% and 100% elution buffer (25 mM Tris-HCl pH 9, 250 mM KCl, 0.5% 
NP 40, 10% glycerol, 10 mM MgCl2 and 250 mM Imidazole) using an Acta FPLC 
system (Amersham Biosciences AB, Uppsala, Sweden) (Figure 3.4, 3.5, and 3.6). 
Proteins were dialysed by passing through a HiPrep 26/10 desalting column 
(Amersham Biosciences AB), and concentrated using a Vivaspin concentrator 
(Sartorius AG, Goettingen, Germany). 
 
2.4.5.  Expression of recombinant ASK (271-674) fragment in E. coli  
ASK (C-terminal 403 amino acids) fragment was amplified from pFastBacA-ASK 
vector by PCR using a primer complementary to the 5’ region of 271 amino acid 
residues of ASK: 5’-AGAATCCAAACAGATGGC-3’ and a primer complementary 
to the 3’ region of 674 amino acid residues of ASK: 5’-ACATTTACTGGCTTTTAG-
3’. The PCR product was cloned into pProEX-HTa expression vector. ASK fragment 
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(271-674) was expressed in Rosetta2 (DE3) plysS cells (Novagen, Madison, WI, 
USA) according to standard protocols. Briefly, cells were transformed with the 
appropriate expression construct and grown overnight at 37ºC with vigorous shaking 
in 20 ml of 2 x TY medium containing 100 µg/ml ampicillin, 34 µg/ml 
chloramphenicol and 1% glucose. The overnight culture was used to inoculate 4 x 500 
ml of fresh 2 x TY medium, supplemented with 100 µg/ml ampicillin, 34 µg/ml 
chloramphenicol and 0.25% glucose. Cultures were grown at 30ºC with vigorous 
shaking until the OD600 reached 0.5.cells and collected from the incubation for 3 hrs at 
30ºC after 1mM IPTG induction. Cells were harvested by centrifugation at 5,000 g for 
20 min, washed in ice cold PBS, the wet weight of cells determined and the pellet 
frozen at -80ºC. 
 
2.4.6.  Purification of bacterial-expressed ASK (271-674) fragment  
Bacterial cell pellets were resuspended in 5 ml of lysis buffer (25 mM Tris-HCl pH 
7.5, 250 mM NaCl, 10% glycerol and 0.02 volumes of complete EDTA-free Protease 
inhibitor cocktail) per gram wet weight, containing bensonase (1 µl/ml), and 
incubated for 30 min at 4ºC. The cells were broken by sonication and the lysate 
cleared by centrifugation at 48,000 g at 4ºC for 1 h. The insoluble fractions were 
resuspended in denature beffer (25 mM Tris-HCl pH 7.5, 500 mM KCl, 2% Triton X-
100 and 6M urea), and incubated with gentle end-over-end inversion for 20 mins at 
room temperature. The suspension was centrifuged at 13000 x g for 10 mins, and the 
supernatants containing solubilised proteins in denature buffer were loaded onto 
HiTRAP chelating IMAC column (Amersham Biosciences). The protein bound to the 
column was renatured for 3 hours by a linear gradient to renature buffer (25 mM Tris-
HCl pH 7.5, 250 mM NaCl, 10% glycerol, and 20Mm imidazole). After renaturation, 
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protein was eluted from the column using a step gradient of 10%, 20%, 40% and 
100% elution buffer (25 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol, and 250 
mM imidazole) (Figure 3.8B). Protein was dialysed by passing through a HiPrep 
26/10 desalting column (Amersham Biosciences AB), and concentrated using a 
Vivaspin concentrator (Sartorius AG, Goettingen, Germany). 
 
2.4.7.  Expression of recombinant human Mcm2 (1-154) fragment in E. coli 
The human Mcm2 (N-terminal 154 amino acids) fragment was amplified from a HeLa 
cDNA library by PCR using a primer complementary to the 5’ region of Human 
Mcm2 containing a restriction site for HindIII: 5’-TGCCCGCAAGCGCCGCCA 
GGTGTAAGCTT-3’ and a primer complementary to the 3’ region of 154 amino acid 
residues of Mcm2: 5’-AAGCTTACACCTGGCGGCGCTTGCGGGCA-3’. The PCR 
product was cloned into the pET100d TOPO cloning vector (Invitrogen, Carlsbad, CA, 
USA) and subcloned into BamHI-HindIII sites of pProEX-HT2 expression vector. 
Mcm2 fragment was expressed in Rosetta (DE3) plysS cells (Stratagene, La Jolla, CA, 
USA) according to standard protocols. Cells were transformed with the appropriate 
expression construct and grown overnight at 37ºC with vigorous shaking in 20 ml of 2 
x TY medium containing 100 µg/ml ampicillin, 34 µg/ml chloramphenicol and 1% 
glucose. The overnight culture was used to inoculate 4 x 500 ml of fresh 2 x TY 
medium, supplemented with 100 µg/ml ampicillin, 34 µg/ml chloramphenicol and 
0.25% glucose. Cultures were grown at 30ºC with vigorous shaking until the OD600 
reached 0.5.cells and collected from the incubation for 3 hrs at 30ºC after 1mM IPTG 
induction. Cells were harvested by centrifugation at 5,000 g for 20 min, washed in ice 
cold PBS, the wet weight of cells determined and the pellet frozen at -80ºC. 
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2.4.8.  Purification of bacterial-expressed human Mcm2 (1-154) fragment  
For purification, cell pellets were resuspended in 5 ml Bugbuster protein extraction 
buffer (Novagen, Madison, WI, USA) per gram wet weight, containing bensonase (1 
µl/ml) and 0.02 volumes of complete EDTA-free Protease Inhibitor Cocktail (F. 
Hoffmann-La Roche, Basel, Switzerland), and incubated for 30 min at 4ºC. The cells 
were broken by sonication and the cell lysate was clarified by centrifugation at 48,000 
g at 4ºC for 1 h, and the supernatant filtered through a 0.45 µm syringe filter. Cell 
lysate was loaded via a peristaltic pump on to a 5 ml HiTrap HP column (Amersham 
Biosciences) and protein was eluted with step gradients of 10%, 20% and 100% 
elution buffer (25 mM Tris-HCl pH 7.5, 250 mM NaCl, 10 % glycerol and 250 mM 
Imidazole). Protein was further purified using a Seperdex 200 Gel filtration column 
(Amersham Biosciences AB), and concentrated to 1 mg/ml using a Vivaspin 
concentrator (Sartorius AG, Goettingen, Germany). 
 
2.4.9.  SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using pre-cast 
Novex 4-20% Tris-glycine gels and the XCell SureLockTM Mini-Cell Electrophoresis 
System (Invitrogen). Prior to loading, protein samples were mixed with 4x laemlli 
buffer, heated to 90°C for 3 min, and pulse centrifuged. Samples were resolved in 1x 
Tris-glycine running buffer at 125 mV for approximately 90 min. After 
electrophoresis, gels were stained with Coomassie Blue R-250 or immunoblotted.  
 
2.4.10. Coomassie Blue staining of SDS-PAGE gels 
For visualisation of recombinant protein, SDS-PAGE gels were stained with 
Coomassie Blue R-250 for 1-2 h with gentle shaking. The gels were destained with 
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Coomassie gel destain solution, with gentle shaking, until the background was 
colourless.  
 
2.5    Immunological techniques 
2.5.1.  Antibodies 
Affinity-purified rabbit polyclonal antibodies against hsgeminin (Wharton et al., 
2004), hsCdt1 (Kingsbury 2005), hsCdc45 and ASK (#SK3681) were generated in-
house. The following commercially supplied antibodies were used: mouse anti-
hsOrc4 (BD Transduction Laboratories, Lexington, KY, USA), mouse anti-
hsMcm2/BM28 (BD Transduction Laboratories), mouse anti-hsCdc6 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), mouse anti-Cdc7 (MBL, Nagoya Japan), 
rabbit phospho-Mcm2 S40/41 (Bethyl, Montgomery, USA), rabbit phospho-Mcm2 
S53 (Bethyl), rabbit anti-Cyclin A (Santa Cruz Biotechnology), mouse anti-Cyclin E 
(Oncogen), mouse anti-His6 (BD Transduction Laboratories), mouse anti- Actin 
(Sigma), HRP-conjugated goat anti-mouse/rabbit IgG (Dako), FITC-conjugated 
mouse anti-CD11B (Beckman Coulter, Miami, FL), RD1-conjugated mouse anti-
CD14 (Beckman Coulter), FITC-conjugated mouse anti-BrdU (Alexis Biochemicals, 
Lausen, Switzerland).  
 
2.5.2.  Preparation of whole cell extracts 
To prepare whole cell extracts, cells were harvested by treatment with trypsin, washed 
in PBS, and resuspended in RIPA buffer (50mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP40, 1% Sodium deoxycholate, 0.1% SDS, 1mM EDTA) containing EDTA-free 
protease inhibitor cocktail (Roche Diagnostics GmbH). After incubation on ice for 30 
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min, the lysate was clarified by centrifugation at 13.000 x g for 15 min at 4°C, and 
stored at -80ºC.  
 
2.5.3.  Immunoblotting 
For immunoblotting, protein was transferred from polyacrylamide gels onto 
nitrocellulose membranes (Amersham Biosciences) by semi-dry electroblotting in 
transfer buffer. Non-specific binding was blocked by incubating the membrane in 
PBS, 5% skimmed milk powder, 0.1% Tween-20 overnight at 4ºC. Membranes were 
incubated in primary antibody in PBS, 5% skimmed milk powder, 0.1% Tween-20 for 
2 h at room temperature, except for some polyclonal antibodies for which PBS, 10% 
skimmed milk powder, 1% Tween-20 was used, followed by six 5 min washes in PBS, 
0.1% Tween-20. Membranes were then incubated with the appropriate secondary 
antibody in PBS/milk/Tween-20 as before for 1 h at room temperature followed by six 
5 min washes prior to visualisation. Immunoreactive bands were visualised on 
Hyperfilm ECL (Amersham Biosciences) by enhanced chemiluminescence (ECL, 
Amersham Biosciences). 
 
2.5.4. Immunoprecipitation 
Total cell lysate was immunoprecipitated with Cdc7 antibody in IP buffer (50 mM 
Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% NP40) containing EDTA-free 
protease inhibitor cocktail for 3h at 4°C. Protein A-Sepharose (Amersham 
Biosciences) was added to cell extract and incubated for 30 min at 4°C. The beads 
were extensively washed three times with IP buffer, incubate with 3 x SDS sample 
buffer and resolved by electrophresis.  
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2.5.5.  Immunohistochemistry 
Three µm sections of formalin-fixed, paraffin-embedded tissues were cut onto DAKO 
Techmate S2024 slides, baked in a 60°C oven overnight to maximise section 
adhesion, dewaxed in xylene and rehydrated through a series of alcohol to water. For 
antigen retrieval, tissues were pressure-cooked for 2 min in 0.1 M Citrate Buffer pH 
6.0. Immunostaining was performed manually using a standard protocol. After antigen 
retrieval, slides were washed twice in TBS, 0.1% Tween and endogenous peroxidase 
activity was quenched with peroxidase blocking solution (DAKO) for 10 min. 
Primary antibodies were applied for 1 h at RT, and detected with a biotin-free 
polymer-based detection system (ChemMate DAKO EnVision). Sections were 
incubated with peroxidase-labelled secondary antibody for 1 h at RT, and the 
immunostain developed with 3,3-diaminobenzidine tetrahydrochloride (DAB) for 10 
min.  Sections were counterstained in Mayer’s Haematoxylin, differentiated in 1% 
acid alcohol, dehydrated, cleared in xylene and coverslips applied using Leica CV 
Mount (Leica, Nussloch, Germany). Primary antibodies were omitted in negative 
controls and appropriate tissue sections were used as positive and negative controls. 
 
2.6.  Cell biology techniques 
2.6.1.  Cell culture and synchronisation 
Hela S3 (CCL-2.2, ATCC®) and WI-38 (CCL-75, ATCC®, LGC Promochem, 
Middlesex, UK) cells were grown in Dulbecco’s modified Eagle’s medium (Gibco-
BRL) supplemented with 10% foetal calf serum (FCS, Gibco-BRL), 100 U/ml 
penicillin and 0.1 mg/ml streptomycin. HL60 (CCL-240, ATCC®) cells were grown in 
RPMI 1640 medium (Gibco-BRL, Paisley, Scotland) supplemented with 10% fetal 
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calf serum (FCS; Gibco-BRL), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Gibco-BRL). Cell cycle synchronisation was performed essentially as described 
(Krude et al., 1997). Briefly, for preparation of cycling cells, HeLa S3 cells were 
synchronised in very early S phase by two sequential 25 h blocks in 2.5 mM 
thymidine separated by a 12 h interval without thymidine (Rao and Johnson, 1970), 
followed by release into fresh culture medium for 2 h. For preparation of cells in 
G2/M phase, cells were released from the second thymidine block for 3 h, followed 
by adding 40 ng/ml nocodazole for an additional 12 h to arrest them in mitosis 
(Johnson et al., 1993), followed by release into fresh culture medium for 2 h. To 
prepare cells in quiescent state, WI-38 cells were driven into quiescence by density-
dependent growth arrest and after five days were released back into cycle by 
subculturing 1 in 4 into fresh growth medium. For differentiation experiments, HL60 
cells were seeded at 1-1.5 x 105 cells/ml 24 h before addition of 1,25 
dihydroxyvitamin D3 (1,25 Vit D3) (Sigma-Aldrich, Dorset, UK). 1,25 Vit D3 was 
diluted in medium from an ethanol stock at 1 mM to a final concentration of 100 nM. 
In experiments the medium containing 1,25 Vit D3 or ethanol was changed every 48 h. 
 
2.6.2.  Bivariate flow cytometric analysis 
For cell cycle analysis of DNA content, DNA was stained by incubating cells in PBS 
containing 20 µg/ml propidium iodide and 50 µg/ml RNase A for 20 min at RT in the 
dark. For cell cycle analysis of bromodeoxyuridine (BrdU) incorporation, cells were 
pulse labelled with BrdU for 1 h and cell samples fixed in 80% ethanol for a 
minimum of 12 h. After fixation, cells were washed in PBS and DNA was denatured 
by incubation in 4 N HCl for 20 min. Subsequently cells were washed twice in PBS, 
incubated for 1 h with a FITC-conjugated BrdU antibody (1:50 dilution; Alexis 
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Biochemicals) in the dark at 4ºC and cells were resuspened in 0.5 ml PBS at room 
temperature. To prevent clumping of cells and loss of sample, 100 µl of 1% BSA was 
added at each step and unautoclaved pipette tips were used. Analyses of light-scatter 
properties and DNA/BrdU incorporation were performed using a FACSCalibur flow 
cytometer (BD Biosciences) (Figure 4.2, 4.4, 4.7 and 6.7). Cell doublets were 
excluded by gating on a dot plot of the width vs the area of DNA fluorescence 
intensity (Erlanson and Landberg, 1998). In most samples, 104 cells were examined 
and data were analysed using CellQuestTM software (BD Biosciences) and WinMDI (V 
2.8).  
 
2.6.3. Monitoring differentiation 
HL60 cell differentiation was monitored as described (Barkley et al., 2007). During 
differentiation time courses, 1 x 106 HL60 cells were harvested at the indicated times, 
washed twice with PBS, and incubated for 45 min at room temperature in the dark in 
0.5 µg of FITC-conjugated mouse anti-CD11B and/or 0.5 µg of RD1-conjugated 
mouse anti-CD14 (Beckman Coulter, Miami, FL). Cells were washed three times with 
PBS and re-suspended in 0.5 ml PBS. Flow cytometric analyses were performed on 
cells which were singly stained (CD11b-FITC or CD14-RD1) and on cells dually 
stained (CD11b-FITC and CD14-RD1) (Figure 4.6).  
 
2.6.4. Assaying for apoptosis 
Apoptosis was quantified using the Annexin V-FITC Apoptosis Detection Kit 
(BioVision, USA), following the manufacturer’s protocol. 1 x 106 cells were stained 
with 5 l of propidium iodide and/or 5 l of Annexin-V FITC in 1 x binding buffer, 
and analysed by flow cytometry (Figure 6.8).  
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2.6.5.  Tissue specimens 
Formalin-fixed, paraffin-embedded archival human oral squamous epithelium and 
liver tissue blocks from diagnostic biopsy or resection specimens were retrieved from 
the archives of the Department of Pathology, University College London, U.K. Slides 
were examined with an Olympus BX51 microscope/CCD camera setup and scanned 
at low magnification to identify areas of high expression for each marker. Three to 
five fields were captured from selected areas at x400 magnification and processed 
using ANAlysis software (SIS, Münster, Germany). Captured images were printed 
and within fields a labelling index was determined for a minimum of 300 cells.  
 
2.7. Kinase Assay Development 
2.7.1.  In vitro kinase assay 
The standard reaction mixtures (25 l) for Cdc7/ASK in vitro kinase assays contained 
50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.1 mM ATP, 1 g of Mcm2 N-
terminal fragment and 50 ng of Cdc7/ASK kinase complex. The reaction mixtures 
were incubated at 30°C for 40 min. After addition of SDS-PAGE sample buffer, the 
reaction mixtures were incubated at 90°C for 3 minutes and loaded on 4-20% gradient 
SDS-PAGE. The reaction products were immunoblotted as described. 
 
2.7.2.  Antibody-based Kinase assay (96-well format) 
HisGrab 96-well plates (Pierce, Rockford, IL, USA) were coated with 1 g of His-
Mcm2 N-terminal fragment in 100 l TBS (Pierce, Rockford, IL, USA) at room 
temperature for 1h with shaking. The plates were washed three times with wash buffer 
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(TBS contained 0.05 % Tween20), blocked with blocking solution (Pierce, Rockford, 
IL, USA) for 1h and washed three times with wash buffer. The kinase reaction was 
started by adding Cdc7/ASK complex in a total volume of 50 l that contained 50 
mM Tris-Hcl pH 7.5, 10 mM MgCl2, 1 mM DTT and 0.1 mM ATP. After incubation 
for 45 minutes at room temperature, the plates were washed three times with wash 
buffer and incubated with 100 l of Phospho Mcm2 antibody (A300-117A, Bethyl, 
Montgomery, TX, USA) in TBS for 1h. Plates were then washed three times with 
wash buffer and incubated with a anti-rabbit immuno-globulins/AP (Dako, Glostrup, 
Denmark) for 1h. P-nitrophenyl phosphate (PNPP) substrate (Sigma, St. Louis, MO, 
USA) solution was added and incubated for 20 min at room temperature for colour 
development. The reaction was stopped by adding 2N NaOH solution and the signal 
was measured at 405nm by a Spectramax plus (PO2877, Molecular Devices). 
 
2.7.3.  High-Throughput Screen for Cdc7 inhibitors (384-well format) 
Assays were performed in a final volume of 20 l/well in 384-well Immobilizer 
Nikel-chelate microplates (Nunc) using automated HTS workstation (Figure 6.1). 
Plates were coated with 250 ng of His-Mcm2 N-terminal fragment in 20l TBS at 
room temperature for 1h with shaking. The plates were washed three times with 80 l 
wash buffer (25 mM Tris-Hcl pH 8, 150 mM NaCl and 0.05 % Tween20). Prior to 
kinase reaction, 2 l of test compounds were added to wells to give 30 M. The 
kinase reaction was started by adding Cdc7/ASK complex in reaction buffer (50 mM 
Tris-Hcl pH 8.5, 10 mM MgCl2, 1 mM DTT) with 0.2 M of ATP. After incubation 
for 60 min at room temperature, the plates were washed, and incubated with 20 l of 
Phospho Mcm2 antibody (A300-117A, Bethyl, Montgomery, TX, USA) and a anti-
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rabbit immuno-globulins/AP (Dako, Glostrup, Denmark) in TBS for 30 min. PNPP 
development (Sigma, St. Louis, MO, USA) buffer was added for colour development, 
and the reaction was stopped by adding 2N NaOH solution. Absorbance A405 was 
read on the Analyst plate reader (Molecular Devices, USA, Serial No. AN0166). 
 
2.8. Computing 
Unless stated otherwise, all image processing and quantitation were performed with 
Adobe Photoshop Version 7.0 (Adobe Systems Inc., USA) using only standard 
contrast and brightness adjustment functions. Graphs were produced in MSExcel, 
(Microsoft Corporation, USA). The text of this thesis was written in MSWord, 
(Microsoft Corporation, USA) and figures were assembled in Adobe Illustrator 
Version 10.0 (Adobe Systems Inc., USA). 
 
2.8.1.  Bioinformatic and database resources 
DNA sequences 
 Entrez nucleotide: http://www.ncb.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide 
Protein sequences 
 Entrez protein: http://www.ncb.nlm.nih.gov/entrez/query.fcgi?db=Protein 
DNA and protein sequence homology 
 BLAST: http://www.ncbi.mln.nih.gov/BLAST/ 
Multiple sequence alignments  
 ClustalW: http://www.ebi.ac.uk/clustalw.html 
Restriction enzyme site identification 
 NebCutter 2: http://www.neb.com/nebcutter.html 
Oligonucleotide primer design 
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 Netprimer: http://www.premierbiosoft.com/netprimer.html 
Protein molecular weight, pI, and extinction coefficient 
 ProtParam: http://ca.expasdy.org/tols/protparam.html 
Protein structure visualisation 
Pymol: http://pymol.sourceforge.net/ 
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CHAPTER THREE 
Purification of active, recombinant Cdc7/ASK complex and  
generation of rabbit polyclonal antibodies to Cdc7 and ASK 
 
3.1. Introduction 
Cdc7 kinase, first identified in Saccharomyces cerevisiae (Hartwell 1973; Patterson et 
al. 1986), is required for at least three aspects of DNA metabolism: initiation of DNA 
replication, cohesin loading, meiotic recombination and DNA repair (Hollingsworth, 
Jr. & Sclafani 1993; reviewed in Swords et al. 2010). Homologues of Cdc7 have been 
identified in Schizosaccharomyes pombe (Masai et al. 1995), mouse (Kim et al. 1998), 
Xenopus and H. sapiens (Jiang et al. 1997; Sato et al. 1997; Hess et al. 1998). Cdc7 is 
a serine/threonine kinase (Figure 3.1A) which is activated by the regulatory protein 
ASK (Activator for S phase Kinase in H. sapiens, also called Dbf4 in S. cerevisiae 
and Dfp1/Him1 in S. pombe) during the cell cycle (Diffley et al. 1995; Masai & Arai 
2002; Sclafani et al. 2002; Stillman 1996) (Table 3.1). A second ASK/Dbf4-related 
molecule in H. sapiens, named Drf1, and its possible homologue in Xenopus have 
been reported (Montagonoli et al. 2002; Yanow et al. 2003). 
 
Cdc7 protein contains conserved kinase domains that are common to all 
serine/threonine protein kinases (Patterson et al. 1986; Hanks et al. 1988; reviewed in 
Sawa & Masai 2008). Sequence analysis of full-length Cdc7 shows that the kinase 
domains of human Cdc7 have 44% and 42% overall identity in amino acid sequence 
with those of Cdc7p and Hsk1, suggesting that human Cdc7 is structurally related to 
 
Cdc7
(H. sapiens)
Cdc7p
(S. cerevisiae)
Hsk1
(S. pombe)
Kinase domains Kinase insert domains(KI)
KI-1 KI-2 KI-3
ASK
(H. sapiens)
Dbf4
(S. cerevisiae)
Dfp1/Him1
(S. pombe)
674 aa
695 aa
545 aa
574 aa
507 aa
507 aa
48-92 214-265 291-331
NLSbipartiteNLS
Motif-N Motif-M Motif-C
Figure 3.1: Schematic drawing and comparison of Cdc7 and Dbf4-related subunits from H. 
sapiens, S. cerevisiae and S. pombe. (A) Comparison of Cdc7-related subunits. Red and yellow 
segments represent conserved kinase domains and less conserved kinase insert sequences 
respectively. (B) Comparison of Dbf4-related subunits. Destruction box indicates a "RXXL" motif, known 
to be targeted by the APC-dependent degradation pathway. Two putative nuclear localization signals 
(NLS) in ASK are shown. Motif-N: related to BRCT, Motif-M: Proline-rich motif and Motif-C: CCHH-Type 
Zinc finger-like motif. 
destruction
box
A
B Cdc7 interaction
Cdc7 interaction
Table 3.1 Cdc7/ASK related Kinase complexes
Human
Xenopus
S. cerevisiae
S. pombe
Mouse
Catalytic subunit
hCdc7
muCdc7
XeCdc7
Cdc7
Hsk1
Regulatory subunit
ASK, Drf1 
muASK
XeDbf4, Drf1
Dbf4
Dfp1/Him1
Substrates
hMcm2-7
Mcm2
Mcm2,3,4,6
SpMcm2,4,6,7
Mcm2
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yeast Cdc7p and Hsk1 (Figure 3.1A) (Jiang & Hunter 1997). All Cdc7 homologues 
contain three kinase insert domains (KI) between the kinase domains, however the 
sequences and lengths of these kinase inserts are not conserved among Cdc7, Cdc7p 
and Hsk1. Sequence analysis has revealed that the degree of conservation of amino 
acid sequences between different species is much lower in the Dbf4-related protein 
family (reviewed in Masai et al. 1999; Kumagai et al. 1999). The overall homology 
identity between Dbf4 and Dfp1/Him1 is less than 25%, and similarity is 46%. 
Almost no similarity was observed between Dbf4 and human ASK, except for three 
short stretches of amino acids - motif-N, motif-M and motif-C - which are well 
conserved in Cdc7 regulatory subunits (Figure 3.1B). Drf1, a second human 
ASK/Dbf4-related protein, contains the three conserved Dbf4 motifs in the N-terminal 
region (35% identity with ASK) and a long C-terminal tail that is much less conserved 
(Yoshizawa-Sugata et al. 2005). Direct interaction between Cdc7 and Dbf4 has been 
demonstrated by the requirement of association with motif-M and motif-C for Cdc7 
kinase activity (Dowell et al. 1994), whilst motif-N is essential for association with 
the replication machinery at origins (Ogino et al. 2001) (Figure 3.1B). Although ASK 
and its functional homologues in other eukaryotes are functionally similar to cyclins 
in terms of kinase activation of the catalytic subunit, their primary structures bear no 
similarity to known cyclins (Masai et al. 1999; Johnston et al 2000). It is well known 
that S-phase specific kinases, CDK and Cdc7 kinases, are essential activators of 
initiation of DNA replication through the recruitment of several replication factors 
(Bell & Dutta 2002; Takeda & Dutta 2005; Sclafani & Holzen 2007; Swords et al 
2010). The mechanisms of these kinases activation of DNA replication in S. 
cerevisiae has been recently reported that CDK phosphorylate Sld2 and Sld3 to 
activate DNA replication initiation, whereas Cdc7 kinase phosphorylate the amino 
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terminal serine/threonine rich domain (NSD) of Mcm4 relieving an inhibitory activity 
for S phase progression (Masai et al 2006; Zegerman & Diffley 2007; Sheu & 
Stillman 2010).   
 
Conservation between yeast and higher eukaryotes of the primary structure of Cdc7 
and its regulatory subunit strongly suggests the functional conservation of these 
kinases in DNA replication (Masai et al. 1995; Sato et al. 1997; Kim et al. 1998; Jiang 
& Hunter 1997; Robert et al. 1999; Masai et al 1999; Masai & Arai 2002; reviewed in 
Sawa & Masai 2008; Figure 3.1). Previous genetic and biochemical studies indicate 
that S. cerevisiae Cdc7p depends on association with Dbf4 for its kinase activity, 
which is required for the activation of individual origins throughout S phase (Bousset 
& Diffley 1998; Donaldson et al. 1998). Hsk1 is also essential for cell viability and S 
phase initiation in S. pombe, suggesting that the function of Cdc7 kinase in eukaryotic 
DNA replication is evolutionarily conserved between the two yeasts (Masai et al. 
1995). Studies in Xenopus egg extracts showed that either addition of XeCdc7 
antibody or depletion of Cdc7 inhibits DNA replication, demonstrating an essential 
role of Cdc7 kinase for efficient DNA replication also in vertebrates (Roberts et al. 
1999; Jares & Blow 2000; Walter 2000). Conditional knockout of the CDC7 gene in 
mouse ES (embryonic stem) cells resulted in a block to DNA replication and 
subsequent cell death (Kim et al. 2002). An essential role of human Cdc7/ASK kinase 
for mammalian DNA replication was demonstrated by the inhibition of DNA 
replication after micro-injection of ASK or Cdc7 antibodies into human fibroblast 
cells (Kumagai et al. 1999; Jiang & Hunter 1997). Furthermore, inhibition of Cdc7 
kinase activity by either RNA interference or small molecule inhibitors in various 
cancer cells caused an abortive S phase progression, followed by growth arrest and 
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apoptotic cell death, highlighting the potential of Cdc7 kinase as a novel target for 
anti-cancer drug development (Montagnoli et al. 2004; Montagnoli et al. 2008; Shafer 
et al.2008).  
 
The initiation of DNA replication, a convergence point for mitogenic and signal 
transduction growth regulatory pathways, is a critical and tightly controlled step in 
cell proliferation, restricting origin activation to once per cell cycle. Cdc7/ASK has 
been shown to be a key regulator of origin activation through phosphorylation of key 
components of the pre-replicative complex (pre-RC) during the initiation of DNA 
replication (see also Chapter One - Introduction). To provide further insights into the 
molecular mechanisms that regulate DNA replication competence during the human 
mitotic cell division cycle and in out-of-cycle states, additional research into 
Cdc7/ASK function is required. Biochemical and functional studies of the human 
Cdc7/ASK kinase complex have been limited in the past by the lack of molecular 
tools, in particular functional recombinant kinase complex and specific antibodies. 
The aim of this part of the work described in this thesis was to generate these 
molecular tools, which were subsequently used to study cell cycle regulation of 
Cdc7/ASK kinase activity in human cells. 
 
3.2. Material and Methods 
For transformation of E. coli (2.2.2.), plasmid isolation (2.2.3.), restriction 
endonuclease digestion (2.2.4), dephosphorylation of linearised vector DNA (2.2.5.), 
ligation of DNA (2.2.6.), polymerase chain reaction (2.2.7.), agarose gel 
electrophoresis (2.2.9.), recovery of DNA from agarose gels (2.2.10.), DNA 
sequencing (2.2.11.), preparation of recombinant baculoviruses (2.3.1), viral DNA 
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isolation (2.3.2.), generation of recombinant baculovirus (2.3.3.), plaque assay (2.3.4.), 
virus titeration (2.3.5.), expression of recombinant His-tagged human Cdc7, ASK and 
mutant Cdc7 in Sf9 insect cells (2.4.2.), expression of recombinant human Cdc7/ASK 
kinase complex in Sf9 insect cells (2.4.3.) purification of Cdc7, ASK, mutant Cdc7 
and Cdc7/ASK complex (2.4.4.), expression and purification of ASK (271-674) 
fragment (2.4.5., 2.4.6.), expression and purification of Mcm2 (1-154) fragment 
(2.4.7., 2.4.8.), SDS-polyacrylamide gel electrophoresis (2.4.9.), Coomassie blue 
staining of SDS-PAGE gels (2.4.10.), antibodies (2.5.1.), preparation of whole cell 
extracts (2.5.2.), immunoblotting (2.5.3.) and immunoprecipitation (2.5.4.) please 
refer to Chapter Two (Materials and Methods). 
 
3.3. Results 
3.3.1. Generation of CDC7 and ASK recombinant baculoviruses 
To characterise in human cells Cdc7/ASK kinase and its role in the initiation of DNA 
replication and cell cycle regulation, functional recombinant Cdc7 and ASK proteins 
were required. Baculoviruses expressing Cdc7, ASK and a kinase-dead mutant Cdc7 
were kindly provided by Dr Wei Jiang (The Burnham Institute, La Jolla, California; 
Jiang et al. 1999). However, the virus stocks received did not express high levels of 
the recombinant proteins. Recombinant CDC7 and ASK baculoviruses were therefore 
generated de novo in the work of this thesis to express high levels of Cdc7 and ASK 
in insect cells, both as individual proteins and together as an active kinase complex.  
 
To generate recombinant CDC7 and ASK baculoviruses, viral DNA was isolated from 
the provided budded viruses and PCR analysis was performed using CDC7 or ASK 
specific primers to amplify the CDC7 and ASK coding genes (Figure 3.2A). DNA 
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sequence analysis confirmed that the PCR products were identical to the reported 
CDC7 and ASK gene sequences. The amplified CDC7 and ASK genes were separately 
cloned into pFastBac baculovirus expression vector containing a six-histidine tag on 
the N-terminus for protein purification (Figure 3.2B). The plasmids were transformed 
into DH10Bac competent E. coli cells to generate a recombinant bacmid by site-
specific transposition. Recombinant bacmids were transfected into Sf9 insect cells to 
generate recombinant baculoviruses that express Cdc7 and ASK proteins (Figure 
3.2C). The recombinant baculoviruses were amplified and titered. High-titer (3 x 109 
pfu/ml: plaque forming units per ml) stock viruses were used for Cdc7 and ASK 
expression.  
 
3.3.2. Expression and purification of Cdc7, ASK and active Cdc7/ASK kinase 
complex in insect cells 
To optimise the expression of Cdc7 and ASK recombinant proteins, Sf9 insect cells 
were infected with recombinant baculoviruses either expressing His-tagged Cdc7 or 
His-tagged ASK proteins. Human CDC7 encodes a protein of 574 amino acids with a 
predicted molecular weight of 58 kDa (Masai & Arai 2002). The gene for its 
regulatory subunit ASK encodes a protein of 674 amino acids with a predicted 
molecular weight of 77 kDa (Jiang et al. 1999). Western blot analysis shows high 
level expression of the 64 kDa His-tagged Cdc7 and the 77 kDa His-ASK proteins in 
insect cells 72 hours after infection (Figure 3.3A). Although both Cdc7 and ASK 
proteins were mainly expressed  at 72 hours post-infection, both proteins were found  
 
 
 
A
CDC7ASKNC
2.0 kbp1.7 kbp
0.75 kbp
B
Pph ATG 6 X His TEV
NcoI XhoI
CDC7 (1.7 kbp)
pFastBac B-Cdc7 (6.5 kbp)
Pph ATG 6 X His TEV
EcoRI XhoI
ASK (2.0 kbp)
pFastBac A-ASK (6.8 kbp)
Transformation in DH10Bac E.coli cells
Transposition
Recombinant bacmid DNA
Transfection
Recombinant protein expression 
in Sf9 cells
C
Figure 3.2: Generation of Cdc7 and ASK recombinant baculoviruses. (A) PCR amplification of CDC7 
and ASK genes from baculoviral template DNA (NC-Negative control). (B) Both CDC7 (1.7kbp) and ASK 
(2.0kbp) PCR products were cloned into pFastBacHT vector to generate pFastBacHT B-Cdc7 and 
pFastBacHT A-ASK. (C) Vector constructs were transformed into DH10Bac competent E.coli to generate 
recombinant CDC7 or ASK bacmids. Recombinant bacmids were transfected into insect cells to generate 
CDC7 or ASK baculoviruses which overexpress Cdc7 and ASK recombinant protein.  
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in both soluble and insoluble fractions prepared from infected Sf9 cells. As shown in 
Figure 3.3A approximately 60% of total ASK protein was insoluble, whereas total 
Cdc7 protein was more soluble (Figure 3.3A).  
 
Previous studies reported that the full-length proteins of Cdc7 and ASK were highly 
aggregated in solution and were too low to be purified for enzymatic characterisation 
(Roberts et al. 1999; Jiang et al. 1999; Kihara et al. 2000). Overexpressed proteins 
often appear to be insoluble when made in a heterologous host (Ouellette et al. 2003). 
To achieve good solubility of overexpressed protein, the most important variable 
conditions are pH and salts in the buffer (Minton & Wilf 1981). The lysis buffer 
conditions described by Lindwall et al. have been developed to encompass many 
conditions known to preserve protein solubility without repetition (Spare matrix) 
(Lindwall et al. 2000). The theoretical pIs of Cdc7 and ASK are 8.96 and 8.03, as 
determined by analysis of the amino acid sequence 
(http://www.expasy.org/tools/protparam). The high pIs of these proteins suit high pH 
buffer conditions, which can result in enhanced yields of active, soluble protein. 
Figure 3.3B shows the solubility of Cdc7 and ASK in buffers at different pH levels. 
Cdc7 was soluble in buffers at pH 6, 7.2, 8 and 9 (NaCl or KCl), however ASK 
showed only low solubility at pH 8 and 9. A lower molecular weight band was seen in 
the Cdc7 soluble fractions in buffers at pH 6, 7.2, 8 and 9 with KCl, but this band 
disappeared in buffer at pH 9 with NaCl (Figure 3.3B). Cdc7 requires ASK for kinase 
activity. Hence Cdc7 and ASK were co-expressed in insect cells with different MOIs 
(multiplicity of infection) to produce the active complex. The pH of the lysis buffers 
(25 mM Tris-HCl, 250 mM NaCl, 0.5% NP 40, 10% glycerol, 10 mM MgCl2 and 
0.02 volumes of complete EDTA-free Protease inhibitor cocktail) was kept constant at  
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Figure 3.3: Optimisation of recombinant Cdc7 and ASK expression. Sf9 cells were infected 
with recombinant viruses expressing Cdc7 or ASK and cells were lysed at 24, 48 and 72 hours after 
infection. (A) Immunoblot analysis of soluble and insoluble fractions from the time course with 
anti-histidine tag antibody. (B) Immunoblot analysis of soluble and insoluble fractions from lysates 
prepared at 72 hours with lysis buffer of varying pH with Cdc7 and ASK antibodies. (C) Immunoblot 
analysis of Cdc7 and ASK co-expressing lysates at various MOIs with anti-histidine tag antibody. 
(WCE - Whole cell extract; Mock - Mock-infected cell; MOI-Multiplicities of infection)  
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pH 9.0. Similar amounts of soluble Cdc7/ASK complex were produced using Cdc7 at 
MOI 5 and ASK at MOIs of 20 and 50 (Figure 3.3C).      
 
After optimisation of small-scale Cdc7 and ASK protein expression, the next stage 
was large-scale protein expression of recombinant Cdc7/ASK kinase complex. Cdc7 
and ASK proteins containing six-histidine tags at the N-terminus were purified using 
immobilized metal affinity chromatography (IMAC) as shown in Figures 3.4 and 3.5. 
Weakly bound proteins were eluted at low imidazole concentrations, whereas both 
Cdc7 and ASK were eluted at imidazole concentrations between 60 mM and 120 mM 
(20%-40%). After nickel affinity purification, Coomassie blue staining and western 
blot analysis of the eluted protein fractions showed single bands with apparent 
molecular weights of ~64 kDa for His-tagged Cdc7 (Figure 3.4B and C) and ~77 kDa 
for His-tagged ASK (Figure 3.5B and C).  
 
Cdc7/ASK kinase complex was purified as described for Cdc7 and ASK proteins. The 
complex was eluted by increasing the concentration of imidazole in lysis buffer  (25 
mM Tris-HCl pH 9, 250 mM NaCl, 0.5% NP 40, 10% glycerol, 10 mM MgCl2) 
(Figure 3.6A). Coomassie blue stained gels show the 64 kDa His-tagged Cdc7 and the 
77 kDa His-ASK proteins after nickel-affinity purification (Figure 3.6B). Western 
blot analysis shows that the Cdc7 and ASK protein bands from co-infected cells have 
lower electrophoretic mobility than those from separate infections. To determine 
whether this difference was due to phosphorylation, the Cdc7/ASK complex was 
treated with -phosphatase prior to loading onto the gel. After treatment, the bands 
corresponding to Cdc7 and ASK were detected at similar sizes compared to when 
Cdc7 and ASK proteins were expressed alone (Figure 3.6C). Interestingly, a stronger  
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Figure 3.4: Expression and purification of His-tagged human Cdc7. (A) Elution profile 
obtained from nickel-affinity chromatography and (B) coomassie stained gel showing 
recombinant Cdc7 protein elution fractions. (C) Purified Cdc7 protein was immunoblotted with a 
anti-histidine tag antibody. (WCE - Whole cell extract; P - Cell pellet; E1/2/3/4/5/6 - Elution 
fractions).
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Figure 3.5: Expression and purification of His-tagged human ASK. (A) Elution profile 
obtained from nickel-affinity chromatography and (B) coomassie stained gel showing 
recombinant ASK protein elution fractions. (C) Purified ASK protein was immunoblotted with a 
anti-histidine tag antibody. (WCE - Whole cell extract; P - Cell pellet; E1/2/3/4/5/6 - Elution 
fractions).
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Figure 3.6: Expression and purification of His-tagged human Cdc7/ASK kinase complex. (A) 
Elution profile obtained from nickel-affinity chromatography and (B) coomassie stained gel showing 
Cdc7/ASK kinase elution fractions (WCE - Whole cell extract; P - Cell pellet; E1/2/3/4 - Elution fractions). 
(C) Purified Cdc7/ASK complex, Cdc7 and ASK were immunoblotted with histidine tag, Cdc7 and ASK 
antibodies. The Cdc7/ASK complex was treated with λ-phosphatase prior to electrophoresis to reverse 
phosphorylat ion, which causes a change in the migrat ion of the protein band on the gel (PP - 
λ-phosphatase; pASK -  phosphorylated ASK).
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immunoreaction with the ASK band was observed with an anti-histidine tag antibody 
after dephosphorylation by -phosphatase treatment compared with no treatment. 
Notably, as observed by others for Cdc7/ASK co-expression (Jiang et al., 1999; Masai 
et al., 2000), these phosphorylation events are dependent on the presence of ASK, 
which is required for the kinase activity of Cdc7 in mammalian cells (Kumagai et al., 
1999). Protein assays after purification showed concentrations of 0.6 mg/ml Cdc7 for 
infection with single virus expressing His-tagged Cdc7, 0.5 mg/ml ASK for infection 
with single virus expressing His-tagged ASK,  and 1.1 mg/ml Cdc7/ASK kinase 
complex for co-infection with CDC7 and ASK viruses.  
    
3.3.3. Generation of Cdc7 and ASK antibodies 
A range of antibodies raised against synthetic polypeptides derived from the Cdc7 
kinase catalytic and ASK regulatory subunit have been reported (Jiang & Hunter 
1997; Jiang et al. 1999; Kumagai et al. 1999). In the work of this thesis, synthetic 
polypeptides corresponding to the C-terminal residues of Cdc7 and ASK (amino acids 
557-574 and amino acids 644-663, respectively), which have been published (Jiang & 
Hunter 1997; Kumagai et al. 1999) , and additional synthetic polypeptides derived 
from Cdc7 and ASK (amino acids 284-298 and amino acids 112-129, respectively) 
were used for generation of Cdc7 and ASK antibodies following a standard 
immunisation protocol (Eurogentech, Seraing, Belgium) (Figure 3.7A). In western 
blot analysis of Cdc7 and ASK recombinant proteins, Cdc7 antibodies (#33576 and 
#33577) detected a single band of the reported molecular weight for Cdc7 (~ 64 kDa) 
(Figure 3.7B). ASK antibodies (#33578 and #33579) also detected a band of the 
reported molecular weights of ASK (~ 77 kDa), however antibody #33579 showed a 
stronger reaction than #33578 when applied at the same dilution (1:200 dilution)  
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Figure 3.7: Generation of Cdc7 and ASK antibodies. (A) Cdc7 and ASK antibodies were raised in rabbits 
following immunisation with synthetic peptides #33576 (RITAEEALLHPFFKDMSL, aa557-574), #33577 
(RSVFGERNFNIHSSI, aa284-298), #33578 (NVLDIWEEENSDNLLTAFF, aa112-129) and #33579 
(YTAETTSPHPSHDGSSF, aa644-663). Immunoblot analysis of recombinant Cdc7 and ASK protein with 
(B) Cdc7 and (C) ASK antibodies. Pre-incubation of Cdc7 and ASK antibodies with peptides blocks 
detection of Cdc7 and ASK recombinant protein. Immunoblot analysis of asynchronous HeLa, HL60 and 
WI-38 whole cell lysates with affinity-purified (D) Cdc7 antibodies (#76 and #77), (E) ASK antibodies (#78 
and #79), (F) Cdc7 K0070-3 antibody from MBL and (G) human Dbf4 antibodies (hDbf4 N-15 and hDbf4 
H-300) from Sata Cruz Biothechnology. (Rec - Recombinant protein; WCE - Whole cell extract)
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(Figure 3.7C). Detection of these bands was blocked when the antibodies were pre-
incubated with the peptides used for immunisation (Figure 3.7B and C). Although 
both Cdc7 antibodies specifically recognised recombinant protein, antibody #33576 
detected two bands in HeLa, HL60 and WI-38 whole cell extracts, whereas #33577 
detected only a faster-migrating band in HeLa and WI-38 cell extracts. The ASK 
antibodies (#33578 and #33579) did not recognise a band corresponding to the 
molecular weight of the ASK protein in whole cell extracts (Figure 3.7C).  
 
At the time when these experiments were conducted, a mouse monoclonal Cdc7 
antibody that recognises mammalian Cdc7 became available through MBL (Nagoya, 
Japan). This antibody detects a 64 kDa single band corresponding to Cdc7 protein in 
HeLa, HL60 and WI-38 cell extracts (Figure 3.7 F). However, commercially available 
ASK antibodies that specifically detect ASK protein in human cell extracts were not 
identified (Figure 3.7 G). Thus additional immunizations with a different ASK-
derived antigen were required. The characterisation of various mutant derivatives of 
ASK (Sato et al. 2003) enabled me to divide the ASK protein into functional domains. 
In order to express the fragments of ASK protein for immunization, I constructed a 
pair of N-terminal and C-terminal truncation fragments of ASK (Figure 3.8A) and 
expressed them in E.coli (Rosetta2 pLysS). However, both ASK truncated fragments 
were found in the insoluble fraction (data not shown). Experiments were undertaken 
to purify the ASK fragments by denaturation and renaturation (see Material and 
Methods). Coomassie blue staining showed the eluted fractions of both ASK 
fragments which recovered in the soluble fraction and were renatured using an on-
column refolding technique (Figure 3.8B and C). To generate a rabbit polyclonal 
antibody against ASK, both fragments were used separately as antigens. However, on- 
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Figure 3.8: Generation of ASK antibody. (A) Schematic drawing of ASK fragments. (B) Chromatogram 
obtained from on-column refolding and nickel-affinity purification. (C) Coomassie stained gel showing ASK 
fragments (ASK 1-270 and ASK 271-674) from 100%IMZ elution fractions. (D) Immunoblot analysis of 
asynchronous HeLa, HL60 and WI-38 whole cell lysates with affinity-purified ASK antibody (SK3681). (E) 
Preincubation of ASK antibody (SK3681) with recombinant ASK fragment blocks detection of endogenous 
ASK from HeLa total cell lysates. (IMZ - Imidazole; M - Marker; E - Elution fraction; WCE - Whole cell 
extract).
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ly polyclonal antibody (#SK3681) raised against the C-terminal 403 amino acids of 
the ASK fragment which contains motif-C (aa 271-674) detected a single band 
corresponding to ASK protein. In western blot analysis of whole cell extracts from 
asynchronously proliferating HeLa, HL60 and WI-38 cells, affinity-purified anti-ASK 
antibody (#SK3681) detected a single band of the reported molecular weight for ASK 
(~77 kDa) (Figure 3.8D). This band was not detected when the ASK antibody was 
pre-incubated with the recombinant C-terminal ASK fragment (1:25 dilution) (Figure 
3.8E).  
 
ASK antibody #SK3681 was reciprocally tested for its ability to co-
immunoprecipitate Cdc7/ASK complex from HeLa whole cell extracts with the 
commercially available Cdc7 mouse monoclonal antibody. The ASK antibody co-
precipitated Cdc7, as detected by immunoblotting with the Cdc7 antibody, and 
conversely the Cdc7 antibody co-precipitated ASK protein (Figure 3.9A). These data 
demonstrate that Cdc7 and ASK form a stable complex in human cells and that the 
newly generated ASK antibody can be used to precipitate the endogenous Cdc7/ASK 
complex from HeLa cells. In addition, the immunoprecipitates were treated with -
phosphatase prior to western blotting. Immunoblot analysis shows that ASK is highly 
phosphorylated when associated with Cdc7 as a complex in HeLa cells (Figure 3.9B), 
consistent with Cdc7/ASK complexes co-expressed in insect cells (Figure 3.6C). 
 
3.4. Discussion and Conclusions 
The initiation of DNA replication is highly regulated in eukaryotic cells and involves 
a large set of proteins. Identification and characterization of DNA replication factors 
that assemble as complexes at replication origins in yeast and Xenopus have advanced  
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Figure 3.9: Characterisation of ASK antibody (SK3681).  (A) Immunoprecipitation (IP) of 
HeLa cell lysates with ASK and Cdc7 antibodies followed by western blot analysis with ASK 
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fractions; Beads - Protein A-sepharose complex with antibody-antigen). (B) λ-phosphatase 
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our understanding of the biochemical mechanisms of the DNA replication initiation 
process. Despite characterisation of the biochemical and functional role of the 
Cdc7/Dbf4 kinase in yeast and Xenopus systems, our understanding of this important 
cell cycle regulator in mammalian cells is still relatively limited. Therefore, in the 
work described in this chapter, I have focused on generating the molecular tools 
essential for a biochemical and functional characterization of Cdc7/ASK kinase 
complex in mammalian cells which is described in the following chapters. 
 
To this end, I produced recombinant human Cdc7/ASK kinase complex by co-
expression in insect cells. Analysis of purified Cdc7/ASK kinase complex allowed a 
characterisation of the phosphorylation state when the two proteins form a complex 
and an investigation of the interaction between the catalytic subunit Cdc7 and its 
regulatory subunit ASK (Figure 3.6). It has been reported that co-expression of ASK 
is required for kinase activity of Cdc7 in transient transfection assays performed in 
mammalian cells (Kumagai et al., 1999). These observations are consistent with my in 
vitro findings (Figure 3.6C) using purified Cdc7/ASK kinase complex discussed in 
this chapter. The active Cdc7/ASK kinase complex was essential for the development 
of a primary screening assay for Cdc7 small molecule inhibitors, which is discussed in 
Chapter 5. Affinity-purified rabbit polyclonal antibodies for Cdc7 and ASK protein 
were raised against synthetic polypeptides (Figure 3.7A) derived from Cdc7 and ASK. 
However, the antibodies did not recognise specific bands for Cdc7 and ASK in human 
cell extracts. A commercial Cdc7-specific monoclonal antibody was thereafter 
identified and used for further experiments. A polyclonal ASK antibody (#SK3681) 
was raised against a C-terminal fragment of ASK (Figure 3.8A). The data discussed in 
this chapter show that the ASK antibody (#SK3681) is specific for endogenous ASK 
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in human cell extracts, detecting a protein with a molecular weight corresponding to 
the reported size of human ASK. These antibodies were essential for investigations of 
the causal molecular events in cell-cycle-dependent regulation of DNA replication in 
human cells. 
 
Taken together, the data presented in this chapter demonstrate that the molecular tools 
required for the work described in the following chapters, including affinity-purified 
ASK antibody and kinase active Cdc7/ASK complex, were successfully generated. 
These molecular tools were utilised for an analysis of the functional role of 
Cdc7/ASK in human cells and the development of a sensitive screening assay for 
Cdc7 kinase activity, which is essential at an early stage in the drug development 
process. Furthermore, these tools were utilised to gain a better understanding of the 
role of Cdc7/ASK in human cell proliferation, thereby providing important target 
validation for exploitation of this kinase as a potential therapeutic target. In the 
following chapter, I discuss the application of these antibodies to in vitro tissue 
culture model systems of proliferation, quiescence and terminal differentiation 
established in our laboratory (Stoeber et al. 2001; Kingsbury et al. 2005), and to 
normal human tissues (self-renewing, stable and permanent) and tumours. By 
analyzing the regulation and activity of Cdc7 kinase in vitro and in vivo, I studied the 
causal molecular events that underlie replication competence during the cell cycle and 
loss of replicative capacity in out-of-cycle states.  
 
 
 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   106 
CHAPTER FOUR 
Cell cycle dependent regulation of Cdc7/ASK kinase complex 
in proliferating cells and out-of-cycle states 
 
4.1. Introduction 
The eukaryotic DNA replication initiation pathway is tightly controlled through the 
assembly of pre-replicative complexes (pre-RCs) and the activation of replication 
origins to ensure correct duplication of the genome during cell division (see also 
Chapter 1, Section 1.5). Cdc7/ASK is an essential kinase required for origin activation 
through initiating by phosphorylation a cascade of protein associations that activate 
the Mcm2-7 replicative helicase (reviewed in Sclafani & Holzen 2007; Swords et al. 
2010). Similar to cyclin-dependent kinase activation, Cdc7 kinase is activated by the 
binding of two regulatory subunits, ASK/Dbf4 which is well understood, and Drf1 
that comparatively lesser known (Jiang et al. 1999; Kumagai et al. 1999; Montagnoli 
et al. 2002; Takahashi & Walter 2005; Yoshizawa-Sugata et al. 2005). 
 
The levels of Cdc7 mRNA and protein are relatively constant during the cell cycle, 
however expression of the regulatory subunits are cell cycle dependent (reviewed in 
Swords et al. 2010) (Figure 4.1A). The ASK mRNA and protein levels are very low in 
early G1 phase and high at G1/S boundary throughout S phase, whereas Drf1 
transcription and protein levels increase at late S phase to G2/M phase (Jiang et al. 
1999; Kumagai et al. 1999; Ferreira et al. 2000; Yoshizawa-Sugata et al. 2005). Since 
Drf1 has been identified only in Xenopus and human cells, the presence of two 
regulatory subunits, ASK/Dbf4 and Drf1, suggest a new level of complexity in the re- 
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Diagrammatic representation of the mitotic cell division cycle. In passing through the cell cycle a 
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Cells can withdraw irreversibly from the cell cycle through the process of terminal differentiation or 
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gulation of DNA replication in vertebrates (Masai et al 2002; Yanow et al. 2003; 
Yoshizawa-Sugata et al. 2005). In other words, different Cdc7 kinase complexes 
might be responsible for the temporal activation of origins through early and late 
firing (Masai et al. 2002; Yoshizawa-Sugata et al. 2005).   
 
Previous studies have shown that the expression of CDC7 and ASK mRNA is 
generally at a high level in most cancer cell lines, except for lung cancer cell line 
A549 (Hess et al. 1998; Kumagai et al.1999). Cdc7 kinase activity is upregulated in 
melanoma cell lines with defects in the DNA damage G1 checkpoint (Kaufmann et al. 
2008). Furthermore, Nambiar et al. identified ASK/Dbf4 as a key factor in melanoma 
development using oligonucleotide microarray-based screening (Nambiar et al. 2007), 
suggesting that alterations in Cdc7/ASK protein abundance or activity may occur 
during tumorigenesis. A recent study showed that expression levels of Cdc7 and ASK 
proteins increased in 50% of the NCI-60 cell lines and additional leukemia cell lines 
(Bonte et al. 2008). It also showed a high correlation between mutated p53 and 
increased Cdc7 and ASK expression levels in primary breast cancer cell lines, 
suggesting that p53 may directly represses the CDC7 and ASK gene, or that p53 
mutations activate CDC7 and ASK gene expression (Bonte et al. 2008). However, on 
the whole the role of Cdc7/ASK kinase and the regulation of its activity in 
tumorigenesis is not fully understood. 
 
Given the essential role of Cdc7/ASK kinase in DNA metabolism, including  
replication initiation, chromosomal segregation and checkpoint pathways, and 
increased expression levels in most cancer cells, Cdc7 kinase has been pursued as an 
attractive target for the therapeutic intervention. Particularly, several reports studied 
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the cellular responses of human cells to loss or inhibition of Cdc7 kinase and showed 
that inhibition of Cdc7 kinase may provoke a differential response in normal and 
transformed cell lines, causing cancer-cell-specific killing (Montagnoli et al. 2004; 
Yoshizaw-Sugata et al. 2005; Im & Lee 2008; Kim et al. 2008; Montagnoli et al 2008). 
These in vitro findings so far have provided a strong rationale for Cdc7/ASK kinase 
as an attractive anti-cancer target. 
 
In mammalian tissues the majority of cells have exited the cell cycle and have arrested 
in out-of-cycle states, either temporally withdrawing into the quiescent state or 
permanently withdrawing from the cell cycle through the processes of terminal 
differentiation or replicative senescence (Pardee 1989; Hayflick & Moorhead 1961: 
Campisi 1996; Myster & Duronio 2000). In order to evaluate Cdc7/ASK as a novel 
target for anti-cancer drug development, it is therefore essential to understand 
regulation of the Cdc7/ASK kinase complex during establishment of the quiescent 
(G0) and differentiated out-of-cycle states, and during re-entry from quiescence into 
the cell cycle. To address these important issues, I used in vitro tissue culture model 
systems that were established to enable generation of a detailed molecular map of the 
replication initiation machinery in cycling cells, in quiescent or differentiated out-of-
cycle states, and during re-entry from quiescence into the cell cycle (Figure 4.1 B). 
 
In vitro and in vivo studies have shown that the Mcm2-7 subunits are a major 
substrate of Cdc7/ASK, and that Cdc7/ASK can phosphorylate several MCM subunits 
with some preference for the Mcm2 subunit (Lei et al., 1997; Sato et al., 1997; 
Montagnoli et al. 2006; Tsuji et al. 2006; Cho et al., 2006; Chuang et al. 2009). High 
resolution mass-spectrometric analysis of the N-terminal region of Mcm2 revealed six 
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phosphorylation sites for Cdc7/ASK, and these phosphorylated sites were confirmed 
using phospho-specific antibodies in cancer cells (Montagnoli et al. 2006; Charych et 
al. 2008). Furthermore, depletion of Cdc7 caused a decrease in the levels of Mcm2 
phosphorylation at serine 40 and serine 53, suggesting that Mcm2 phosphorylated at 
serine 40 and serine 53 is completely dependent on Cdc7/ASK activity in human cells 
(Montagnoli et al. 2006; Tenca et al. 2007). Therefore, to determine the role of the 
Cdc7/ASK kinase complex in activating DNA replication origins in human tissues, in 
this chapter I discuss the study of Cdc7 expression dynamics and its activity as 
determined by Mcm2 phosphorylation in self-renewing and conditional renewal 
tissues to investigate the growth regulatory strategies in normal and cancerous human 
tissues. The aim of these studies was to provide further target validation for Cdc7 
kinase as a novel theranostics target.  
 
4.2. Material and Methods 
For antibodies (2.5.1.), preparation of whole cell extracts (2.5.2.), immunoblotting 
(2.5.3.), immunoprecipitation (2.5.4.), immunohistochemistry (2.5.5.), cell culture and 
synchronisation (2.6.1.), bivariate flow cytometric analysis (2.6.2), monitoring 
differentiation (2.6.3.), tissue specimens (2.6.5.) and assaying for cell differentiation 
please refer to Chapter Two (Materials and Methods).  
 
4.3. Results 
Characterization of pre-RC/pre-IC regulation, and in particular the role of Cdc7/ASK 
kinase, in an in vitro tissue culture model system is essential before progressing to 
human tissue studies to understand growth regulatory mechanisms that often operate 
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strictly in normal cells but are defective in tumour cells. To generate a molecular 
picture of pre-RC assembly during the cell cycle, exit into G0, re-entry from 
quiescence, and in the differentiated state, and to study the role of Cdc7/ASK kinase 
in activating assembled pre-RC to form pre-initiation complex (pre-IC) in these 
processes, I prepared whole cell extracts at various time points following cell cycle 
arrest, contact inhibition, release from contact inhibition and during 1,25 
dihydroxyvitamin D3 (1,25 Vit D3) induced differentiation of HL60 cells. 
 
4.3.1. Expression dynamics and regulation of Cdc7/ASK kinase in cycling cells 
Chemical cell synchronization methods such as double-thymidine block or 
hydroxyurea treatment affect DNA synthesis and arrest cells at the G1/S border (Puck 
1964; Stubblefield et al 1967). Thymidine is an inhibitor of the deoxyribonucleotide 
triphosphates. Excess thymidine in the medium results in the inhibition of DNA 
synthesis. Cells in the S phase remain blocked in this phase, while cells that are 
outside at S phase continue their route until being blocked at the G1/S boundary. The 
thymidine excess is then removed, and the cells are released. A second thymidine 
blockade then gives final cell synchronization at the end of G1. These methods 
generally do not work for cell lines with intact p53 apoptotic responses, but can be 
used to produce highly synchronized populations of p53 deficient cell lines such as 
HeLa and U2-OS (Pederson & Robbins 1971). Nocodazole, a microtubule inhibitor, is 
commonly used to arrest cells at mitosis (Sentein 1977). In the work of this thesis, I 
chose HeLa S3 cells to perform analysis of Cdc7/ASK regulation in cycling cells. 
Cells at various stages of S and G2/M phases were obtained by releasing cells arrested 
at the G1/S boundary by a double thymidine block (see Material and Methods). For 
synchronization in mitosis, thymidine arrested cells were released and treated with 
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nocodazole to arrest them in mitosis (see Material and Methods). Following release, 
these cells divided synchronously and progressed as a cohort through the sequential 
stages of the cell cycle.  
 
Cell cycle distribution of synchronized HeLa cell populations was determined by flow 
cytometry (Figure 4.2). Flow cytometric analysis of DNA content shows that most of 
cells (94%) were arrested in mitosis by blocking in nocodazole after thymidine arrest. 
After release from the nocodazole block, cells were divided synchronously within 2 
hours of release from the arrest, more than half of the original M phase cells (63%) 
moved into G1 phase 4 hours after release and cells began to enter S phase by 10 
hours after release. Upon release from thymidine block, cells progressed into S phase 
4 hours after release, the majority of cells (78%) reached G2/M phase by 6 hours, and 
41% of cells entered G1 phase 10 hours after release from thymidine block (Figure 
4.2).  
 
To generate detailed molecular maps of pre-RC constituents and to study the role of 
Cdc7/ASK kinase in regulating pre-RC to pre-IC transition during the mitotic division 
cell cycle, whole cell extracts from synchronised HeLa cells were immunoblotted 
with antibodies against human Orc4, Cdc6, Cdt1, Mcm2, Mcm2 phosphorylated at 
serine 40/41 (pMcm2 S40/41), Mcm2 phosphorylated at serine 53 (pMcm2 S53), 
Cdc45, Mcm10, Cdc7, ASK, cyclin A, cyclin E and the cytoskeletal filamentous 
protein -actin to control for protein level (Figure 4.3A, also see Material and 
Methods). Orc4 and Mcm2 were detectable throughout the cell cycle. Notably, levels 
of pMcm2 S40/41 was present as a fast-migrating form at G2/M, but on entry into G1, 
the protein was converted into a slow-migrating form. With the onset of S phase, the  
C
el
l n
um
be
r
C
el
l n
um
be
r
DNA content
DNA content
0
2
4
6
8
10h
0
2
4
6
8
10h
Nocodazole
Thymidine
0 2 4 6 8 10h
Figure 4.2: Flow cytometric DNA profiles of cycling HeLa cells. (A) Cells were 
arrested in mitosis by blocking with nocodazole after thymidine arrest. After release 
from the nocodazole block,  cells entered G1 2 hours after release. (B) Cells were 
arrested at G1/S by a double thymidine block. After release from thymidine arrest, cells 
started to progress through S phase between 2 and 4 hours, and reached G2/M 6 hours 
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 slow-migrating form was progressively converted into the fast-migrating form 
(Figure 4.3A). Phosphorylation analysis of Mcm2 (BM28, the human homologue of 
the S. cerevisiae MCM2) shows both fast and slow-migrating forms of the protein are 
phosphorylated, and the fast-migrating form of the protein appears to be 
hyperphosphorylated than the slow-migrating form (Todorov et al. 1995). Although 
this is opposite to the relationship usually found for phsphorylated proteins, it might 
be related to the abnormal mobility of Mcm2 in SDS-polyacrylamide gels (Todorov et 
al. 1994). Cdc6 levels were slightly increased as cells went through late G1 phase (10 
hours after release from nocodazole arrest) and remained high throughout S phase. 
Protein levels of Cdt1 peaked between two and four hours after release from 
nocodazole arrest and rapidly disappeared at the onset of S phase (Figure 4.3A). As 
cells were released from the nocodazole block, Cdt1 migrated faster than in 
nocodazole arrested cells (Figure 4.3A), indicating that Cdt1 accumulates in a 
modified form in the mitotic block (Nishitani et al. 2001). The origin licensing 
repressor geminin, required for preventing re-replication through interaction with 
Cdt1, was present at low levels during G1 with levels increasing during S phase 
(Eward et al. 2004; Wharton et al. 2004). To indirectly confirm activation of the pre-
RC through the phosphorylation status of endogenous Mcm2, I performed western 
blots with antibodies detecting phosphorylated Mcm2 at serine 40/41 and 
phosphorlyated Mcm2 at serine 53. The levels of pMcm2 S40/41, Cdc7- and CDK-
dependent phosphorylation sites, showed a similar pattern as Mcm2, whereas levels of 
pMcm2 S53, known to be a target for Cdc7, increased as the cells moved through late 
G1 and S phase (Figure 4.3A).  
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Figure 4.3: Expression dynamics and regulation of DNA replication initiation 
factors during the cell cycle. (A) Immunoblot analysis of DNA replication initiation 
factors and loading control (actin) in HeLa whole cell extracts at the indicated times. 
(B) Immunoblot analysis of Cdc7 and ASK proteins after immunoprecipitation using 
Cdc7 antibody from HeLa cell extracts. (IP - immunoprecipitation; WCE - Whole cell 
extract; pMcm2 S40/41 - Mcm2 phosphorylated at serine 40/41; pMcm2 S53 - Mcm2 
phosphorylated at serine 53)
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It has been reported that protein levels of human Cdc7 are nearly constant and appear 
to be stable during the cell cycle (Sato et al. 1997; Takeda et al. 1999). However, 
Figure 4.3A shows that in my experimental system Cdc7 protein levels are low in 
early G1 phase, increase towards the G1/S boundary and remain high throughout S to 
G2/M phase. Protein levels of ASK also increased in late G1 phase and stayed high 
during S phase (Figure 4.3A), suggesting that expression of ASK is regulated during 
the cell cycle, in keeping with a previous report (Jiang et al. 1999). To determine the 
formation of Cdc7/ASK complexes during the cell cycle, synchronized HeLa cells 
were lysed at various stages and the lysates immunoprecipitated with an antibody 
against Cdc7. Immunoprecipitates were resolved by gel electrophoresis and 
subsequently immunoblotted with Cdc7 and ASK antibodies (Figure 4.3B). The levels 
of endogenous Cdc7 and ASK proteins detected in Cdc7 immunoprecipitates were si 
milar to those detected by western blotting of lysates prepared from cells progressing 
synchronously though the cell cycle. These results show that levels of Cdc7 and ASK 
proteins vary during the cell cycle, thus regulating the formation of Cdc7/ASK kinase 
complex (Figure 4.3B). Consistent with this, Mcm2 phosphorylation on serine 53, 
which is a Cdc7-dependent phosphorylation site, showed a similar cell cycle 
dependent variation (Figure 4.3A), indicating that Cdc7 kinase activity during the cell 
cycle correlates with Cdc7-bound ASK complex levels. 
 
Levels of Cdc45, required for loading of DNA polymerase- onto chromatin (Mimura 
& Takisawa 1998; Mimura et al. 2000; Walter & Newport 2000), increased two hours 
after release from thymidine arrest (Figure 4.3A). Protein levels of Mcm10 were also 
low in early G1 and increased as cells reached late G1 and progressed though S phase 
(Figure 4.3A). Cyclin A became detectable in S phase, whereas cyclin E levels peaked 
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during the G1/S transition and decreased during early S phase (Dulic et al. 1992; Dou 
et al. 1993; Desdouets et al. 1995). Taken together, these data show that the pre-RC 
constituents ORC, Cdc6 and Mcm2-7 are present throughout the human proliferative 
cell cycle, and that the MCM loading factor Cdt1 is regulated at least in part through 
the controlled expression of geminin. The data also show that cell cycle dependent 
regulation of Cdc7 activity occurs through association with its regulatory subunit 
ASK, levels of which increase at the onset of S phase. Moreover, phosphorylation of 
Mcm2 on serine 53 is dependent on Cdc7/ASK activity and correlates with increased 
levels of Cdc45 and Mcm10 proteins during S phase progression, demonstrating that 
Cdc7/ASK kinase activity is essential for S phase progression. 
 
4.3.2. Expression dynamics and regulation of Cdc7/ASK kinase during exit into 
G0 and re-entry into the cell cycle 
Density dependent growth arrest and serum starvation have been widely used as a 
synchronization method to arrest cells in the resting, quiescent G0 state. Cultures are 
allowed to reach confluency, and cells are incubated without medium change. Some 
cell types, for example several murine fibroblast cell lines (NIH3T3, Balb/c3T3, 
Swiss3T3) and primary fibroblast cultures (MEF-mouse embryonic fibroblast, HDF-
human diploid fibroblast, WI-38 human embryonic fibroblast) can be synchronized in 
G0 in this way. Arrested cells can be stimulated to re-enter the cell cycle by 
subculturing with medium containing fresh serum (Pardee 1974). Transformed cell 
lines typically cannot be synchronized in G0 by these methods, because they have 
acquired mutations that allow them to grow independent of growth factors (Schorl & 
Sedivy 2006). To generate a molecular picture of the levels of pre-RC/pre-IC 
constituents, and to study the regulation of Cdc7/ASK kinase during exit into G0 and 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   118 
re-entry into cycle, in the work of this thesis I synchronised WI-38 human diploid 
fibroblasts in G0 by contact-inhibition and subsequently released the cells from 
quiescence by subculturing at lower density. In the experimental model, cells begin to 
enter S phase approximately 21 hours after release, as determined by flow cytometry 
(Stoeber et al. 2001; Kingsbury et al. 2005).  
 
To monitor exit of WI-38 fibroblasts from cycle into quiescence, flow cytometric 
analysis of DNA content was performed on asynchronously proliferating cells and 
cells progressively becoming contact-inhibited (Figure 4.4A). Cells began to arrest 
when contact-inhibited (C) (3% of cells in S phase), and the majority of cells entered 
a viable state of growth arrest five days after contact-inhibition, confirming that WI-
38 fibroblasts were synchronized in quiescence by density-dependent growth arrest. 
But there is a subpopulation (14-17%) of cells in G2/M phase which might have been 
introduced to quiescence population as contaminants. Re-entry of WI-38 fibroblasts 
into the cell cycle was continuously monitored following subculturing of cells at 
lower density five days after contact-inhibition (Figure 4.4B). The percentage of cells 
entering S phase increased from 2 % at 0 hours to 5 % at 18 hours and 12 % at 21 
hours after release from contact-inhibition, confirming that WI-38 fibroblasts 
synchronously re-enter the cell cycle from quiescence approximately 21 hours after 
release from contact-inhibition. 
 
Orc4 protein levels did not change during density-dependent growth arrest and 
remained relatively constant during re-entry into the cell cycle (Figure 4.5A). Mcm2 
protein levels began to decrease within 48 hours of exit from the cell cycle into 
quiescence and increased 18 hours after release from contact inhibition (Figure 4.5A). 
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Figure 4.4: Flow cytometric DNA profiles during exit into quiescence and re-entry into 
the cell cycle. (A) Exit of WI-38 fibroblasts into quiescence by density-dependent growth 
arrest was monitored by flow cytometric analysis of propidium iodide stained cells. An 
asynchronously proliferating population (AS) showed a normal DNA content distribution. 
Cells began to arrest in G1 when contact inhibited. (B) Re-entry of WI-38 fibroblasts into the 
cell cycle from quiescence was also monitored by flow cytometric analysis. After release 
from quiescence, cells progressed into S phase between 18 and 21 hours after release. 
Tab les show the pe rcen tages o f ce l l s w i th G1 , S , and G2 /M DNA con ten t . (AS - 
asynchronous; SC - semi-confluent; C - confluent; C1 - 15-days in density dependent growth 
arrest)  
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Phosphorylation of Mcm2 on serine 40/41 decreased with the onset of quiescence, and 
increased in a similar pattern to that observed for Mcm2 during re-entry into the cell 
cycle. Phosphorylation of Mcm2 on serine 53 decreased more rapidly, becoming 
undetectable 48 hours after exit from cycle and detectable again 24 hours after release 
from quiescence (Figure 4.5A). Cdc6 protein levels were downregulated 48 hours 
after exit from cycle, in keeping with previous reports (Stoeber et al. 2001; Kingsbury 
et al. 2005) and started to reappear 12 hours after re-entry into cycle. Cdt1 and 
geminin proteins were also downregulated within 48 hours of density-dependent 
growth arrest. During re-entry into cycle, Cdt1 was detectable at 12 hours and started 
to decrease by 21 hours. Geminin was also detectable at 12 hours, with levels peaking 
18 hours after release from quiescence (Figure 4.5A). Cdc45 and Mcm10 were down- 
regulated with a similar pattern to that observed for Cdt1 and geminin, however their 
de novo expression during re-entry into the cell cycle occurred later than Cdt1 and 
geminin (Figure 4.5A). Cyclin A was downregulated in G0 and became detectable 
again 24 hours after cells re-entered the cell cycle (Figure 4.5A). 
 
Cdc7 and ASK protein levels rapidly decreased 48 hours after exit from cycle into 
quiescence. During re-entry into cycle, Cdc7 and ASK levels were detectable by 15 
hours and were significantly increased 24 hours after the release (Figure 4.5A). The 
formation of the Cdc7/ASK complex in quiescent cells and during re-entry into the 
cell cycle was determined by coimmunoprecipitation with a Cdc7 antibody (Figure 
4.5B). Endogenous Cdc7 was bound to ASK in asynchronously proliferating and 
semi-confluent cells, with both proteins being downregulated rapidly following the 
onset of quiescence. 
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Figure 4.5: Expression dynamics and regulation of replication initiation factors 
during exit into G0 and re-entry into cycle. (A) Immunoblot analysis of replication 
initiation factors and loading control (actin) in WI-38 fibroblasts whole cell extracts at the 
indicated times. (B) Immunoblot analysis of Cdc7 and ASK proteins after 
immunoprecipitation using Cdc7 antibody from WI-38 cell extracts. (IP - 
immunoprecipitation; WCE - whole cell extract; pMcm2 S40/41 - Mcm2 phosphorylated 
on serine 40/41; pMcm2 S53 - Mcm2 phosphorylated on serine 53)
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Although Cdc7 and ASK proteins were detectable 15 hours after release from G0, 
Cdc7 association with ASK did not occur until 21 hours (Figure 4.5B), coinciding 
with phosphorylation of Mcm2 on serine 53 (Figure 4.5A). Taken together, these data 
show that downregulation of replication initiation factors, except Orc4, results in loss 
of DNA replication competence which contributes to the suppression of proliferative 
capacity in quiescence. Notably, Cdc7/ASK kinase activity is not only dependent on 
expression of Cdc7 and ASK proteins, but also their ability to associate during re-
entry into the cell cycle. 
  
4.3.3. Expression dynamics and regulation of Cdc7/ASK kinase in terminally 
differentiated cells 
Differentiating cells normally mature over the passage of time to form functionally 
competent cells for a particular tissue, culminating in terminal maturation or 
differentiation (Lajtha 1979). A wide range of cellular regulators are involved in 
coordinating the proliferation-differentiation switch in mammalian cells, including 
p21cip1, p27kip1, pRB and p53 (Coffman & Studzinski, 1999). Induction of the 
differentiation pathway in cultured HL60 cells, derived from a patient with acute 
promyelocytic leukaemia, with agents such as the phorbol ester phorbol 12-myristate 
13-acetate (PMA) and 1,25 dihydroxyvitamin D3 (1,25 Vit D3) is a well characterised 
in vitro model system for studying the relationship of cell proliferation and 
differentiation (Collins 1987). To investigate how regulation of the Cdc7/ASK kinase 
complex is linked to the molecular mechanisms that control DNA replication 
initiation during differentiation, in the work of this thesis I induced differentiation of 
promyeloblastic HL60 cells down the macrophage lineage. HL60 cells can be induced 
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to differentiate in vitro into monocyte-, granulocyte-, or macrophage-like cells by a 
number of physiological and non-physiological agents (Collins 1987). Exposure of 
HL60 cells to 1,25 dihydroxyvitamin D3 (1,25 Vit D3) results in cellular 
differentiation indicated by morphological changes, acquisition of markers 
characteristic of mature monocytes, and accumulateion of cells in G1 phase (Wang & 
Studzinski 2001). To generate a molecular picture of pre-RC/pre-IC constituents and 
to study the regulation of Cdc7/ASK kinase during differentiation, HL60 total cell 
extracts were prepared at 6 hour-intervals after administration of 1,25 Vit D3 as 
described (Barkley et al. 2007). 
 
To monitor the differentiation process, I measured expression of the cell surface 
markers CD11b and CD14 by bivariate flow cytometry (Figure 4.6A). Sixty percent 
of HL60 cells expressed CD11b by 24 hours, whereas 40% of cells expressed CD14. 
Maximum expression of both markers was detected by 72 hours after 1,25 Vit D3 trea 
tment (Figure 4.6B). In addition, flow cytometric analysis of DNA content shows that 
cells began to arrest in G1 by 36 hours, with 86% of cells accumulated in G1 phase 
120 hours after 1,25 Vit D3 treatment (Figure 4.7A). These data are in keeping with 
bromodeoxyuridine (BrdU) cell proliferation assays, which indicate that 45% of 
asynchronously proliferating HL60 cells incorporated BrdU during a one hour pulse. 
In contrast, the BrdU labelling index decreased to 20% at 48 hours and to less than 
10% 72 hours after the addition of 1,25 Vit D3 (Figure 4.7B), confirming 1,25 Vit D3 
induced accumulation of HL60 cells in G1 phase by 48 hours together with a decrease 
in DNA synthesis. 
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Figure 4.6: Expression of the monocyte/macrophage differentiation markers 
CD11b and CD14 in HL60 cells after addition of 1,25 Vit D3. (A) Cytogram of CD11b 
and CD14 expression in HL60 cells induced by 1,25 Vit D3 for 120 hours compared to 
asynchronously proliferating cells (AS).  (B) HL60 cells were incubated with 1,25 Vit D3 
for the indicated times to determine CD11b and CD14 positive cells by flow cytometry. 
(AS - asynchronous) 
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Protein levels of the Orc4 subunit were constant during differentiation. Mcm2 protein 
levels were downregulated during differentiation after the addition of 1,25 Vit D3 
(Figure 4.8A). Phosphorylation of Mcm2 on serine 40/41, which is indicative of 
phosphorylation by Cdc7 and CDK, started to decrease by 72 hours, whereas 
phosphorylation of Mcm2 on serine 53 which is Cdc7-dependent phosphorylation site  
decreased more rapidly within 48 hours (Figure 4.8A). Cdc6 and Cdt1 proteins were 
undetectable 72 hours after 1,25 Vit D3 addition. Geminin protein levels started to 
decrease slightly by 72 hours. Mcm10 became undetectable 36 hours after the 
addition of 1,25 Vit D3 (Figure 4.8A). PMA (4-phorbol 12-myristate 13-acetate)-
induced differentiation along the megakaryocytic phenotype is accompanied by down-
regulation of cyclin E (Bermejo et al. 2002) and cyclin A, indicating that cells exit 
from cell cycle (Pollok et al. 2007). Similarly, data generated in my experimental 
differentiation model show that cyclins A and E became undetectable 72 hours after 
1,25 Vit D3 addition (Figure 4.8A). 
 
During HL60 differentiation, protein levels of Cdc7 and ASK were found to be 
downregulated by 72 hours after 1,25 Vit D3 addition (Figure 4.8A). The formation of 
Cdc7/ASK kinase complex during differentiation was determined by 
coimmunoprecipitation with a Cdc7 antibody. Endogenous Cdc7-bound ASK 
complex was undetectable 72 hours after 1,25 Vit D3 addition (Figure 4.8B). Notably, 
phosphorylation of Mcm2 on serine 53 was undetectable by 72 hours, coinciding with 
down-regulation of Cdc7 and ASK protein and the loss of Cdc7-bound ASK complex 
at this time point, indicating that phosphorylation of Mcm2 is dependent on active 
Cdc7/ASK kinase complex (Figure 4.8B). 
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Figure 4.7: Flow cytometric DNA profiles of HL60 cells undergoing differentiation. 
Differentiation of HL60 cells after 1.25 Vit D3 treatment was monitored by bivariate flow 
cytometric analysis of (A) DNA content and (B) BrdU incorporation. Cells began to 
arrest in G1 at 36 hours and  85% of cells accumulated in G1 phase 120 hours after 
1,25 Vit D3 treatment. In BrdU assays, 45% of asynchronously proliferating HL60 cells 
incorporated BrdU. The BrdU labelling index decreased to 20% by 48 hours and to less 
than 10% 72 hours after the addition of 1,25 Vit D3.  
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 Taken together, these data show that loss of proliferative capacity as cells undergo 
differentiation is associated with down-regulation of replication initiation factors, 
including Cdc7 and ASK. Importantly, the essential role of Cdc7/ASK kinase in 
activating pre-RCs in proliferating cells its tight downregulation in out-of-cycle states, 
if confirmed for human tissues, raises the possibility that inhibition of this kinase 
might represent a powerful approach for the development of anti-cancer agents. 
 
4.3.4. Cdc7 and Mcm2 protein expression and Cdc7-dependent phosphorylation 
of Mcm2 on serine 53 profile analysis in human tissues 
As discussed above, the studies in tissue culture model systems show that the 
replication initiation machinery is assembled in a cell cycle dependent manner in 
proliferating humans cells, and that downregulation of initiation factors is linked to 
loss of proliferative capacity as cells exit into quiescent (G0) and differentiated states 
(Figures 4.3, 4.5, 4.8). Previous work has shown repression of the DNA replication 
initiation pathway through downregulation of Cdc6 and MCM proteins in a wide 
range of human organ systems, and that Cdc6, Cdt1 and Mcm2-7 expression is dysre 
gulated in human cancers (Williams et al. 1998; Freeman et al. 1999; Stoeber et al. 
1999; Going et al. 2002; Stoeber et al. 2001; Stoeber et al. 2002; Karakaidos et al. 
2004; Korkolopoulou et al. 2005). Cdc7 expression also appears altered in some 
cancer cell lines and primary tumours (Hess et al. 1998; Bonte et al. 2008), and in a 
wide range of melanocytic lesions (Clarke et al. 2009). Moreoever, a recent study 
showed that Cdc7 and CDK-dependent phosphorylation of Mcm2 at Ser40/41 is an 
indicator of S phase progression during the cell cycle re-entry of neurons in 
Alzheimer Disease (Bonda et al. 2009).  
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Figure 4.8: Expression dynamics and regulation of replication initiation factors 
during 1,25 Vit D3 induced differentiation in HL60 cells. (A) Immunoblot analysis of 
replication initiation factors and loasing control (actin) in HL60 whole cell extracts at the 
indicated times. Table shows the percentage of cells with G1, S, and G2/M DNA content. 
(B) Immunoblot analysis of Cdc7 and ASK proteins after immunoprecipitation using 
Cdc7 antibody from HL60 cell extracts. (IP - immunoprecipitation; WCE - whole cell 
extract; pMcm2 S40/41 - Mcm2 phosphorylated on serine 40/41; pMcm2 S53 - Mcm2 
phosphorylated on serine 53)
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 However, while the above studies have shed some light on Cdc7 regulation in vivo, I 
sought to add systematically to our understanding of Cdc7/ASK kinase activity 
(indirectly determined by Mcm2 phosphorylation at Ser 53) in different types of 
normal and cancerous human tissues.  
 
Human tissues can be divided into three classes: self-renewing (e.g. skin, 
gastrointestinal mucosa and the haemopoetic system), conditional renewal (e.g. liver 
or thyroid) and permanent (e.g. nerve or skeletal muscle) (Leblond, 1963). Tissues in 
adults with the most rapid turnover are self-renewing stem cell systems such as skin, 
colon or uterine cervix, typically showing a grading of cellular development from 
stem cells to terminally-differentiated mature cells via transient amplifying cells 
(reviewed by Watt & Hogan 2000). In the work of this thesis, I sought to define the 
regulation of Cdc7/ASK activity during tissue maintenance in the adult, especially in 
self-renewing system and conditional renewal tissue, and to determine the likely 
response of these tissues to pharmacological Cdc7 inhibitors. I analyzed Cdc7 and 
Mcm2 expression, as well as phosphorylation of Mcm2 on serine 53 (readout of 
Cdc7/ASK activity in vivo), in a typical self-renewing system, oral squamous 
epithelium (Figure 4.9), and in a typical conditional renewal tissue, liver (Figure 4.10).  
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Figure 4.9: Detection of Mcm2, Cdc7 and phospho Mcm2 in oral squamous epithelium and 
oral squamous cell carcinoma (OSCC). Photomicrographs of formalin fixed paraffin-embedded 
tissue sections of normal oral squamous epithelium and OSCC immunostained with antibodies 
against Mcm2, Cdc7 and pMcm2 S53. Original magnification, x400. (A) Immunostaining of 
normal oral squamous epithelium shows that expression of Mcm2, Cdc7 and phosphorylation of 
Mcm2 on serine 53 are restricted to the basal compartment of oral squamous epithelium, which 
corresponds to the proliferative zone. Mcm2, Cdc7  and pMcm2 were not detected in epithelial 
cells during the transition to a terminally differentiated phenotype. (B) Immunostaining of OSCC 
shows a high proportion of Cdc7 and Mcm2 expressing cells, and phospho Mcm2 on serine 53, 
indicating that a large proportion of tumour cells are engaged in the mitotic cell division cycle. 
(pMcm2 S53 - Mcm2 phosphorylated on serine 53)
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Figure 4.10: Detection of Mcm2, Cdc7 and phospho Mcm2 in human liver and 
hepatocellular carcinoma (HCC). Photomicrographs of formalin fixed paraffin-embedded tissue 
sections of normal liver and hepatocellular carcinoma (HCC) immunostained with antibodies 
against Mcm2, Cdc7 and pMcm2 S53. Original magnification, x400. (A) Immunostaining of 
normal liver is for Mcm2, Cdc7 and phospho Mcm2 consistent with withdrawal of hepatocytes 
from the cell cycle into a replication-incompetent quiescent state. (B) Immunostaining of HCC 
shows a high proportion of Mcm2 and Cdc7 expressing cells as well as phospho Mcm2 on serine 
53  coinciding with re-entry into the proliferative cycle. (pMcm2 S53 - Mcm2 phosphorylated on 
serine 53)  
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For Mcm2, Cdc7 and phosphorylated Mcm2 protein expression profiling, five cases 
of oral squamous cell carcinoma (OSCC) and hepatocellular carcinoma (HCC) were 
selected and analysed using immunohistochemistry 1 . Three to five fields were 
captured from selected areas and representative immunostained tissue sections are 
illustrated in Figure 4.9 and 4.10. Semi-quantitatve labelling indices for each proteins 
are shown in Table 4.1, and images with amounts of labelling indices spanning ranges 
of  >0% to 25%, >25%  to 75%,  and >75% were assigned scores of +1, +2, and +3, 
respectively (Table 4.1). Immunostaining of oral squamous epithelium showed that 
Mcm2 and Cdc7 expression and Mcm2 phosphorylation is restricted to the 
proliferative, basal compartment. Mcm2, Cdc7 and phosphorylated Mcm2 were not 
detected in epithelial cells during the transition to a mature differentiated phenotype 
(Figure 4.9A and Table 4.1). These findings are in keeping with the in vitro data, 
which show that the Mcm2 and Cdc7 replication initiation factors are present in 
proliferating cells and downregulated during differentiation. In contrast, 
immunostaining of oral squamous cell carcinoma (OSCC) shows a high proportion of 
Mcm2 and Cdc7 expressing cells as well as phosphorylation of Mcm2, indicating a 
greater number of cells engaged in the cell cycle due to deregulation of normal 
controls over cell proliferation (Figure 4.9B and Table 4.1). In normal oral squamous 
epithelium, Mcm2 expression levels are highest in the anatomical zone corresponding 
to the proliferative compartment. Compared to Mcm2 staining, a smaller population 
of cells in the proliferative compartment are positive for Cdc7 and phosphorylated 
Mcm2, indicating that licensed replication origins are not simultaneously fired by 
Cdc7/ASK dependent phosphorylation. 
                                                 
1 Technical assistance in the immunostaining and analysis of histological sections was provided by 
Marco Loddo and Mohammed Rashid (Research Department of Pathology, UCL). 
Table 4.1 Mcm2, Cdc7 and phosphorylated Mcm2 expression profile 
in oral squamous eipthelium and liver tissue 
Expression restricted to the basal proliferative compartment of normal oral squamous epithelium.∗
∗
Tissue Name Case No Mcm2 Cdc7 pMcm2 S53
U07-1678 + + + +
U07-6589 + + + +
Norm al U06-18395 + + + +
U06-16463 + + + +
Oral squamous epithelium U06-14973 + + + +
U07-1543 + + + + + + + +
U06-14206 + + + + + +
O S C C U06-17635 + + + + + + +
U06-16421 + + + + + + + +
U06-16463 + + + + + + + +
U07-7402 - - -
U08-14363 - - -
Norm al U07-4805 - - -
U08-10970 - - -
Liver U07-15351 - - -
U03-5003 + + + + + + +
U05-2634 + + + + + + +
HC C U06-8092 + + + + + + +
U08-14222 + + + + + + +
U04-19197 + + + + + + +
OSCC - Oral squamous cell carcinoma; HCC - Hepatocellular carcinoma
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To determine whether downregulation of Cdc7/ASK kinase activity during 
withdrawal from cycle into the quiescent state in vitro extends to conditional renewal 
tissues systems, the expression of Mcm2 and Cdc7 proteins and Mcm2 
phosphorylation were examined in normal and cancerous liver tissues. Normal liver 
shows little growth in adult life but retains proliferative capacity for further growth 
(Leblond et al. 1963). After hepatocyte loss as a result of surgery/transplantation, 
viruses or toxins, quiescent hepatocytes re-enter the mitotic cell cycle and proliferate 
to restore liver function and mass. In keeping with liver physiology, in normal liver, 
staining of Mcm2, Cdc7 and phosphorylated Mcm2 was observed in only a small 
percentage (<1%) of cells (Figure 4.10A and Table 4.1). Positive immunostaining, 
however, was evident in hepatocellular carcinoma, indicative of cell cycle re-entry 
and increased proliferation (Figure 4.10B and Table 4.1). These in vivo findings are 
consistent with the in vitro data generated in the fibroblast quiescence model system, 
which show that downregulation of some replication initiation factors and Cdc7/ASK 
kinase activity is coupled to reversible loss of proliferative capacity (Figure 4.5). 
Furthermore, the acquisition of proliferative capacity following re-entry into cycle is 
linked to induction of replication licensing and origin firing. Taken together, the data 
presented in this chapter show that Mcm2 and Cdc7 are present in actively 
proliferating cells and downregulated in resting and differentiated cells, both in vitro 
and in vivo. Importantly, Cdc7 immunostaining revealed a positive correlation with 
phosphorylation of Mcm2 on serine 53, confirming the activation of Cdc7/ASK 
kinase in preparation for origin firing and cell proliferation in vivo. The high 
proportion in human cancers of Cdc7 expressing cells with phosphorylated Mcm2 has 
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important implications for the potential use of Cdc7 as a diagnostic and prognostic 
biomarker and as a therapeutic target. 
 
4.4. Discussion and Conclusions 
An understanding of cell cycle regulation of chromosomal replication in human cells 
is fundamental to the understanding of diseases characterized by disorder in cell 
growth and division (reviewed in Negrini et al. 2010). Loss or alterations of cell cycle 
controls, for example, have been implicated in the development of certain cancers 
(Deshpande et al. 2005). In mammalian tissues the majority of cells exit the cell cycle 
reversibly into an out-of-cycle, quiescent state (G0), or alternatively withdraw 
irreversibly from the cell division cycle through the processes of terminal 
differentiation or replicative senescence (Pardee 1989; Myster & Duronio 2000; 
Hayflick & Moorhed 1961; Campisi 1996). Downregulation of DNA replication 
initiation factors has been previously linked to exit from the cell cycle into quiescence, 
differentiation and senescence (Williams et al. 1998; Stoeber et al. 2001; Kingsbury et 
al. 2005). Although the role of Cdc7/ASK kinase the DNA replication initiation 
pathway has been well characterised in yeast and Xenopus, and the increased 
Cdc7/ASK expression has been shown in some cancer cell lines and tumour 
specimens, its potentially important role in growth regulation of human tissues and 
their respective tumours warrants further investigation. In the work of this thesis, I 
used tissue culture model systems to characterise the expression dynamics of 
replication initiation factors, including Cdc7/ASK kinase, during the cell cycle, and 
during exit into the quiescent and differentiated out-of-cycle states. A second aim was 
to extrapolate Cdc7/ASK expression dynamics to an investigation of Cdc7 kinase 
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activity in selected normal and cancerous human tissues, to test its diagnostic utility 
and to provide target validation of Cdc7 for cancer therapy. 
 
Previous reports have shown that the amount of human Orc2 and Mcm2-7 (Stoeber et 
al. 2001; Tsuruga et al. 1997) and Cdc45 (Pollok et al. 2007) remain constant during 
the cell cycle, whereas levels of Cdc6 (Stoeber et al. 2001; Petersen et al. 2006), Cdt1 
(Wohlschlegel et al. 2000), geminin (Eward et al. 2004; Wharton et al. 2004) and 
ASK (Jiang et al. 1999; Yamada et al. 2002) appear to fluctuate. In the work of this 
thesis, the protein levels of pre-RC/pre-IC constituents are consistent with a model in 
which a core set of replication initiation factors sequentially assemble at origins 
during G1 phase (Figure 4.2A). As the replication initiation factors assemble onto the 
origin and form the pre-RC, activation of S-phase specific kinases, CDKs and Cdc7, 
triggers the transition from pre-RC to pre-IC (reviewed in Sclafani & Holzen 2007). 
Phosphorylation of Mcm2 at multiple sites correlates with pre-RCs being activated by 
S-phase specific kinases (Montagnoli et al. 2006; Cho et al. 2006; Tsuji et al. 2006; 
Charych et al. 2008). The data discussed in this chapter show that expression levels of 
Cdc7 and ASK were found to be upregulated as cells progressed into S phase 
coinciding with increased levels of Mcm2 phosphorylation on serine 53. This suggests 
that Cdc7/ASK kinase activity is required for pre-RC activation through 
phosphorylation of Mcm2 which is essential for S phase entry and progression (Figure 
4.2A). The data also show that downregulation of some replication initiation factors, 
including Cdc7 and ASK results in loss of DNA replication competence which 
contributes to the suppression of proliferative capacity in quiescent and differentiating 
human cells (Figure 4.5A and 4.8A). 
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Cdc7 requires association with ASK, forming a complex to generate its kinase activity 
which is essential for pre-RC activation (Jiang et al.1999; Kumagai et al. 1999; 
reviewed in Swords et al. 2010). Immunoprecipitation experiments show that levels of 
Cdc7-bound ASK fluctuate with the same temporal sequence as Cdc7 and ASK 
proteins (Figure 4.3). Interestingly, the association of Cdc7 with ASK is not 
detectable until 21 hours after release from quiescence, correlating with 
phosphorylation of Mcm2 on serine 53, while the individual proteins are re-expressed 
already 15 hours after the release (Figure 4.5B). These data argue that Cdc7/ASK 
kinase activity is not only dependent on expression of the two subunits but also their 
ability to associate and form a complex. Indeed, phosphorylation of Mcm2 on serine 
53 was detectable in late G1 and S phase with the same kinetics as Cdc7-bound ASK 
complex (Figure 4.3A and B), suggesting that phosphorylation of Mcm2 at this 
residue is dependent on Cdc7/ASK kinase complex activity. 
 
Most cells in human out-of-cycle tissues reside in differentiated and quiescent states, 
and start to proliferate in response to external growth stimulation (Masai et al. 2005). 
Immediate responses of resting cells to growth factors include induction of a set of 
immediate early genes, including Fos, Jun, Ets and Myc, which induce cyclin D 
expression (Masai et al. 2005). Cyclin D-Cdk4 phosphorylates retinoblastoma (Rb) 
protein, releasing members of the E2F family of transcription factors for activation of 
their target genes. It is well known that the E2F family is essential for coordinating 
transcription during the mammalian cell cycle (Harbour & Dean, 2000). A number of 
factors involved in the DNA replication initiation machinery and regulation of its 
assembly and functions are targets of E2F. These include Orc1 (Ohtani et al. 1996), 
Mcm4 and 7, Cdc6, Cdc45 (Arata et al. 2000), geminin (Markey et al. 2004), Cdc7 
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(Kim et al. 1998) and ASK (Yamada et al. 2002). It has been reported that E2F-
regulated promoters are transcriptionally silenced in quiescent and senescent cells 
(Ogawa et al. 2002; Narita et al. 2003). E2F-binding sites were identified in the 
promoter regions of genes coding for Mcm5 (Tsuruga et al.1997), Cdc6 (Ohtani et al. 
1998), DNA polymerase- (Pearson et al. 1991), Cdc45 (Arata et al. 2000), Geminin 
(Markey et al. 2004), Cdc7 (Kim et al. 1998) and ASK (Yamada et al. 2002). The 
presence of E2F binding sites in the CDC7 and ASK genes and their observed 
downregulation in non-cycling cells suggests that Cdc7 and ASK could be regulated 
via the Rb-E2F pathway (Kim et al.1998; Kumagai et al. 1999; reviewed in Masai & 
Arai 2002). 
. 
Previous studies have shown that Cdc7 and ASK are often overexpressed in various 
tumour specimens, but not in matched normal tissues (Hess et al. 1998; Bonte et al. 
2008). Mcm2-7 expression is restricted to cycling cells and has been identified as a 
powerful diagnostic and prognostic marker in a wide range of malignancies (Williams 
& Stoeber 2007). Since phosphorylation of Mcm2 is regulated by Cdc7/ASK activity, 
the labelling index for Mcm2 phosphorylated on serine 53 could also be a potential 
biomarker downstream of Mcm2-7, however it has yet to be shown in human tissues. 
In the work of this thesis, expression profiling in oral squamous epithelium showed 
that cells of the transient amplifying compartment display a replication phenotype 
indicative of cycling cells, with positive immunostaining for Mcm2, Cdc7 and 
phosphorylated Mcm2. Progression into the terminally-differentiated compartment, 
where cells obtain a functional phenotype and lose their proliferative capacity, is 
associated with downregulation of these replication initiation factors and loss of 
Mcm2 phosphorylation (Figure 4.9A). These results are consistent with previous 
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reports that differentiation and DNA replication licensing are mutually exclusive 
processes in self-renewing human tissues (Stoeber et al. 2001), and are in keeping 
with the concept of antagonism between the cellular circuits that control proliferation 
and differentiation (reviewed by Olson & Spiegelman 1999). Notably, in the 
proliferative compartment the labelling index for Mcm2 is higher than those for Cdc7 
and phosphorylated Mcm2, indicating that replication origins in most cells are 
licensed, as determined by Mcm2 protein expression, but origins are not fired in every 
cell. This suggests that in vivo in addition to out of cycle cells and actively cycling 
cells there is a third population of cells that has the potential to proliferate (licensed 
origins) but is not actively cycling. 
 
Expression profiling in liver shows that reversible loss of proliferative capacity is also 
coupled to repression of the replication initiation machinery, as defined by 
downregulation of Mcm2 and Cdc7 expression and loss of Mcm2 phosphorylation on 
serine 53 (Figure 4.10A). By contrast, hepatocellular carcinoma showed high levels of 
cells positively stained for Mcm2, Cdc7 and phosphorylated Mcm2 (Figure 4.10B), 
indicative of cell cycle re-entry and proliferation. Importantly, the downregulation of 
Cdc7 during withdrawal of cells from cycle into quiescence and the fact that the 
majority of cells in the stem-progenitor compartment are unlicensed (Williams & 
Stoeber, 2007) suggests that conditionally renewing and self-renewing tissues should 
be largely refractory to therapeutic Cdc7 inhibitors. Moreover, the data generated for 
Cdc7 suggest that determination of its labelling index in human tumours may yield 
important prognostic information. Indeed this concept has already been proven for 
epithelial ovarian cancer (Kulkarni et al. 2009). 
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Several conclusions can be drawn from the in vitro and in vivo data discussed in this 
chapter. Firstly, Cdc7 and ASK are required for S phase entry and progression and 
phosphorylation of Mcm2 on serine 53 is dependent on Cdc7/ASK activity. Secondly, 
downregulation of replication initiation factors, including Cdc7/ASK, leads to loss of 
replication competence, which contributes to the suppression of proliferative capacity 
in quiescent and differentiated out-of-cycle states. Thirdly, in self-renewing systems 
such as oral squamous epithelium, Cdc7 is expressed in the transit amplifying 
compartment and downregulated in the terminally-differentiated compartment, in 
keeping with data generated in the HL60 in vitro differentiation system. Fourthly, the 
presence of Cdc7 and phosphorylation of Mcm2 on serine 53 in proliferating cancer 
cells, while the kinase in downregulated in normal liver (quiescence) and squamous 
epithelial cells (terminally-differentiated state), argues for Cdc7 as a potential 
diagnostic and prognostic target. Finally, the data presented in this chapter can be 
used to predict how normal cell populations may respond to pharmacological Cdc7 
inhibitors.  
 
Most functional cells reside in a reversible quiescent or terminally differentiated state 
with an unlicensed replication phenotype. Cancer cells generally show uncontrolled 
cell growth and a high proportion of cycling cells. Therefore, agents that specifically 
inhibit the replication initiation machinery are promising candidates for effective anti-
cancer drugs. This contrasts with normal cycling cell populations which have a 
licensed phenotype and thus could be targeted by pharmacological Cdc7 inhibitors. 
Experimental evidence, however, has shown that RNAi against Cdc7 causes tumour 
cell lines to progress through a defective S phase leading to p53-independent 
apoptotic cell death, while primary fibroblasts avoid this lethal event by activating a 
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p53-dependent cell cycle checkpoint at G1/S (Montagnoli et al. 2004). Thus, 
Cdc7/ASK inhibitors may serve as powerful agents to selectively kill tumour cells, 
either alone or in combination with standard genotoxic drugs. 
 
In the work of this thesis, I developed a sensitive assay for Cdc7 activity to identify 
small molecule inhibitors. In the following chapter, I describe the development of this 
antibody-based kinase assay, in conjunction with the generation of a homology model 
for Cdc7 and its active site, which provided the groundwork for the design of selective 
inhibitors of Cdc7. 
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CHAPTER FIVE 
Development of a Cdc7 kinase assay   
5.1. Introduction 
The in vitro data discussed in the previous chapter indicate that Cdc7/ASK kinase is 
required for S phase progression, and that downregulation of this kinase is coupled to 
repression of origin licensing in quiescent and differentiated human cells. In keeping 
with the in vitro data, tissue specimen show the presence of Cdc7 and Mcm2 
phosphorylated on serine 53 in a high proportion of proliferating cancer cells, and 
their absence in normal quiescent liver and differentiated oral squamous epithelial 
cells. It follows from this that Cdc7 may constitute a potential diagnostic and 
therapeutic target. Cdc7 inhibitors should not affect non-cycling cell populations in 
human tissues, thus ensuring that the majority of normal cells within the body are 
protected from potential cytotoxic effects.  
 
Several steps in the DNA replication initiation pathway have been identified as 
potential targets for the discovery of new anti-cancer agents (see Chapter 1). Among 
them, small molecule inhibitors of CDKs have already shown some success in clinical 
development, but are compromised by the wide spectrum of action of these global cell 
cycle regulators and the rapid development of resistance (Blagden & de Bono, 2005). 
Cdc7/ASK kinase, which like CDKs is required for origin activation, has very few 
protein substrates (reviewed in Takeda & Dutta, 2005) and therefore could be a novel 
attractive target for anti-cancer therapy. Montagnoli et al. have demonstrated that 
Cdc7 knockdown by siRNA causes tumour cell lines to progress through a defective S 
phase, leading to p53-independent apoptotic cell death. In contrast, primary normal 
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human dermal fibroblasts avoid this lethal event by activating a putative p53-
dependent cell cycle checkpoint leading to cell-cycle arrest (Montagnoli et al. 2004). 
Based on these findings, Cdc7/ASK kinase has been actively pursued as a target for 
anti-cancer drug discovery and development.  
 
Recently, a series of small molecule Cdc7 inhibitors have been reported by Nerviano 
Medical Sciences (Vanotti et al. 2008) and one compound (PHA-767491) has been 
characterized in vitro and in vivo (Montagnoli et al. 2008). PHA-767491 affects the 
Cdc7/ASK dependent phosphorylation sites, on Mcm2, blocks DNA synthesis, and 
induces cell death in multiple cancer cell lines. PHA-767491 anti-cancer activity was 
confirmed in AML (Acute myeloid leukaemia), colon and breast cancer xenograft 
models (Montagnoli et al. 2008), and also in a rodents with induced mammary 
tumours (Benakanakere et al. 2006). However, it also shows off target effects on 
Cdk9 and subsequent RNA polymerase II phosphorylation. NMS-354, another 
Neviano compound, was reported as an orally available Cdc7 inhibitor (Montagnoli et 
al. 2008). This compound demonstrated p53-dependent anti-proliferative activity and 
induction of apoptosis in a broad panel of cancer cell lines, and tumour regression of 
up to 80% in different xenograft tumour models including ovarian, colon, mammary 
and leukemia and also in rat mammary carcinogenic-induced tumour models (DMBA 
model) (reviewed in Sawa & Masai 2008; Swords et al. 2010). In addition to the 
Nerviano compounds, several other compounds are in development and various potent 
Cdc7 inhibitors have been reported in the patent literatures (reviewed in Sawa & 
Masai 2008; Swords et al. 2010). Roche (Zhao et al. 2005), Novartis (Shafer et al. 
2008), Pfizer (Tonani et al. 2004) and Sanofi-Aventis (Leroy et al. 2008) have all 
generated potent compounds capable of inhibiting Cdc7 kinase with low-nanomolar 
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activity. However, more detailed evaluations of these compounds at the cellular level 
or in animal models are required for further Cdc7 inhibitor development.  
Interestingly, Exelixis/Bristol Myer Squibb (BMS) has developed a potent Cdc7 
inhibitor (BMS-863233) that is currently under clinical evaluation (reviewed in 
Swords et al. 2010). 
 
The drug discovery and development process involves several steps, ranging from 
target identification/validation, assay development, high throughput screening (HTS), 
hit validation, hit to lead (lead generation/optimization), preclinical and clinical 
studies to final registration of a drug (Bleicher et al. 2003, also see Chapter 1, section 
1.4). Recent drug development has focused on small molecule compounds that 
specifically inhibit and/or modify tumour-specific molecular biological changes (Saijo 
et al. 2003). To identify a specific small molecule inhibitor of Cdc7, a well-
characterized, functional primary assay is essential at an early stage in the drug 
development process. An advantage in the development of a primary assay for Cdc7 
inhibitors is that Cdc7/ASK has few downstream targets and that specific Cdc7-
dependent phosphorylation sites on Mcm2 have been identified in vitro and in vivo. 
Cdc7/ASK kinase activity is required for initiation of DNA replication through 
phosphorylation of the Mcm2-7 complex (Jares et al. 2000; Zou & Stillman 2000; 
Walter 2000). An abundance of biochemical data show that the Mcm2-7 complex is a 
downstream target of the Cdc7/ASK kinase complex (Lei et al. 1997; Sato et al. 1997; 
Jares et al. 2000). Among the six subunits that form the Mcm2-7 complex, Mcm2 is a 
good substrate for Cdc7/ASK kinase (Cortez et al. 2004; reviewed in Charych et al 
2008). Several reports have demonstrated Cdc7/ASK-dependent phosphorylation sites 
within the N-terminal region of Mcm2 (Montagnoli et al. 2006; Cho et al. 2006; Tsuji 
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et al. 2006; Charych et al. 2008). These phosphorylated sites can be recognized by 
serine phosphorylated antibodies, which provides a useful readout for Cdc7/ASK 
kinase activity in vitro and in vivo (reviewed in Charych et al. 2008). Exploiting these 
reagents in the work of this thesis, I sought to develop an antibody-based primary 
screening assay for identification and characterisation of Cdc7 inhibitors.  
 
In recent years a number of kinases have been implicated in the development and 
progression of human diseases and, thus, modulation of kinase activity by small 
molecules has been proposed as an attractive strategy for drug discovery programmes 
(Cohen 1999; reviewed in Malumbres & Barbacid 2007). Protein kinases share a 
relatively high degree of sequence similarity, with conserved, regulatory elements, a 
similar three-dimensional structure, and the same catalytic mechanism of gamma 
phosphate transfer from ATP to a serine, threonine or tyrosine residues on a protein 
substrate (Fedorov et al. 2007). These established kinase structural aspects and the 
binding modes of various known CDK inhibitors can be used to improve potency and 
specificity in drug discovery and design (Sridhar et al., 2006). High-resolution 
structural information of the catalytic domain of the kinase family is important for the 
rational design of selective inhibitors. More than 80 high-resolution structures of 
Cyclin dependent kinase (Cdk) 2 (De Bondt et al. 1993), Cdk5 (Lew et al. 1995) and 
Cdk6 (Russo et al. 1998), both alone and in complex with inhibitors, have been 
published. The kinase domain of Cdc7, a member of the serine/theronine kinase 
family, has sequence similarities with other kinases, but, the three-dimensional 
structure of this domain has not yet been reported. The available structural 
information for other kinases may therefore provide a useful starting point for 
building a structural homology model of Cdc7 which could be used to develop more 
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specific Cdc7 inhibitors. Such a model could be validated using a biochemical kinase 
activity assay which allows high-throughput screening of compound libraries (Gaarde 
et al. 1997; Mallon et al. 2001). 
 
In this chapter, I describe the development of an antibody-based kinase assay for 
Cdc7/ASK kinase activity which allows high-throughput screening of compound 
libraries to identify Cdc7 inhibitors. Furthermore, applying a homology model for 
Cdc7 based on available crystal structures, analysis of the Cdc7 active sites which are 
essential for mediating its activity and mutagenesis of key residues in the Cdc7 active 
site to produce kinase-dead Cdc7 mutants are described. 
 
5.2. Material and Methods 
For preparation of recombinant baculoviruses (2.3.1), viral DNA isolation (2.3.2.), 
generation of recombinant baculovirus (2.3.3.), plaque assay (2.3.4.), virus titeration 
(2.3.5.), expression of recombinant His-tagged human Cdc7, ASK and mutant Cdc7 in 
Sf9 insect cells (2.4.2.), expression of recombinant human Cdc7/ASK kinase complex 
in Sf9 insect cells (2.4.3.) purification of Cdc7, ASK, mutant Cdc7 and Cdc7/ASK 
complex (2.4.4.), expression and purification of ASK (271-674) fragment (2.4.5., 
2.4.6.), expression and purification of Mcm2 (1-154) fragment (2.4.7., 2.4.8.), SDS-
polyacrylamide gel electrophoresis (2.4.9.), coomassie blue staining of SDS-PAGE 
gels (2.4.10.), antibodies (2.5.1.), preparation of whole cell extracts (2.5.2.), 
immunoblotting (2.5.3.), immunoprecipitation (2.5.4.), in vitro kinase assay (2.7.1.) 
and antibody-based kinase assay for 96-well format (2.7.2.) please refer to Chapter 
Two (Materials and Methods). 
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5.3. Results 
5.3.1. Development of an antibody-based Cdc7 kinase assay 
To identify small molecule inhibitors of Cdc7/ASK kinase activity as potential anti-
cancer agents, the development of a primary screening assay is essential. Such an 
assay should measure the ability of small molecules to inhibit phosphorylation of a 
substrate peptide. Since Mcm2 is the major physiological substrate of Cdc7/ASK 
kinase and phosphorylation of Mcm2 at Ser-53 by Cdc7/ASK can be specifically 
detected by a pMcm2 S53 antibody, recombinant human Mcm2 protein containing the 
N-terminal 154 amino acids was expressed in E. coli and purified using immobilized 
metal affinity chromatography (IMAC). Coomassie blue stained gels show the 30 kDa 
N-terminal fragment of Mcm2 and a small amount of a ~29 kDa Mcm2 degradation 
product after purification (Figure 5.1A). Protein assays after purification showed 
concentration of 1 mg/ml Mcm2 protein. To establish whether the N-terminal 
recombinant fragment of Mcm2 can serve as a substrate for Cdc7/ASK in an in vitro 
kinase assay, the fragment was incubated with purified Cdc7/ASK kinase complex in 
the presence of ATP (Figure 5.1B). Recombinant Cdc7/ASK kinase complex which 
was used in this in vitro kinase assay had been generated in the work described in 
Chapter Three (Figure 3.6). Using this assay, I was able to demonstrate that the N-
terminal region of Mcm2 protein is phosphorylated by purified Cdc7/ASK in the 
presence of ATP, which is detectable with a pMcm2 S53 antibody (Bethyl, 
Montgomery, USA). In the absence of ATP, no phosphorylation of Mcm2 was 
observed (Figure 5.1C). The data discussed in Chapter Four show that the level of  
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Figure 5.1: Kinase assay with purified human Cdc7/ASK kinase complex and Mcm2 fragment. 
(A) Coomassie stained gel showing N-terminal fragment of human Mcm2 expressed and purified in 
E.coli. (B) In vitro kinase assays were conducted with the purified Cdc7/ASK complex in the presence 
of Mcm2 fragment as a substrate. (C) After incubation the reaction products were separated by 
SDS-PAGE and immunoblotted with Mcm2 phosphorylated on serine 53 and Mcm2 antibodies 
(pMcm2- phosphorylated Mcm2). (D) Schematic of the antibody-based kinase assay which was 
developed using pMcm2 S53 antibody in 96 well plates. (E) Intensity in colourimetric assay is 
dependent on kinase concentration (absorbance at 405nm). Cdc2/CyclinB kinase was used as a 
positive control for the kinase reaction.
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pMcm2 S53 oscillates in parallel to the level of Cdc7-bound ASK complex (Figures 
4.3, 4.5, and 4.8), reinforcing the notion that phosphorylation of Mcm2 is dependent 
on Cdc7/ASK kinase activity. Consistent with this finding, pMcm2 S53 antibody 
recognised phosphorylated Mcm2 after in vitro kinase reactions with recombinant 
Cdc7/ASK (Figure 5.1C and 5.2B).  
 
The activity of the Cdc7/ASK complex can be determined using a 32P-ATP assay in 
which the transfer of 32P is measured. Such assays have been routinely employed in 
the past, for example for cyclin-dependent kinases, and generic peptide substrates 
have been identified for several classes of kinases (Xu et al., 2003). However, due to 
several limitations, such as radioactive waste management and the short half-life of 
reagents, there is a need for more robust non-radioactive assays. With this in mind, I 
sought to develop a non-radioactive antibody-based assay to measure Cdc7/ASK 
kinase activity. To allow for high-throughout screening, the original kinase assay was 
further modified in that purified recombinant Mcm2 fragment was coated onto 
HisGrab 96-well plates before the kinase reaction. The degree of phosphorylation was 
determined with a colorimetric method by measuring absorbance at 405nm after the 
kinase reaction as described in Materials and Methods (Figure 5.1D and E). Taken 
together, these data indicate that recombinant Cdc7/ASK kinase and its protein 
substrate Mcm2 can be used for an antibody-based kinase assay system that allows 
discrimination of specific phosphorylation of the Mcm2 fragment by Cdc7/ASK 
without using radioactive phosphate.  
 
5.3.2. Optimisation of antibody-based kinase assay for primary screening 
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To determine the concentration of Mcm2 fragment for maximum coating in each well, 
varying concentrations of Mcm2 protein were added to 96-well plates. Plates were 
washed and incubated with reaction buffer and Cdc7/ASK complex to allow 
phosphorylation of Mcm2. The phosphorylated Mcm2 was then detected using the 
pMcm2 S53 antibody. Half maximal absorbance was obtained with 500 ng/well of 
Mcm2 protein, and maximal absorbance was from 1g/well where binding to the 
surface reached a plateau (Figure 5.2A). Hence this Mcm2 concentration was used in 
all further experiments. To determine the dependence of the assay on enzyme 
concentrations, the assay was performed with increasing amounts of Cdc7/ASK 
kinase. A titration curve of Cdc7/ASK shows that the Mcm2 phosphorylation signal 
increases with increasing Cdc7/ASK concentration of up to 15.6M of Cdc7/ASK 
kinase complex, indicating that the signal is dependent on enzyme concentration and 
reflects the phosphorylation status of Mcm2 (Figure 5.2B). The assay was also 
performed with increasing concentrations of ATP (0-10 M) to determine an ATP 
concentration sufficient to obtain reasonable reaction kinetics and still allowing the 
detection of potential ATP competitive inhibition. Figure 5.3A shows that the Km for 
ATP in the phosphorylation of Mcm2 by Cdc7/ASK is 0.3 M, indicating that the 
Cdc7/ASK kinase complex has a high affinity for ATP in this assay (Figure 5.3A).  
 
To establish a robust automated high-throughput screening (HTS) platform, I 
examined additional parameters such as enzyme stability and pH optimum. The 
purified Cdc7/ASK kinase aliquots were stored at -80C for a total duration of up to 
six months. Cdc7/ASK activity was found to be stable for up to four months (Figure 
5.3B). Moreover, the activities of kinase complex purified from different batches of  
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Figure 5.2: Optimisation of antibody-based kinase assay for Cdc7/ASK kinase activity. 
(A)Titration of Mcm2 protein binding capacity on the 96-well plates. Coating step with various 
concentrations of Mcm2 fragment was followed by a one hour incubation at room temperature 
with Cdc7/ASK kinase complex in the presence of ATP. (B)Titration of Cdc7/ASK kinase. 
Various concentrations of Cdc7/ASK kinase complex were incubated with Mcm2 fragment in 
the presence of ATP at room temperature for one hour. pMcm2 S53 antibody and secondary 
antibody incubations for one hour were followed by the addition of a development reagent. The 
colorimetric signal was detected as absorbance units at 405nm. 
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Figure 5.3: Optimisation of antibody-based kinase assay for Cdc7/ASK kinase activity. 
(A)Km for ATP of Cdc7/ASK. ATP was titrated in serial dilutions in the presence of Cdc7/ASK 
and Mcm2 fragment. (B)Stability test of Cdc7/ASK. The activity of Cdc7/ASK was tested after 
storage of the purified protein for the indicated periods. 
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insect cell pellets were consistently high (Figure 5.4A). The kinase reaction reaches a 
maximum signal at pH 8.5 in reaction buffer and slightly decreases at pH 9.0 (Figure 
5.4B). These data suggest that this non-radioactive antibody-based kinase assay can 
be adapted for high-throughput screening of compound libraries. In Chapter Six, I will 
be discussing how I have adapted this assay to an automated assay platform for high-
throughput screening with guidance from the Cancer Research UK Technology (CRT) 
assay development team.  
    
5.3.3. Cdc7 homology modelling and structural analysis of Cdc7 active site 
In order to generate an effective screening library, it is necessary to identify 
compounds with a high probability of being hits in a given assay. When crystal 
structures or homology models of the target protein are available, a screening library 
can be constructed from a structure-based perspective (Sridhar et al. 2006).  
 
I wish to clearly state that the Cdc7 homology modelling and structural analysis of the 
Cdc7 active site described in this section are entirely the work of Dr. A. Okorokov 
(Wolfson Institute for Biomedical Research, UCL, UK). These data are included here 
as part of the connected argument because they provide the rationale for the 
mutational analysis described in 5.3.4., performed entirely by myself in the work of 
this thesis. 
 
Cdc7 is a member of the serine/threonine protein kinase family. Most of the kinases 
belonging to this family share a similar structure in their catalytic domain which 
consists of two lobes, a smaller N-terminal lobe and a larger C-terminal lobe (Hanks 
& Hunter 1995). The N-terminal lobe consists of mostly antiparallel -sheets and one  
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Figure 5.4: Optimisation of antibody-based kinase assay for Cdc7/ASK kinase 
activity. (A) Assays were performed with Cdc7/ASK purified from different batches of 
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-helix, whilst the C-terminal lobe is mainly helical. ATP binds in a pocket formed 
between the two lobes which are linked by a segment referred to as the hinge loop 
(Hanks & Hunter 1995). In order to identify the most suitable structure for a 
modelling template, human Cdc7 kinase protein sequence (aa 54-208) was used to 
predict secondary structure and compared with the known atomic structures in the 
PDB (Protein data bank) by 3D Threader and Protein Homology/analogy Recognition 
software packages (Imperial College, London). A computer model of the Cdc7 kinase 
subdomain based on the crystal structures of human Cdk2 and rat Erk2 is shown in 
Figure 5.5. The predicted structural homologues with highest accuracy (>90%) were 
used to derive a 3D structure model of the human Cdc7 kinase core domain which is 
the most structurally conserved domain within the Cdc7 protein. The highest score 
(95% accuracy) identified rat Erk2 kinase (PDB 1D 1gol) as the closest structural 
homologue of human Cdc7 (Figure 5.5B and C). The resulting 3D model of the Cdc7 
kinase domain was aligned onto the corresponding domain in Erk2 from structures 
available at PDB to fine tune the model in PyMOL and SwissModel software 
packages.  
 
The model allows the location and comparison of amino acid residues of Cdc7 
forming the ATP-binding pocket and the catalytic site (Figure 5.6A). In this model, 
aspartic acid (D) residues 177 and 196 are predicted to be involved in direct catalysis, 
lysine (K) residues 90 and 179 appear to be important for phosphoryl transfer 
reactions, whilst  threonine (T) 68, known as the “gatekeeper”, is involved in the H2O-
Mg2 activity in the Cdc7 active site (Figure 5.6A). These residues are highly 
conserved among the Cdc7 kinase family and other serine/theonine kinases. Structure-
based library design is typically carried out by computationally docking sets of  
Figure 5.5: High-degree of conservation at molecular level between Cdk2, Erk2 and Cdc7 
demonstrated by comparison of kinase structures. Structures of Cdk2 (A), Erk2 (B) and a 3D 
model of the Cdc7 kinase domain (C) (PDB entries 1 W0X and 1 GOL; Andrei Okorokov, unpublished 
data). (D)Super-imposed kinase active sites of Cdk2 (shown in orange) and Cdc7 (shown in blue) 
demonstrate subtle differences in amino acid residues around the ATP binding site, with main 
alterations corresponding to Cdk2 positions Val 64, Phe 82 and His 84 residues. The active site is 
occupied by an inhibitor molecule, olomucine (shown in green).
Olomucine
ATPOlomucine
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compounds into a rigid model of the protein active site. In the past, docking methods 
were used to identify small sets of molecules which would be active against a single 
target. More recently, docking methods have been used to create screening libraries 
focused on specific gene families such as kinases (reviewed in Walters & Nmchuk 
2003). Most existing small molecule inhibitors target the ATP-binding pocket of 
kinases and compete with ATP. Figure 5.6B shows a comparison of amino acid 
residues that are found to be important in the ATP-binding pocket of Cdc7 and several 
related kinases. Importantly, residues F15, S16, I29, A50, Q60, Y68, E86, H87, V104, 
N110, F112, A114, V128 and A142 are not conserved between Cdc7 and other 
kinases, thereby providing a starting point for the design of selective inhibitors of 
Cdc7 (Figure 5.6B).  
 
5.3.4. Biochemical analysis of wild-type and mutant Cdc7 kinase activity 
Mutation of the conserved lysine in the kinase subdomain has become a standard 
method for inactivating protein kinases. It has previously been demonstrated that the 
mutation of lysine (K) 90 to arginine in the Cdc7 kinase subdomain II inactivates the 
catalytic activity of Cdc7/Dbf4 complex (Jiang & Hunter 1997; Jiang et al 1999; 
Masai et al. 2000). To validate the activity prediction of the Cdc7 three-dimensional 
model, K90, D177 and D196 were replaced with alanines (A) to negate catalytic 
activity using site-directed mutagenesis (see Material and Methods). The presence of 
the site-specific mutations was confirmed by DNA sequencing. Three mutants (K90A, 
D177A and D196A) and wild-type Cdc7 were individually co-expressed with ASK 
protein and purified from insect cells as described in Chapter Three.  
 
 
K179
D177
T68 K90
D196
A
B
Figure 5.6: Modelling of the Cdc7 ATP-binding pocket. (A) Structure model of the Cdc7 
ATP-binding pocket with bound ATP (shown in red). Five residues (T68, K90, D177, K179 and D196) 
around the ATP-binding pocket are indicated (Andrei Okorokov, unpublished data). (B) Sequence 
alignment of the conserved motifs from human Cdc7 and selected kinases (human Cdk2, Cdk4 and rat 
Erk2), showing 14 unique residues (shown in yellow) of the Cdc7 domain and five key residues (shown 
in gray) of the Cdc7 active site. Three residues (K90, D177 and D196) were targeted for mutagenesis 
in the work of this thesis. 
T68 K90
D177 K179 D196
CDK2_HUMAN -----------------MEN--FQKVEKIGEGTYGVVYKARNKLTG---EVVALKKIRX- 37
CDK4_HUMAN -----------------MATSRYEPVAEIGVGAYGTVYKARDPHSG---HFVALKSVRVP 40
ERK2_RAT MAAAAAAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNK---VRVAIKKISP- 56
CDC7_HUMAN ------------------LSNVFKIEDKIGEGTFSSVYLATAQLQVGPEEKIALKHLIP- 41
A
CDK2_HUMAN --DTETEGVPSTAIREISLLKELN---HPNIVKLLDVIHT-----ENKLYLVFEFLHQDL 87
CDK4_HUMAN NGGGGGGGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDL 100
ERK2_RAT ---FEHQTYCQRTLREIKILLRFR---HENIIGINDIIRAPTIEQMKDVYIVQDLMETDL 110
CDC7_HUMAN ------TSHPIRIAAELQCLTVAGG--QDNVMGVKYCFRK-------NDHVVIAMPYLEH 86
CDK2_HUMAN KKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLIN-TEGAIKLADF 146
CDK4_HUMAN RTYLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVT-SGGTVKLADF 159
ERK2_RAT YKLLKTQHLS---NDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLN-TTCDLK---- 162
CDC7_HUMAN ESFLDILNSLS--FQEVREYMLNLFKALKRIHQFGIVHRDVKPSNFLYNRRLKKYALVDF 144
A A
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                                                              HK Hong   
University College London 158
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   159 
To determine the kinase activity of these proteins, activity was measured in the 
antibody-based kinase assay under optimized conditions established for the wild-type 
protein. As shown in Figure 5.7A, kinase activity was only detected for wild-type 
Cdc7/ASK complex but not for the three mutants. An ADP accumulation assay is a  
biochemical assay to measure ADP generation resulting from kinase phosphorylation 
of a substrate. This assay is useful for determining substrate Michaelis-Menten 
kinetics and for profiling inhibitor potency and mode of action. To confirm the 
importance of the three residues (K90, D177 and D196) in the catalytic site for kinase 
activity, the amount of ADP produced as a result of kinase activity was measured after 
in vitro kinase reactions with wild-type and mutant Cdc7/ASK complexes (Figure 
5.7B). The amount of ADP increased linearly with wild-type Cdc7/ASK over time. 
However, ADP accumulation with the mutant D177A reached only 50% level relative 
to wild type Cdc7/ASK and K90A and D196A mutants showed only 30% level of 
ADP accumulation (Figure 5.7B). These data indicate that three residues, K90, D177 
and D196 form part of the catalytic site of Cdc7, and that mutation of K90 and D196 
has created a catalytically inactive Cdc7 kinase as predicted by the structural model.  
 
5.4. Discussion and Conclusions 
The initiation of DNA replication, which lies downstream of oncogenic and mitogenic 
signalling transduction pathways, is a critical step in cell proliferation. Because 
Cdc7/ASK is an essential kinase required for the regulation of DNA replication 
initiation, a specific inhibitor of Cdc7/ASK activity could be an attractive anti-cancer 
agent. The anti-cancer potential of targeting Cdc7 kinase has led to an increasing 
interest in selective inhibitors that could represent lead compounds for drug 
development. In an effort to generate Cdc7 inhibitors, various compounds were  
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Figure 5.7: Kinase activity analysis of wild-type and Cdc7 mutants. Using 
site-directed mutagenesis, K90, D177 and D196 were replaced with alanines to 
negate catalytic activity. Three mutants (K90A, D177A and D196A) and wild-type 
Cdc7 were co-expressed with ASK and purified from insect cells.  Increasing 
concentrations of wild-type and mutant Cdc7 and ASK kinase complex were 
incubated with Mcm2 fragment in the presence of ATP. Kinase act iv i ty was 
measured in the antibody-based kinase assay (A) and in the ADP Quest assay with 
kinetic mode (B).  
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recently reported as potent Cdc7 inhibitors, some of which were shown to potently 
induce apoptotic cell death in multiple cancer cell lines and to cause tumour growth 
inhibition in animal models (reviewed in Sawa & Masai 2008; Swords et al. 2010). As  
a result, several compounds are currently undergoing pre-clinical and/or clinical 
evaluation, and the search for more specific small molecule Cdc7 inhibitors continues.  
 
The development of a primary screening assay is essential for the identification and 
development of a potent small molecule inhibitor of Cdc7 kinase. In the case of kinase 
assays, the expression and purification of active protein is often a limiting step and 
restricts the targets pursued or the methods used for screening (Walters & Namchuk 
2003). In the antibody-based kinase assay established during the work of this thesis, 
active baculovirus-expressed human Cdc7/ASK complex (Figure 3.6) and human 
Mcm2 protein (Figure 5.1A) as a substrate have been used to measure the 
phosphorylation of Mcm2 by Cdc7/ASK kinase (Figure 5.1D and E). Figure 5.2B 
shows that the effect of kinase concentration on Mcm2 phosphorylation is dose 
dependent and only low amounts (2.34M) of Cdc7/ASK kinase are required for a 
sufficient phosphorylation signal, indicating the high sensitivity of this assay for 
Cdc7/ASK activity (Figure 5.2B). Furthermore, the kinase activity is stable for up to 
four months (Figure 5.3B) and kinase activity from different batches of cell pellets is 
consistent (Figure 5.4A). These data show that the availability of active protein such 
as recombinant Cdc7/ASK kinase and its substrate Mcm2 provided significant 
advantages for the development of a specific primary assay suitable for high-
throughput screening (HTS) of compound libraries.  
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In the past, kinase activity tests mostly relied on the incorporation of radioactive 
phosphate into proteins, but for large-scale investigations radioactive waste products 
should and can be avoided. Human Mcm2 has been shown to be phosphorylated by 
Cdc7/ASK kinase and distinct phosphorylation sites in the Mcm2 N-terminal region 
were identified in vitro and in vivo (Montagnoli et al. 2006; Cho et al. 2006; Tsuji et 
al 2006; Charych et al. 2008). Furthermore, phospho-specific Mcm2 antibody 
recognising serine 53 phosphorylation site was generated and have been used as a 
marker of Cdc7/ASK kinase activity in cells (Montagnoli et al. 2006; Charych et al. 
2008). By using the pMcm2 S53 antibody recognised Cdc7-dependent-
phosphorylated Mcm2 I was able to demonstrate that the antibody-based assay 
described in this chapter is a reliable and a convenient kinase assay suitable to 
screening of large compound libraries. 
 
Biochemical assays can generally be classified into separation-based assays and 
homogeneous assays (reviewed in Walters & Namchuk 2003). Homogeneous assays 
in which the detection of the product does not require a separation step can have assay 
artefacts from the reaction product. Separation-based assays in which the reaction 
product is detected after its separation from the starting material on the other hand 
have the advantage of minimal interference from the reaction product (reviewed in 
Walters & Namchuk 2003). In keeping with this rationale, the antibody-based assay 
was designed to include wash steps, and therefore interference from the compound 
library should be minimal. However, it needs to be considered that the requirement for 
additional steps such as pre-wash and blocking steps may increase total screening 
time and assay complexity. 
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In the absence of the crystallographic structure of the Cdc7 catalytic subunit, a three-
dimensional model of Cdc7 was built based upon homology with other kinases 
(Figure 5.5). It is evident from the model that the structural scaffold of the Cdc7 
kinase subdomain is very similar to those of human Cdk2 and MAP kinase Erk2 
(Figure 5.5A, B and C). The model allowed the location and comparison of amino 
acid residues of Cdc7 (Figure 5.6) that are known to be important for catalysis, and 
are highly conserved among the Cdc7 families, suggesting the model can be used for 
recognition of functionally important elements for a structure-based perspective.  
Using site-directed mutagenesis, three conserved residues located in the Cdc7 active 
site were mutated to alanine to examine their role in kinase activity. Figure 5.7A 
shows that the three mutants produce inactive kinases, confirmed by the specificity of 
Cdc7-dependent phosphorylation of Mcm2 in the antibody-based assay (Figure 5.7A). 
In addition, the ADP accumulation assays clearly show that phosphorylation activity 
is impaired in the K90, D177 and D196 mutants (Figure 5.7B), suggesting that these 
residues are involved in creating catalytically inactive Cdc7, thus drastically negating 
kinase activity as predicted by the structural model.  
 
Interestingly, disruption of the ATP binding mode is a mechanism of regulation of 
protein kinase, for example the reduced activity of Cdk2 associated with the K52 
position mutation is due to non-productive binding of ATP (De Bondt et al. 1993). 
The exquisite sensitivity to the position and conformation of ATP may serve a 
regulatory role in preventing kinases from hydrolyzing ATP in the absence of protein 
substrates (Robinson et al. 1996). An in silico approach has been used with great 
success in the design of selective inhibitors of Cdk4 (Ikuta et al 2001). Initial 
prospective inhibitors were improved by 1.5 log units by analyzing the sequence 
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differences around the ATP-binding site and incorporating this information into the 
rational design of compounds optimized for the kinase of interest. Importantly, Figure 
5.6B shows that the 14 amino acid residues of the ATP binding pocket were found to 
be less conserved within the Cdc7 kinase family and among other kinases providing a 
structural rationale for medicinal chemistry to design selective Cdc7 inhibitors.  
 
In summary, the data presented in this chapter show the development of an assay for 
Cdc7 kinase activity based on measuring Cdc7-dependent phosphorylation of Mcm2 
using a phospho-specific antibody. The assay was optimized for parameters including 
substrate binding capability, optimum pH for kinase buffer and kinase stability, which 
is essential for robust, automated high-throughput screening of compound libraries 
identifying Cdc7 inhibitors. In addition, a computer model of Cdc7 kinase showed 
highly conserved amino acid residues which form the catalytic site of Cdc7 kinase. 
Furthermore, a comparison of amino acid residues in the ATP-binding pocket 
revealed 14 unique residues of Cdc7 kinase, suggesting that this difference in the 
composition of the ATP-binding pocket may provide a platform for future design of 
selective Cdc7 inhibitors. In the following chapter, I discuss how, after further 
optimisation, the screening assay was successfully transferred into a 384-well format 
for HTS. Automation of the assay has been accomplished by employing a batch-mode 
operation using automated workstations for buffer handling and plate washing, which 
are in principle amenable to fully automated operation. Using the HTS platform, 
Cdc7/ASK kinase was screened against the Biomol Kinase Inhibitor Plates (Biomol 
Research Laboratories, USA) and the main CRT DL chemical libraries (60000 
compounds). As discussed in Chapter Six, one of the “hits” that emerged from 
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screening was validated and exploited to further study the response of transformed 
cells to origin activation repression. 
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CHAPTER SIX 
Compound screening and characterization of  
small molecule Cdc7 inhibitors 
 
6.1. Introduction 
The rapidly growing interest in kinases as drug targets has prompted the development 
of biochemical assays which can be adapted to high-throughput screening (HTS), 
wherein large libraries of compounds are tested for the identification of kinase 
inhibitors. Accordingly, HTS has become an important component of modern drug 
discovery research. This screening is very much influenced by advances in 
automation and miniaturization technology and is under constant development (Fox et 
al. 2002; Bajorath 2001). The interference of compounds on the detection system is an 
important consideration in the development of suitable HTS for large compound 
library screening. Homogeneous HTS assays that allow the addition of all reaction 
reagents in one well without separation steps could be compromised by compounds 
affecting the reaction product. Separation-based HTS assays in which the reaction 
product is detected after its separation from the starting material, on the other hand, 
have the advantage of minimal compound interference on the reaction product 
(reviewed in Walters & Namchuk 2003). The data discussed in the previous chapter 
show that the establishment of a primary assay based on measuring Cdc7-dependent 
phosphorylation of Mcm2 using a phospho-specific antibody offers significant 
advantages for the development of a specific Cdc7 kinase assay suitable for HTS of 
compound libraries. Furthermore, this assay contains wash steps and therefore 
expected interference from compounds should be minimal.  
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Over the past few years, diverse computational concepts and methods have been 
introduced to analyse screening data, extract information from HTS experiments and 
derive predictive models of activity, thereby attempting to exploit the complementary 
nature of HTS and combinatorial chemistry (Bajorath 2001). These computational 
approaches that ‘dock’ small molecules into the structures of targets and ‘score’ their 
potential complementarily to binding sites are widely used in hit identification and 
lead optimization (Kitchen et al. 2004). The data presented in the previous chapter 
indicate that a homology model of the Cdc7 active site based on published crystal 
structure data of other kinases which highlight the unique residues of the Cdc7 ATP-
binding pocket, may provide a structural-chemical basis for designing selective Cdc7 
inhibitors.  
 
In this chapter, I describe how an antibody-based primary assay was successfully 
transferred after further optimisation into an automated 384-well format HTS to 
identify Cdc7 inhibitors alongside the Cancer Research UK Technology (CRT) assay 
development team (based at Wolfson Institute for Biomedical Research, UCL, UK). 
CRT has a large collection of diverse molecules (approximately 60,000 compounds) 
which is being screened in this automated HTS primary assay to search for Cdc7 
kinase inhibitors. Through a series of screening, 16 compounds showed inhibition of 
Cdc7/ASK kinase and were selected for further hit validation studies. In order to 
identify a reference compound for screening, Cdc7/ASK kinase was screened against 
the Biomol Kinase Inhibitor Plates (Biomol Research Laboratories, USA). Compound 
GW5074 was identified from Biomol Kinase Inhibitor Plates and used as a standard 
compound for screening. Furthermore, I describe a second three-dimensional model 
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of the Cdc7 active site based on sequence identity over the kinase domain in this 
chapter to validate initial hit compounds which are currently being taken forward into 
lead identification/optimization by CRT for the development of selective Cdc7 
inhibitors. In order to develop a cell-based assay system for assessing the cellular 
activity of compounds, I used the Nerviano compound PHA-767491 (referenced to as 
CRT100115) as a reference compound in SK-OV3 ovarian cancer cells and BT549 
breast cancer cells to study cellular effects in this Chapter. 
 
6.2. Material and Methods 
For preparation of recombinant baculoviruses (2.3.1), expression of recombinant 
human Cdc7/ASK kinase complex in Sf9 insect cells (2.4.3.) purification of Cdc7, 
ASK, mutant Cdc7 and Cdc7/ASK complex (2.4.4.), expression and purification of 
Mcm2 (1-154) fragment (2.4.7., 2.4.8.), SDS-polyacrylamide gel electrophoresis 
(2.4.9.), antibodies (2.5.1.), preparation of whole cell extracts (2.5.2.), 
immunoblotting (2.5.3.), bivariate flow cytometric analysis (2.6.2), assaying for 
apoptosis (2.6.4.) and high-throughput screen for Cdc7 inhibitors (2.7.3.) please refer 
to Chapter Two (Materials and Methods). For synthesis of PHA-767491 compound 
please see Appendix B. 
 
6.2.1. HTS automation equipment 
The assay was performed in clear, 348-well, Nunc Immobilizer Nickel-chelate 
microplates (ThermoFisher Scientific, USA). For HTS procedures, each assay 
component was added to individual wells using the Matrix Plate Mate (ThermoFisher 
Scientific, USA, Serial No.501-1-05214), Matrix Well Mate (ThermoFisher Scientific, 
USA, Serial No.201-2-0170) and Perkin Elmer FlexDrop (Perkin Elmer, USA, Serial 
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No.560301). All wash steps were performed using the Bio-tek ELx405 Select CW 
Microplate Washer (Bio-tek, USA, Serial No. 202242). To measure absorbance, the 
Analyst plate reader (Molecular Devices, USA, Serial No. AN0166) was used (Figure 
6.1).  
 
6.2.2. HTS reagents and supplies 
TBS, wash buffer (TBS containing 0.05% Tween-20), kinase reaction buffer (50 mM 
Tris-HCl pH 8.5, 10 mM MgCl2, 1 mM DTT), diethanolamine buffer (1 M 
diethanolamine pH 9.8, 0.5 mM MgCl2), development reagent (one P-nitrophenyl 
phosphate (PNPP) tablet was dissolved in 20 ml diethanolamine buffer) and stop 
solution (1 M NaOH) were used as described in Chapter Two (Material and Methods). 
I made his-tagged Cdc7/ASK kinase and N-terminal fragment of Mcm2 as described 
in Chapter Two (Material and Methods). Rabbit anti-phospho Mcm2 S53 (BL3353) 
was purchased from Bethyl (Universal Biologics, USA) and anti-rabbit/AP secondary 
antibody was obtained from Dako (Glostrup, Denmark). P-nitrophenyl phosphate 
(PNPP) substrate was purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
Biomol kinase inhibitor plate (Catalogue No. 2832-0001) was supplied by Biomol 
Research Laboratories (USA) and the main CRT DL chemical libraries were made 
available by the CRT chemistry department.  
 
6.2.3. Antibody-based assay protocol for HTS 
384-wells of a clear Nickel-chelate micro-plate were pre-coated in one hour 
incubation with 250 ng of Mcm2 fragment (substrate). Non-bound protein was 
removed by washing the plate three times with wash buffer. Cdc7/ASK kinase  
 
A B
Figure 6.1: HTS automation equipment. (A) CRT DL chemical libraries (60,000 compounds). (B) Matrix 
well Mate and Perkin Elmer Flex Drop. (C) Matrix Plate Mate (D) Bio-tek ELx405 Select CW Microplate 
Washer. (E) Analyst Plate Reader.  
E
C D
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reactions were assembled by stepwise addition of compound in 4% DMSO, 
Cdc7/ASK kinase and ATP in kinase reaction buffer. The final concentrations of 
Cdc7/ASK, compounds and ATP were 5 ng/well, 30 M and 0.2 M respectively in 
20 l of final assay volume. After one hour incubation for the kinase reaction, the 
plate was washed and incubated for 30 min with a primary pMcm2 S53 antibody. 
Non-bound antibody was removed by washing with wash buffer, and the plate was 
incubated with secondary antibody for 30 min, followed by three washes and the 
addition of a development reagent. Signal development was stopped after one hour by 
addition of sodium hydroxide. Raw data were collected as absorbance units at 405 nm 
using the Molecular Devices Analyst (Molecular Devices, USA, Serial No. AN0166) 
and were normalized as percentage inhibition of Cdc7/ASK kinase relative to the 
percentage control values. I used GW5074 as a standard inhibitor compound, which 
was identified from the Biomol kinase inhibitor plate (Biomol Research Laboratories, 
USA) and included on every plate at 100 nM as a positive control.  
   
6.3. Results 
6.3.1. Optimization of automated HTS 
Initial experiments were focused on transferring the antibody-based assay to the 384-
well format for automated HTS2. In preliminary experiments several automation 
issues were encountered. Firstly, due to the high number of washing steps in the assay 
system and the limitations of the micro-plate washer, a daily throughput of only 10 
plates could be achieved. In order to achieve this throughput, pre-wash and blocking 
                                                 
2  Experiments were done with guidance from the CRT assay development team. CRT operates 
laboratory automated HTS workstations that are robust enough to support the screening of CRT DL 
chemical libraries. I established the antibody-based kinase assay, and provided active baculovirus-
expressed human Cdc7/ASK kinase complex and human Mcm2 protein as substrate.  
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steps were eliminated and antibody incubation times were also reduced. Secondly, 
Cdc7/ASK kinase was added using the Perkin Elmer Flex Drop (Perkin Elmer, USA, 
Serial No.560301). Patterns of low signal in the first wells dispensed were observed in 
early experiments, indicating low enzyme levels in these wells. However, this issue 
was eliminated by the inclusion of a prime plate at the start of the run. Thirdly, 
problems were encountered with the Matrix Well Mate (ThermoFisher Scientific, 
USA, Serial No.201-2-0170). This system was used to add 20 l of primary and 
secondary antibodies. The tubing became blocked after 4-5 days of screening, even 
with vigorous washing with 0.1 M NaOH and dispensing accuracy/precision errors 
were noticeable. However, when dispensing steps were carried out using the Dynex 
Multidrop 384 plate dispenser (Magellan Bioscience, USA), the issue was resolved. 
Thus the antibody-based assay was eventually made suitable for automated HTS small 
molecule Cdc7 inhibitors. 
 
6.3.2. HTS assay reproducibility 
Assay quality has been traditionally judged by several metrics such as signal to noise 
ratio or signal to background ratio (Zhang et al. 1999). These metrics enable definition 
of significant results from a screen and are also useful for maintaining the same 
standard for assay data over multiple days screening, or for comparison of data quality 
across screens. The main quality parameter in HTS is the Z factor (Z’), as described 
by equation (1): 
                                             Z’=1-(3 δ + + 3 δ -)/(μ + - μ -)                                          (1) 
where δ + is the standard deviation for the positive control, δ - is the standard deviation 
for the negative control for the assay. μ + - μ - defined the mean value for the positive 
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and negative control (Zhang et al. 1999). The Z factor has the advantage of expressing 
the noise in relation to the signal window and, thus, gives a more complete estimation 
of assay quality than signal to noise or signal to background alone would do. Z factors 
above 0.5 indicate a large separation band between the values for the positive (100% 
activity) and negative controls (0% activity). Therefore, in practice, assays with 
values Z’> 0.5 have acceptable characteristics for HTS. Figure 6.2 shows the scatter 
plots from all 198 plates over screening. Each plate contains up to 320 test compounds. 
The average of percentage error in controls and blanks across the entire screening 
were 3.6% and 5.7 % respectively. The Z factor of all accepted plates was greater than 
0.5, with a Z factor of 0.41 in one data set and an overall average Z factor of 0.7 
(Figure 6.2). These data confirm the reproducibility of the assay, indicating that the 
precision and robustness of the assay were high enough to support HTS campaigns.  
 
6.3.3. Cdc7 primary screen of the Biomol kinase inhibitor plate and hit 
characterization 
The Biomol Kinase Inhibitor Plate (Biomol Research Laboratories, USA) contains 80 
known kinase inhibitors of well-defined activity. To demonstrate assay sensitivity and 
robustness of the overall screening process, I tested the inhibitor plate for inhibition of 
Cdc7/ASK in triplicate at two different ATP concentrations (0.2 M and 5 M) using 
automated HTS conditions. Each test compound was assayed at a single concentration 
of 10 M in 2% DMSO, with 12 compounds showing inhibition of Cdc7/ASK kinase 
of greater than 50% at the ATP Km 0.2 M (Table 6.2). Notably, two known 
compounds, Staurosporine and GW5074, were revealed to be potent inhibitors of 
Cdc7/ASK kinase, with IC50 values of 0.010 M and 0.108 M, respectively, in the  
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Step Parameter Value Description
1 Substrate 20 ml Incubated over night at 4oC
2 TBS/Tween wash 3 x 80 ml
3 Library compounds 2 ml
4 Cdc7/ASK kinase 13 ml containing kinase buffer
5 ATP 5 ml Incubated 60 min at RT
6 TBS/Tween wash 3 x 80 ml
7 Primary antibody 20 ml Incubated 30 min at RT
8 TBS/Tween wash 3 x 80 ml
9 Secondary antibody 20 ml Incubated 30 min at RT
10 TBS/Tween wash 3 x 80 ml
11 Colour Development 20 ml Incubated 60 min at RT
12 Stop solution 20 ml Absorbance read at 405nm
Table 6.1 HTS protocol
Figure 6.2: Z factor distribution for the CRT main library screen of 348-well 
microplates. 198 plates were screened, each plate containing up to 320 test 
compounds. All accepted plates had a Z factor of > 0.5 (except one set; Z factor 0.41), 
overall average Z factor is 0.7. 
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presence of 5 M ATP (Figure 6.3A, B). GW5074 is a potent and selective cell 
permeable inhibitor of cRAF1 kinase (IC50 9 nM), which is downstream of Ras in the 
MAPK signalling pathway (Lackey et al. 2000). It also shows 100-fold selectivity 
over Cdk1, Cdk2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm (Lackey et al. 
2000). To assess Cdc7/ASK kinase inhibition by GW5074 in intact cells, I examined 
Mcm2 phosphorylation at serine 53 in GW5074 treated HeLa cells (Figure 6.3C). I 
used a CDK inhibitor olomucine as a comparison. Western blotting results showed 
that 10 M of GW5074 inhibits phosphorylation of Mcm2 at serine 53 after 24 hours, 
compared with either non-treated or olomucine treated cells (Figure 6.3C). These 
results show that GW5074 significantly affects cellular Cdc7/ASK activity in HeLa 
cells, indicating the HTS assay described here is specific for the identification of 
small molecule Cdc7 inhibitors. For the kinase list of the Biomol Kinase Inhibitor 
Plate please refer to Appendix C. 
 
6.3.4. CRT DL main library screening and Hit analysis 
The CRT main library (approximately 60,000 compounds) was screened in the 384-
well formatted HTS assay to identify small molecule inhibitors of Cdc7/ASK kinase 
using optimized assay conditions3. Due to the high number of washing steps and the 
limitations of the washer, the screen achieved a throughput of approximately 3200 
compounds per day. Each compound was assayed at a single concentration of 30 M, 
and any compound that resulted in greater than 50 % inhibition of Cdc7/ASK signal 
was considered a hit compound. The initial screens identified 787 compounds with  
                                                 
3 Technical assistance in the iterative screening of the CRT main library was provided by the CRT 
assay development team. In the work of this thesis, I analysed and interpreted the screening data, which 
had been generated from main library screening. 
BA
Table 6.2 Screening results of Biomol kinase inhibitor plates 
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Figure 6.3: Cdc7/ASK primary screen of the Biomol Kinase Inhibitor Plate. IC50 determination of 
Staurosporine (A) and GW5074 (B). Cdc7/ASK kinase reactions were performed in triplicate using 
HTS optimized conditions and assayed in the presence of varying concentrations of each compound. 
(C) Immunoblot analysis of cellular effects of GW5074 and olomoucine on the phosphorylation of 
Mcm2 serine53 (actin - loading control) in HeLa cells at the indicated treatment times. (NT- non 
treated cells; pMcm2 S53 - Mcm2 phosphorylated at serine 53) 
Inhibitor (µΜ)
µΜ
STAUROSPORINE 0.01 95.7
GW 5074 0.108 111.3
KENPAULLONE 3.7 105.2
INDIRUBIN-3’’-MONOOXIME 5 94.9
TYRPHOSTIN 51 7.0 82.0
5-IODOTUBERCIDIN 8.2 60.1
HYPERICIN 9.4 77.6
TYRPHOSTIN 47 9.5 70.6
SP 600125 25.2 61.7
QUERCETIN 52.7 59.8
ROTTLERIN 67.6 53.5
GF 109203X >120 5.0
H-7 >120 59.5
H-9 >120 -0.6
µΜ µΜ
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greater than 50 % Cdc7/ASK inhibition for retest, and 365 out of 787 compounds 
showing percent inhibition values greater than 50 % were selected as confirmed hits  
for a 0.8 % hit rate. Of the 365 hit compounds, 120 of the top compounds showing the 
highest percent inhibition were selected for IC50 determination and a compound purity 
and kinase specificity test. As shown in Table 6.3, 16 hits from 120 compounds 
showed an IC50 of < 1 M and Hill slope values were approximately one, except for 
two compounds with Hill slope values of 0.673 (CRT0059174) and 0.5 
(CRT0003767) (Table 6.3). A Hill slope can be useful in describing the binding or 
kinetic behaviour of a target with compound (reviewed in Walters & Nmchuk 2003). 
If ATP and compound compete for a single binding site, the Hill slope for the titration 
of a compound should be approximately one. However, if Hill slope values are far 
from one, the interpretation is that multiple binding sites for interaction may exist and 
compounds have low potential as leads. Two of 60,000 compounds (CRT compound 
ID CRT0058701 and CRT0001660) showed inhibition against Cdc7/ASK kinase with 
an IC50 value of 0.018 M and 0.349 M respectively (Figure 6. 4 A, B). Hit 
compounds were also initially examined for their ability to inhibit the activity of a 
selected panel of 10 kinases by implementing an IMAP-base HTS assay (Millipore, 
USA) (Table 6.4) 4 . Four of the hit compounds (CRT0055760, CRT0001660, 
CRT0012241 and CRT0003767) were either inactive or lacked reproducible 
inhibition against this set of kinases, and were confirmed as Cdc7 inhibitors with IC50 
values below 1 M (Table 6.4). These identified hits were classified based on their 
chemical composition using a chemical classification program, which groups 
compounds based on structural fragments and overall molecule topological features.  
Figure6.4
                                                 
4 Details of the kinases tested are commercially sensitive and are therefore not disclosed here. 
Table 6.3 Screening results of CRT DL main library 
against Cdc7/ASK kinase
Purity
CRT0058701 0.018 1.188 103.31 62
CRT0055760 0.221 1.04 100.97 100
CRT0001660 0.349 0.962 95.58 100
CRT0059174 0.639 0.673 88.68 0
CRT0064299 0.677 0.967 98.72 100
CRT0012241 0.729 1.049 99.35 94
CRT0003767 0.747 0.53 85.47 100
CRT0039235 0.773 0.785 84.57 100
CRT0016575 0.819 1.072 102.67 100
CRT0012536 0.823 0.797 93.12 66
CRT0005504 0.857 0.84 102.08 100
CRT0056182 0.897 0.943 103.1 87
CRT0058541 0.918 0.934 102.89 100
CRT0058541 0.952 1.058 103 100
CRT0039234 1.042 0.958 93.77 98
CRT0058545 1.066 0.817 102.5 100
CRT0058701
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Figure 6.4: Cdc7/ASK primary screen of CRT DL main library. IC50 determination of 
CRT0058701 (A) and CRT0001660 (B). Cdc7/ASK kinase reactions were performed in triplicate 
using HTS optimized conditions and assayed in the presence of varying concentrations of each 
compound.
a
a The variable Hillslope describes the steepness of the IC50 curve. This variable is called 
the Hillslope or the slope factor. When Hillslope is less than 1.0, the curve is more 
shallow. When Hillslope is greater than 1.0, the curve is steeper.
µΜCompound ID IC50 (     ) Hillslope MaximumInhibition
µΜ
CRT0001660
concentration (     )µΜ
b
b A purity value of 70-90% based on UV detection is generally considered acceptable for 
compounds that will be used for early drug discovery. The common target purity of a 
compound for activity is between 90% and 95% pure.
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The homogeneity and redundancy were adjusted to generate chemically relevant 
classes, resulting in three structural classes. Three structurally unrelated compounds at 
submicromolar concentrations were selected and have been the subject of a hit to lead 
programme over the last 18 months. For raw data of CRT main library screening 
please refer to Appendix C. 
 
6.3.5. Three dimensional modelling of the Cdc7 active site 
In most cases small molecules have been found to have poor selectivity in the first 
instance, and it is only following optimization for a specific kinase that selectivity is 
achieved (reviewed in Walters & Nmchuk 2003). The availability of sequence and 
structural information makes such an optimization of activity and selectivity a realistic 
objective. In the previous chapter, I discussed a homology model for Cdc7 based on 
structural information of the active site for Cdk2 and Erk2 (Figure 5.3). I identified 
several unique amino residues in the Cdc7 ATP-binding pocket (Table 5.1) and 
validated the Cdc7 homology model for activity prediction using site-direct 
mutagenesis (Figure 5.4 and 5.5).  
 
A second homology model of Cdc7 was constructed using CK2 (1M2R.pdb) as a 
template by Dr Susan Boyd (CompChem Solutions) as part of the Cdc7 drug 
discovery programme steered by CRT Ltd (Figure 6.5)5. BLAST searching revealed 
CK2 as the closest homologue to CDC7 based on sequence identity over the whole 
kinase domain (residues 18-391), with 21% of residues being identical. In contrast to 
previous homology model described in Chapter 5 (Figure 5.5), Erk2 was found to be 
17% identical, as was Cdk2.  Additionally, on alignment of all four kinases, it can be 
                                                 
5 Discussed here as part of the connected argument.  
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seen that the Gly-rich loop of Cdk2 is a relatively closed conformation compared with 
that of Erk2. The CK2 Gly-rich loop actually sits in an intermediate position between 
those of the other two structures (Figure 6.5). This second Cdc7 model was 
constructed and refined using the Molecular Operating Environment software from 
Chemical Computing Group Inc (Montreal, Canada).  Refinement was carried out 
using the Amber 99 forcefield (UC San Francisco), which is a set of molecular 
mechanical force fields for the simulation of bio-molecules, with Gas Phase solvation 
(i.e. no solvation model applied) and On/Off cutoff parameters set to 10 and 12, 
respectively, to define limits of non-bonded interactions to be included in the 
computation. The active site underwent additional refinement to expand the volume 
accessible to ligand structures, by selection of appropriate rotamers of side-chains and 
by restrained minimisation to attempt to replicate the position of the CK2 hinge 
backbone atoms. As shown in Figure 6.5A, this new hinge position represents the 
greatest change over the initial model described, but it should be noted that the Gly-
rich loop positions also vary significantly. Otherwise, the models show much 
similarity in the position of both the backbone and side chain atoms, with an overall 
RMSD (Root mean square deviation) of around 5A (Figure 6.5A).  The second model 
covers the entire range of the kinase domain (residues 18-391), whilst the previous 
models only covered discrete regions of the kinase domain, with the Erk2 model only 
covering residues 54-207.  Figures 6.5B and 6.5C show the second interaction model 
of ATP and reference compound (CRT100115) in the Cdc7 ATP-binding pocket. The 
adenine ring of ATP directly hydrogen bounds with Pro135 and Leu137 residues of 
the hinge region (Figure 6.5B). This model is currently being validated with early 
potent Cdc7 inhibitors and will be used for structure-activity relationship (SAR) 
studies to identify modifications and substituents that might increase potency against  
A B
C
Figure 6.5: Three dimensional model of the Cdc7 active site. (A) High degree of 
conservation at molecular level demonstrated by comparison of the initial model (shown in 
green, constructed by Dr A Okorokov) and the second model (shown in red, constructed by Dr 
S Boyd).  Second model of the Cdc7 active site is occupied by ATP (B) and CRT100115 
compound (C). 
LEU137
PRO135
PRO135
LEU137
LYS90
Mg2+
Gly-rich loop
Hinge region
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                                                              HK Hong   
University College London 182
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                 HK Hong 
 
 
 
 
University College London   183 
Cdc7 kinase. This structural-chemical basis will enable rapid identification of those 
scaffolds with the best suitability for optimization as Cdc7 inhibitors. 
 
6.3.6. Development of a cell-based assay for Cdc7 inhibitors 
Although many compounds showed a good efficacy in the in vitro HTS assay, they 
not always elicit a cellular effect due to cell permeability and active export 
mechanisms in cells (Copeland 2005). In order to test for correlation between in vitro 
efficacy of compounds and their target-specific cellular activity, it is essential to take 
forward into a cell-based assay these hits that demonstrate potent activity in HTS. 
Cell-based assays are becoming a more frequent assay format in target validation, lead 
identification and optimization, and have been developed as a variety of assays that 
measure cell proliferation, cell cycle progression, toxicity, apoptosis induction, 
production of signal transduction and morphology. To develop a cell-based assay and 
to examine the effects of a reference Cdc7 inhibitor on cellular phenotype, I made use 
of PHA-767491 (CRT100115) which was synthesized by the CRT Chemistry 
department (Figure 6.6A; see Appendix B). Notably, PHA-767491 has been 
previously reported by Nerviano Medical Sciences as a potent Cdc7 inhibitor with an 
IC50 value of 10 nM in the presence of 1.5 M ATP (Vanotti et al. 2008). Treatment 
with either 5 or 10 M of PHA-767491 for 24 hours was sufficient to cause cell death 
in multiple cancer cell lines (Montagnoli et al. 2008).  
 
In order to characterize the cellular response to CRT100115 as a reference Cdc7 
inhibitor, in the work of this thesis I treated with either 1 or 10 M of CRT100115 in 
multi-drug resistant SK-OV3 ovarian cancer cells and BT549 breast cancer cells for  
Control 1 10 
SK-OV3
BT549
 
N
N
H
NH
O
A
SK-OV3 
C 1 10 C 1 10 C 1 10
24h 48h 72h
BT549
C 1 10 C 1 10 C 1 10
24h 48h 72hB
CRT100115
IC50 = 10 nM
C
Figure 6.6: Cellular effects of CRT100115 on SK-OV3 and BT549 cells. (A) CRT100115 
molecular structure. (B) Immunoblot analysis of CRT100115 treated cells. Cells were incubated with 
either 1 or 10       of CRT100115 for the indicated time. Total cell lysates were prepared and 
analyzed by immunoblot with pMcm2 S53 (target of Cdc7 kinase) and pMcm2 S27, S41 (target of 
CDKs) antibodies. (C - control; pMcm2 S53 - Mcm2 phosphorylated at serine 53; pMcm2 S41 -  
Mcm2 phosphorylated at serine 41; pMcm2 S27 - Mcm2 phosphorylated at serine 27) (C) Phase 
contrast micrographs of SK-OV3 and BT549 cells treated with either 1 or 10       of CRT100115 at 
72 hours (original magnification 100x).  
µΜ
µΜ µΜ
µΜ
µΜ
pMcm2 S53
pMcm2 S41
pMcm2 S27
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48 and 72 hours. Western blot data show that phosphorylation of Mcm2 at serine 53 
was largely abolished with 10 M treatment for 48 hours in both cell lines (Figure 6.6 
 
B). Phosphorylation at serine 27 and 41, phosphorylation sites for CDKs (Ishimi et al. 
2001; Montagnoli et al. 2006) were not affected in SK-OV3 cells, whereas the levels 
of phosphorylation of serine 27 and 41 were decreased by 48 hours in 10 M treated 
BT549 cells (Figure 6.6B), suggesting that in BT549 cells CRT100115 also inhibits 
Cdc7/ASK kinase activity and possibly other kinases. Phase contrast microscopy 
showed a decline in both SK-OV3 and BT549 cell numbers following 10 M of 
CRT100115 treatment, whereas control and 1 M of CRT100115 treated cells 
remained viable (Figure 6.6C).  
 
To examine whether CRT100115 interferes with cell cycle progression in SK-OV3 
and BT549 cells, I treated with either 1 or 10 M of CRT100115 for 72 hours. Flow 
cytometric analysis of DNA content showed that in both SK-OV3 and BT549 cells 
that CRT100115 caused an abnormal cell cycle profile. SK-OV3 cells treated with 
10M CRT100115 reveal two different subpopulations of cells in G1 (36%) and 
G2/M (35%) with a very small fraction of S phase (7%) cells, whereas BT549 cells 
mostly show a delayed/abortive S phase progression compared to control cells and 
those treated with 1 M of CRT100115 (Figure 6.7). The data also show sub-G1 
populations, indicative of cell death, in both cell lines (22% in SK-OV3 and 42% in 
BT549) with 10 M CRT100115. To quantify the CRT100115-induced cell death, 
cells were analyzed using the annexin-V apoptosis assay after treatment with either 1 
or 10 M of CRT100115 over a 96 hours course (Figure 6.8A). In the presence of 10  
4N
SK-OV3 BT549
G2/M
G1
S
G2/M
Figure 6.7: Flow cytometric DNA profile of SK-OV3 and BT549 cells treated with 
CRT100115. Cells were incubated with either 1 or 10       of CRT100115 for 72 hours. DNA 
content of cell cycle populations was measured by flow cytometry. Tables show the percentage 
of cells with sub-G1, G1, S, and G2/M DNA content.  (sub-G1- cell population with DNA content 
below 2N; G1- cell population in G1 phase (2N DNA content); S- cell population in S phase; 
G2/M- cell population in G2/M phase (4N DNA content)
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M CRT100115, 10% of the SK-OV3 population were annexin-V positive at the 24 
hours and 60% of the population were positive 96 hours after treatment, whereas 60% 
of the BT549 population became annexin-V positive after 24 hours, and by 96 hours 
90% of the population were positive (Figure 6.8A). No significant annexin-V positive 
fraction was induced by treatment with 1 M CRT100115 or in control populations of 
both cells. Cell growth curves indicate that the cell growth inhibition effected by 
CRT100115 was dose and time dependent (Figure 6.8B). Taken together, the data 
presented in this chapter show that CRT100115 affects the phosphorylation of Mcm2 
at a Cdc7-specific phosphorylation site as well as Cdk-dependent phosphorylation site 
in BT549 cells, and affects normal cell cycle distribution by inducing apoptotic cell 
death in SK-OV3 and BT549 cells, suggesting that the cellular phenotypes induced by 
Cdc7 inhibition can be applicable to development of a cell-based assay and Mcm2 
phosphorylation at serine 53 is a good biomarker to verify the activity of Cdc7 
inhibitors.  
 
6.4. Discussion and Conclusions  
Screening for protein kinase inhibitors usually requires a high-throughput kinase 
assay, which is a well-established process in lead discovery for pharmaceutical 
research. The development of a suitable assay system to test the target activity and to 
screen a large compound library is crucial for obtaining solid and reliable results from 
HTS. In the past, kinase activity determinations mostly relied on the incorporation of 
radioactive phosphate into proteins, but for large scale investigations radioactive 
waste products should be avoided (Rykx et al. 2007). In this chapter, I describe the 
development, validation, and implementation of a 384-well automated antibody-based  
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Figure 6.8: Cellular effects of CRT100115 on SK-OV3 and BT549 cells. Cells cultured in the 
presence of either 1 or 10       of CRT100115 were harvested at the indicated time, and apoptosis 
was assessed by flow cytometry after annexin-V and propidium iodide staining. (A) Annexin-V 
positive cells were indicated as the percentage of gated cells undergoing apoptosis. (B) Cell growth 
rate of control and CRT100115 treated cells of either 1 or 10       that is measured at the indicated 
time shown as fold increase in cell numbers.    
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HTS assay designed to identify Cdc7 inhibitors. The assay described in this chapter, 
although somewhat laborious due to the plate-coating with Mcm2 protein and several 
wash steps, is specific, sensitive, and in particular, free of radiolabeling. In 
preliminary experiments, several automation issues were encountered. However, 
through the introduction of the robotic liquid handler and automated plate washer to 
the antibody-based HTS platform, these limitations were overcome.  
 
Using the Biomol Kinase Inhibitor Plate to evaluate high-throughput assay robustness 
and reproducibility, I found twelve known kinase inhibitors, including GW5074 
which was selected as a standard inhibitor compound (Figure 6.3). The validated HTS 
assays identified 365 compounds showed greater than 50% of Cdc7/ASK inhibition 
from initial screening of the CRT DL main library (60,000 compounds), giving an 
overall 0.8 % hit rate. One hundred twenty of these top compounds which show the 
highest % inhibition were selected for IC50 determination, 16 of which showed an IC50 
of < 1 M (Table 6.2) against Cdc7/ASK kinase activity and were selected for further 
hit validation studies. I also examined the inhibition ability of identified 16 
compounds against a selected panel of other kinases, and found that four of the hit 
compounds were either inactive or lacked reproducible inhibition (Table 6.4). These 
compounds should be useful as hits compounds which will take forward to be a lead 
compound for the development of new selective Cdc7 inhibitors.   
 
Targeting the catalytic site of kinase with ATP competitive inhibitors appears to be 
the most promising approach for drug intervention. Thus, protein crystallization and 
structure modelling are well established as important tools for drug design (Fabbro et 
al. 2002). Indeed, the recent progress made in the crystallization of Cdk2 kinase-
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inhibitor complex and the structure modelling of Cdk4 ATP-binding pocket provides 
the great success in the design of selective inhibitors (Ikuta et al. 2001; Fabbro et al. 
2002: Rossi et al. 2005). In the absence of the crystallographic structure of the Cdc7 
catalytic subunit, in the work of this thesis, I sought to build a three-dimensional 
model of Cdc7 based on available structural information for other kinases. The model 
of Cdc7 active site discussed in this chapter showed the location and interaction 
model of ATP and reference compound in the Cdc7 ATP-binding pocket (Figure 6.5). 
This model is currently being validated with early potent Cdc7 inhibitors and an 
iterative cycle of chemistry and modelling will be applied in the search for potent and 
selective Cdc7 inhibitor. 
 
Due to the interest in Cdc7 as an attractive target for cancer therapy (Montagnoli et al. 
2004; Yoshizaw-Sugata et al. 2005; Im & Lee 2008; Kim et al. 2008; Montagnoli et al. 
2008), several reports of first-in-class Cdc7 inhibitors have been published, and 
various lead compounds are being validated in order to identify available Cdc7 
inhibitors for clinical trials (Sawa & Masai 2008; Swords et al 2010). Lack of 
selectivity for particular protein kinases is always encountered when developing 
inhibitors against kinases, all of which share highly conserved catalytic domains 
(Smyth & Collins 2009). PHA-767491 was identified as a potent inhibitor of Cdc7 
(IC50 = 10 nM) from HTS and showed anti-cancer activity in several cancer cell lines 
and in a range of pre-clinical animal models (Vanotti et al. 2008; Montagnoli et al. 
2008). However, it also showed off target effects on Cdk9 and RNA polymerase II 
which may be important for cellular mechanisms that cause unpredictable cellular 
responses to this compound. Notably, Figure 6.6B showed that the levels of Mcm2 
phosphorylation at serine 27 and 41 (Cdk specific phosphosites) were decreased by 
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CRT100115 in BT549 cells, indicating that PHA-767491 not only affects Cdc7 kinase 
but also other kinases. During the work of this thesis, PHA-767491 was the only 
reported Cdc7 inhibitor. Although questions remain as to whether this compound 
could be a reference compound, I decided to make use of this molecule as a reference 
compound during work towards a cell-based assay development for evaluation of hits 
identified through antibody-based HTS of the CRT DL main library.   
 
After initial screening for hits, the next step in the drug discovery process is generally 
to evaluate the efficacy of selected hits in intact cells to select lead compounds for 
further preclinical evaluation in animal models (Verkman 2004). Recently another 
series of phenol pyrimidin-2(1H)-ones (IC50 = 3 nM, 30 nM) have been identified as 
inhibitors of Cdc7 (Shafer et al 2008). However, although the phenol pyrimidin-
2(1H)-one analogs showed marked affinity for Cdc7 in in vitro assays, these series of 
compounds showed weak cellular activity with low membrane permeability (Shafer et 
al. 2008). In fact, over the last year various lead compounds have been reported as 
potential Cdc7 inhibitors, and most of these compounds are currently being evaluated 
at the cellular level or in animal models prior to entering clinical trials (Sawa & Masai 
2008; Swords et al 2010). Thus, using the cell-based screening assay as a more 
biologically relevant surrogate to validate the efficacy of hits is important during the 
hit to lead development stage in the drug discovery process. 
 
Cell-based assays have been developed in various assay formats that measure cellular 
phenotypes, including cell proliferation, cell cycle progression, apoptosis induction, 
substrate phosphorylation and cell morphology. Several studies have shown that the 
cellular responses to inhibition of Cdc7 kinase by either siRNA or small molecule 
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inhibitors caused an impaired Cdc7-dependent phosphorylation of Mcm2, an abortive 
S phase progression, growth arrest and apoptotic cell death in a large number of 
tumour cell lines of different origins and irrespective of their p53 status (Montagnoli 
et al. 2004; Yoshizaw-Sugata et al. 2005; Im & Lee 2008; Kim et al. 2008; 
Montagnoli et al 2008). In keeping with previous reports, the data presented in this 
chapter show that treatment of two different cell lines, SK-OV3 (p53-null/Rb-
negative) and BT549 (p53 mutated), with CRT100115 impairs cell cycle progression, 
leading to p53-independent apoptotic cell death (Figure 6.6B, 6.7 and 6.8). These 
results suggest that the cellular phenotype induced by Cdc7 inhibitors can be used as a 
biomarker for hit validation. Notably, the findings discussed in Chapter 4 indicate that 
phosphorylation of Mcm2 at serine 53 is a reliable marker of Cdc7/ASK kinase 
activity both in cells and tissue specimen, suggesting that measuring phosphorylation 
of Mcm2 at serine 53 is a specific biomarker in a cell-based assay system that allows 
discrimination of putative Cdc7 inhibitors. 
 
In summary, the robust and sensitive HTS assay for Cdc7 activity in conjugation with 
the three dimensional model of the Cdc7 active site described in this chapter may help 
to overcome specificity concerns by enabling structural-chemical design of potent, 
selective Cdc7 inhibitors. Importantly, Table 6.4 shows that four compounds from 16 
hits have a promising selectivity prolife against a selected panel of 10 kinases and are 
now progressing through a hit-to-lead development programme. Small molecule 
inhibitors identified in the screen will be subsequently tested for their effect(s) on the 
DNA replication initiation pathway and the cellular response of transformed and 
untransformed human cell lines. Thus, the development work discussed here provides 
a platform for further development of pharmacological inhibitors of Cdc7 kinase. 
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CHAPTER SEVEN 
Conclusions and implications 
 
A large number of conventional chemotherapeutic strategies act by targeting DNA 
synthetic pathways, based on the concept that sufficient amounts of DNA damage will 
inevitably kill cancer cells. As our knowledge of the biological and molecular basis of 
cancer has increased, a new chemotherapeutic strategy has emerged in the concept of 
targeted therapy, hitting crucial signalling pathways and transduction mechanisms in 
cell growth regulation. However, despite the development of a large number of new 
approach chemotherapies, the impact on cancer mortality so far has been modest, with 
many of these agents compromised by their lack of specificity, poor efficacy, limited 
response, toxic side effects, and the development of drug resistance (Widakowich et al. 
2007). 
 
To improve the rate of success of new anti-cancer drug development, three main 
stages involved in this process are essential to implementing such drug discovery 
projects. The first stage is target identification and validation, a process of biological 
hypothesis generation and testing in available experimental models, and the most 
difficult step associated with new drug discovery. The second stage is lead 
identification and optimization which requires assay development that can be applied 
to high-throughput screening and large compound collections that are screened 
against molecular targets on HTS platforms for lead finding. Finally, the third stage is 
preclinical and clinical studies that are concerned with whether the compound can be 
made into a drug that will treat cancer, has minimum toxic side effects, good efficacy, 
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stability and safety requirements for new drug development. The work of this thesis 
has generated data which provide a strong rationale for exploiting the replication 
initiation pathway as a novel anti-cancer target, and have resulted in the development 
of HTS and cell-based assays which are able to detect biological activity of the target 
to identify a lead compound from screening.  
 
The initiation of DNA replication is a crucial decision point in cell proliferation that 
lies at the point of convergence of oncogenic signalling and transduction pathways.  
Unlike those branched, redundant and parallel pathways, there appears to be a single 
mechanism of DNA replication initiation and basic components of this mechanism are 
conserved in all eukaryotic species studied. Many studies have shown that DNA 
replication initiation factors are dysregulated in a wide range of premalignant 
dysplasia and cancers (reviewed in Lau et al. 2007; Blow & Gillespie 2008). 
Therefore, various points in the replication initiation pathway may be considered as 
potential therapeutic targets and drugs targeting this pathway should be of clinical 
benefit in a wide range of different tumour types, independent of genetic background. 
This is in stark contrast to drugs targeting upstream events where great heterogeneity 
exists between subgroups of even single tumour types.  
 
Strong clues for the potential to exploit inhibition of the DNA replication initiation 
pathway as a therapeutic target have come from early studies, which showed that 
normal and cancer cells may respond differently to replication initiation inhibitors 
(Shreeram et al. 2002; Feng et al. 2003; Montagnolie et al. 2004). Cancer specific cell 
killing appears to be a distinctive feature of the inhibition of replication initiation by 
targeting either pre-RC assembly or origin activation. Although the exact mechanisms 
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accounting for the cancer cell specific cell killing are not yet clear, it has been 
suggested that an origin activation checkpoint may exist in normal cells to monitor 
insufficient replication-competence at origins of replication, whereas a defective 
checkpoint in cancer cells may allow cells to progress through S phase in spite of 
incomplete DNA replication which then results in stalled replication forks and the 
generation of DNA double-strand breaks, causing the induction of apoptosis 
(reviewed in Blow & Gillespie 2008; Sawa & Masai 2008; Swords et al. 2010).  
 
Cdc7 kinase is essential for origin activation. Depletion of Cdc7 kinase by siRNA in 
various cancer cell lines induces defective S phase progression leading to p53-
independent apoptotic cell death caused by genomic instability resulting from stalled 
replication forks, whereas primary fibroblasts avoid entering an abortive S phase by 
activating a p53-dependent cell cycle checkpoint (Im & Lee 2008; Kim et al. 2003; 
Montagnoli et al. 2004; Yoshizawa-sugata et al. 2005). Importantly, in contrast to 
replication fork blockade, Cdc7 depletion does not cause sustained activation of the S-
phase checkpoint kinases (Montagnoli et al. 2004). Therefore, inhibition of Cdc7 
kinase which should minimize collateral damage to the DNA could be a new strategy 
for anti-cancer therapy. The data shown in this thesis take the concept further and 
validate Cdc7 kinase as a novel and promising therapeutic target. The results 
discussed in Chapter Four indicate that Cdc7 kinase is required for S phase 
progression during the cell cycle and down-regulation of this kinase in response to 
reversible and irreversible loss of proliferation capacity is coupled to repression of 
origin licensing. In keeping with the in vitro studies, the finding that functional cells 
in self-regenerating, stable and permanent tissues including quiescent and 
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differentiated cell populations show a lack Cdc7 and its activity indicates that these 
cells should be refractory to a Cdc7 inhibitor. Consequently, the majority of normal 
cells within the human body do not present a target, minimising potential cytotoxic 
effects of Cdc7 inhibitors.  
 
The critical importance of Cdc7 kinase in normal cell cycle progression, its absence in 
non-cycling cell populations, and the cancer cell specific death following Cdc7 
depletion makes Cdc7 kinase an attractive novel target for new anti-cancer drug 
development. However, there is a possibility that Cdc7 kinase inhibitors may affect 
normal stem cell viability and germ line cell cycle progression. Inducible inactivation 
of Cdc7 in mouse ES (embryonic stem) cells results in the arrest of DNA synthesis 
and checkpoint responses, including recombination repair of replication forks, G2/M 
block and activation of p53, and cells undergo p53-dependent apoptosis (Kim et al. 
2002; Kim et al. 2004). Furthermore, knockout Cdc7 genes in mice lead to early 
embryo death and sterility with testicular and ovary atrophy (Kim et al. 2002). In 
addition, Cdc7 kinase has been implicated in chromosomal segregation in mitosis 
through cohesion loading in Xenopus egg extracts models (Takahashi et al. 2008), and 
in homologous chromosomal segregation in meiosis by initiation of recombination 
and monoorientation in yeast models (Wan et al. 2006, 2008; Sasanuma et al. 2008; 
Matos et al. 2008; Marston 2008; Katis et al. 2010). Therefore, further Cdc7 inhibition 
studies in human stem cell models are required to investigate whether Cdc7 inhibition 
will adversely affect cells in stem-progenitor compartments and also germ cell 
development.  
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Cdc7 and its regulator protein ASK were observed to be up-regulated in both cancer 
cell lines and primary tumour tissues in comparison to their respective normal 
counterparts, suggesting that alterations in Cdc7/ASK protein abundance or activity 
may occur during tumorigenesis. (Hess et al. 1998; Nambiar et al. 2007; Bonte et al. 
2008; Clarke et al. 2009). However, the role of Cdc7/ASK kinase in tumorigenesis 
and the prognostic significance of this kinase is not fully understood. Recently, the 
association between increased Cdc7 expression levels and the development of an 
aggressive tumour phenotype has been shown in epithelial ovarian carcinoma 
(Kulkarni et al. 2009). Mcm2-7 has been identified as powerful prognostic markers 
and as molecular tools for cancer screening and surveillance in a wide range of 
malignancies (Williams & Stoeber 2007). In the work of this thesis, expression 
profiling in human cancers shows positive immunostaining for Cdc7, Mcm2 and 
Mcm2 phosphorylated on serine 53. Importantly, the differences in labelling indices 
for phospho Mcm2 and Mcm2 in the proliferative compartment of human tissues 
suggest that Cdc7 and phosphorylation of Mcm2 on serine 53 can be use as a potential 
biomarker for proliferation and prognosis (see Chapter Four). Further studies on a 
wide range of malignancies will reveal whether the findings shown in this work can 
be generalised for cancers of different genetic background and histological type.  
 
Many genes are likely to participate in cancer development by mechanisms that 
involve changes in expression levels or in their pattern of expression, but only a 
limited number of genes encode anti-cancer targets for which suitable drugs can be 
generated (reviewed in Malumbres & Barbacid 2007). Among them, protein kinases 
represent the most suitable targets for small molecule inhibitors. The drugable nature 
of kinases in general, along with the frequent misregulation of CDK activity in human 
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cancer has led to intensive efforts to develop selective CDK inhibitors (Malumbres & 
Barbacid 2007). However, none of them have yet successfully completed the clinical 
development, mainly due to toxic effects (Shapiro 2006). A number of Cdc7 
inhibitors were recently reported, and were shown to have anti-cancer activity not 
only in cancer cell lines but also in animal xengraft tumour models (Montagnoli et al. 
2008; reviewed in Sawa & Masai 2008; Swords et al. 2010). BMS-863233, a potent 
Cdc7 inhibitor developed by Exelixis and Bristol Myer Squibb (BMS), is the first 
compound which is in phase I clinical evaluation (Swords et al. 2010). 
 
As a member of the family of serine/threonine kinase, Cdc7 kinase has conserved 
catalytic domains that form the ATP-binding site which is a prime target for the 
design and development of selective inhibitors. To identify a specific small molecule 
inhibitor of Cdc7, the development of a convenient, well-characterized and sensitive 
primary assay is crucial prior to initiating HTS at an early stage in the drug 
development process. In the work of this thesis I developed the antibody-based kinase 
assay, a non-radioisotope, phosphorylated Mcm2 quantitative detection assay for 
Cdc7 kinase activity (see Chapter Five). This assay has since been fully automated 
and become the primary assay operated by Cancer Research Technology Ltd, the 
technology transfer arm of Cancer Research UK, for determining Cdc7 kinase activity 
in HTS. Although the antibody-based HTS assay required additional steps which 
increase total screening time and assay complexity, the precision and robustness of the 
assay indicated that it is acceptable for HTS of Cdc7 inhibitors (see Chapter Six). The 
HTS assay identified 16 hits showing an IC50 of < 1 M (Table 6.2) from the CRT 
main library (60,000 compounds) against Cdc7/ASK kinase activity which have been 
the subject of further hit-to-lead development over the last 18 months. In addition, 
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analysis of key residues of the Cdc7 kinase active site based on a three-dimensional 
homology model indicates that 14 amino acid residues are unique in the Cdc7 ATP-
binding pocket, providing a structural rationale for medicinal chemistry to design 
selective Cdc7 inhibitors. A further refined homology model of Cdc7 kinase is 
validated with early potent inhibitors from screening and used for structure-activity 
relationship (SAR) studies to identify modifications and substituents that might 
increase selectivity and potency against Cdc7 kinase. Importantly, hit compounds 
were either inactive or lacked reproducible inhibition against a selected panel of 10 
kinases (Table 6.4). By exploiting the combination of extensive combinatorial 
chemistry with well-characterized HTS and a structural homology model for Cdc7, 
the efficiency of the lead identification and optimization stage is enhanced, thereby 
improving the quality of the output of hit finding, and offers a more economical route 
for hit identification during the drug discovery and development programme.  
 
Promising drug candidates arising from lead identification and optimization will be 
subsequently subject to toxicology and other preclinical studies, before being tested 
further in clinical trials involving both healthy and sick patients. The process of 
selecting which hits to take forward into lead optimisation, based on those which offer 
the most suitable overall profile of potency, efficacy in animal models of proliferation, 
preliminary safety profile, predicted human ADME (Absorption, Distribution, 
Metabolism and Excretion) properties and transplant models of tumour growth 
(Xenograft) is beyond the scope of this thesis. However, the work presented in this 
thesis provides a strong biological rational for therapeutic targeting of the DNA 
replication initiation pathway and development of Cdc7 inhibitors as novel anti-
cancer agents, which is essential for the process of drug discovery. Future studies of 
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the cellular response to replication initiation inhibitors will further advance our 
understanding of how origin activation is linked to the cellular circuits that control 
proliferation, DNA damage response and apoptosis. Such studies will also help to 
characterise the molecular nature of the origin activation checkpoint and its 
mechanism of action, and moreover comparative studies of normal and transformed 
human cells will help to understand loss of this checkpoint function in cancer cells. 
Therefore, identification and development of early stage Cdc7 inhibitors and further 
study of the response of cells to origin activation repression will be beneficial for the 
ultimate goal of developing a new class of non-genotoxic and specific anti-cancer 
agents. 
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Apendix A : Summary of data from antibody-based Cdc7/ASK 
kinase assay (1) 
Figure 5.2 A           
Mcm2  
concentration (µg) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1316  0 .1199  0 .1349  0 .1288  0 .004551  
0 .5  0 .3359  0 .3922  0 .3917  0 .373266667  0 .018684  
1  0 .6038  0 .554  0 .6545  0 .6041  0 .029012  
1 .5  0 .6045  0 .6439  0 .6583  0 .635566667  0 .01608  
2  0 .6491  0 .6811  0 .6641  0 .664766667  0 .009244  
 
Figure 5.2 B           
Cdc7/ASK 
concentration (µM) Set1 Set2 Set3 
Mean of 
Signal St Dev 
0 0 .1009  0 .0904  0 .0984  0 .096566667  0 .003167  
0 .39  0 .3362  0 .136  0 .2445  0 .2389  0 .057861  
1 .17  0 .3806  0 .2316  0 .3599  0 .324033333  0 .046601  
2 .34  0 .5084  0 .3814  0 .4486  0 .446133333  0 .036682  
3 .9  0 .5177  0 .5033  0 .443  0 .488  0 .022881  
7 .8  0 .4854  0 .6121  0 .581  0 .5595  0 .038122  
15.6  0 .6819  0 .675  0 .5645  0 .640466667  0 .038036  
31.2  0 .4279  0 .6619  0 .6277  0 .5725  0 .072971  
 
Figure 5.3 A           
ATP 
concentration 
(µM) Set1 Set2 Set3 
Mean of 
Signal St Dev 
0 0  0  0  0  0  
0 .25  0 .2412  0 .36  0 .365  0 .322066667  0 .040459  
0 .5  0 .3267  0 .513  0 .476  0 .438566667  0 .056944  
1 .5  0 .4992  0 .482  0 .481  0 .4874  0 .005907  
5  0 .4823  0 .67  0 .558  0 .5701  0 .054521  
10  0 .5006  0 .618  0 .546  0 .554866667  0 .034179  
 
Figure 5.3 B       
Cdc7/ASK 
concentration (µM) Test in Sep Test in Oct Test in Nov 
0 0 .113  0 .099  0 .1037  
0 .39  0 .387  0 .319  0 .1553  
1 .17  0 .47  0 .502  0 .2207  
2 .34  0 .509  0 .545  0 .3272  
3 .9  0 .561  0 .673  0 .3649  
7 .8  0 .582  0 .655  0 .3714  
15.6  0 .778  0 .691  0 .313  
31 .2  0 .873  0 .686  0 .2735  
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Figure 5.4 A           
  Batch1         
Cdc7/ASK 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .0904  0 .1832  0 .1311  0 .1349  0 .02686  
0 .39  0 .136  0 .198  0 .1857  0 .173233333  0 .01895  
1 .17  0 .2316  0 .2846  0 .2552  0 .257133333  0 .01533  
2 .34  0 .3814  0 .4248  0 .3704  0 .3922  0 .01661  
3 .9  0 .5033  0 .5244  0 .4918  0 .5065  0 .00955  
7 .8  0 .6121  0 .6536  0 .5892  0 .6183  0 .01885  
15.6  0 .675  0 .7355  0 .6294  0 .679966667  0 .03073  
31.2  0 .6619  0 .7941  0 .7969  0 .750966667  0 .04454  
  Batch2         
Cdc7/ASK 
concentration (µM)  Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1299  0 .1265  0 .0955  0 .1173  0 .01094  
0 .39  0 .134  0 .1422  0 .1151  0 .130433333  0 .00802  
1 .17  0 .1461  0 .1427  0 .1354  0 .1414  0 .00316  
2 .34  0 .1789  0 .1916  0 .1949  0 .188466667  0 .00488  
3 .9  0 .2352  0 .22  0 .2264  0 .2272  0 .00441  
7 .8  0 .439  0 .4165  0 .6411  0 .498866667  0 .07141  
15.6  0 .5517  0 .5378  0 .662  0 .583833333  0 .03929  
31.2  0 .7271  0 .7122  0 .8259  0 .755066667  0 .03568  
  Batch3         
Cdc7/ASK 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1221  0 .1253  0 .0993  0 .115566667  0 .00819  
0 .39  0 .1355  0 .1235  0 .1098  0 .122933333  0 .00742  
1 .17  0 .1215  0 .1236  0 .1284  0 .1245  0 .00204  
2 .34  0 .1328  0 .1374  0 .1693  0 .1465  0 .01148  
3 .9  0 .1591  0 .1629  0 .2448  0 .188933333  0 .02795  
7 .8  0 .3065  0 .2906  0 .7542  0 .450433333  0 .15195  
15.6  0 .3702  0 .3874  0 .7638  0 .507133333  0 .12843  
31.2  0 .4819  0 .5062  0 .9144  0 .634166667  0 .14029  
  Batch4         
Cdc7/ASK 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .129  0 .1296  0 .0984  0 .119  0 .0103  
0 .39  0 .1486  0 .1577  0 .2445  0 .1836  0 .03056  
1 .17  0 .1762  0 .196  0 .3599  0 .244033333  0 .05821  
2 .34  0 .2479  0 .2439  0 .4486  0 .313466667  0 .06758  
3 .9  0 .3088  0 .32  0 .443  0 .357266667  0 .04299  
7 .8  0 .545  0 .5668  0 .581  0 .564266667  0 .01047  
15.6  0 .6532  0 .6989  0 .5645  0 .638866667  0 .03945  
31.2  0 .7317  0 .9867  0 .6277  0 .782033333  0 .10665  
 
Apendix A : Summary of data from antibody-based Cdc7/ASK 
kinase assay (2) 
Cdc7/ASK kinase as a novel target for anti-cancer drug development programmes                                                              HK Hong   
University College London 253
Apendix A : Summary of data from antibody-based Cdc7/ASK 
kinase assay (3) 
Figure 5.4 B           
  pH 7.5         
Cdc7/ASK 
concentration (µM) Set1 Set2 Set3 Mean of signal St Dev 
0 0 .008  0 .01  0 .096  0 .038  0 .029006  
15.6  0 .31  0 .288  0 .376  0 .324666667  0 .026441  
31.2  0 .284  0 .401  0 .372  0 .352333333  0 .035177  
  pH 8         
Cdc7/ASK 
concentration (µM) Set1 Set2   Mean of signal St Dev 
0 0 .008  0 .004  0 .096  0 .036  0 .030022  
15.6  0 .332  0 .32  0 .408  0 .353333333  0 .027552  
31.2  0 .328  0 .487  0 .416  0 .410333333  0 .045987  
  pH 8.5         
Cdc7/ASK 
concentration (µM) Set1 Set2   Mean of signal St Dev 
0 0 .003  0 .007  0 .091  0 .033666667  0 .02869  
15.6  0 .46  0 .377  0 .465  0 .434  0 .028537  
31.2  0 .42  0 .486  0 .508  0 .471333333  0 .026441  
  pH 9         
Cdc7/ASK 
concentration (µM) Set1 Set2   Mean of signal St Dev 
0 0 .015  0 .004  0 .103  0 .040666667  0 .031328  
15.6  0 .322  0 .339  0 .427  0 .362666667  0 .032539  
31.2  0 .37  0 .39  0 .458  0 .406  0 .026633  
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Apendix A : Summary of data from antibody-based Cdc7/ASK 
kinase assay (4) 
Figure 5.7 A           
  Cdc7(WT)/ASK          
Kinase 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1385  0 .1181  0 .1537  0 .136766667  0 .01031331  
0 .78  0 .3102  0 .2726  0 .2939  0 .292233333  0 .01088613  
1 .95  0 .3514  0 .2665  0 .3586  0 .3255  0 .02957313  
3 .9  0 .4789  0 .3309  0 .424  0 .411266667  0 .04319569  
7 .8  0 .6802  0 .4902  0 .7456  0 .638666667  0 .07659646  
15.6  0 .7799  0 .5253  0 .732  0 .679066667  0 .07811689  
31.2  0 .8508  0 .5408  0 .8535  0 .748366667  0 .10378626  
            
  Cdc7(D196A)/ASK         
Kinase 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .121  0 .1168  0 .1572  0 .131666667  0 .01282411  
0 .78  0 .1194  0 .1131  0 .1234  0 .118633333  0 .00299796  
1 .95  0 .1207  0 .1121  0 .1302  0 .121  0 .00522717  
3 .9  0 .1213  0 .1129  0 .1251  0 .119766667  0 .00360432  
7 .8  0 .153  0 .1302  0 .1457  0 .142966667  0 .00672219  
15.6  0 .1775  0 .1526  0 .1668  0 .165633333  0 .00721164  
31.2  0 .2074  0 .1593  0 .1851  0 .183933333  0 .01389752  
            
  Cdc7(D177A)/ASK         
Kinase 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1385  0 .1269  0 .1299  0 .131766667  0 .00347627  
0 .78  0 .1195  0 .1203  0 .1121  0 .1173  0 .00261024  
1 .95  0 .1251  0 .1264  0 .1139  0 .1218  0 .00396779  
3 .9  0 .1179  0 .1246  0 .1104  0 .117633333  0 .00410135  
7 .8  0 .146  0 .1742  0 .1277  0 .1493  0 .01352442  
15.6  0 .1733  0 .1725  0 .1455  0 .163766667  0 .00913625  
31.2  0 .1953  0 .1555  0 .1615  0 .170766667  0 .01238835  
            
  Cdc7(K90A)/ASK         
Kinase 
concentration (µM) Set1 Set2 Set3 
Mean of 
signal St Dev 
0 0 .1332  0 .1238  0 .1362  0 .131066667  0 .00373512  
0 .78  0 .1411  0 .1235  0 .1297  0 .131433333  0 .00515407  
1 .95  0 .1237  0 .115  0 .1433  0 .127333333  0 .00836906  
3 .9  0 .1297  0 .119  0 .1345  0 .127733333  0 .00458124  
7 .8  0 .1954  0 .1569  0 .1571  0 .1698  0 .01280013  
15.6  0 .2036  0 .1606  0 .1857  0 .1833  0 .0124709  
31.2  0 .1947  0 .1563  0 .1806  0 .1772  0 .01121472  
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Figure 5.7 B         
  Cdc7(WT)/ASK Cdc7(D196A)/ASK Cdc7(D177A)/ASK Cdc7(K90A)/ASK 
Cycle 
number         
1C  1788  1506  1407  1386  
2C  2360  1648  1980  1830  
3C  3115  1864  2528  2243  
4C  3953  2127  3139  2688  
5C  4862  2424  3802  3140  
6C  5782  2741  4496  3606  
7C  6718  3056  5195  4045  
8C  7548  3346  5773  4377  
9C  8397  3650  6334  4671  
10C  9173  3904  6739  4929  
11C  9881  4194  7050  5094  
12C  10507  4427  7343  5197  
13C  11099  4656  7484  5334  
14C  11633  4900  7679  5418  
15C  12194  5111  7783  5475  
16C  12624  5348  8035  5605  
17C  12990  5489  8167  5681  
18C  13279  5640  8321  5803  
19C  13559  5721  8411  5814  
20C  13329  5706  8309  5702  
21C  13637  5785  8347  5688  
22C  13346  5924  8350  5740  
23C  13407  6007  8212  5826  
24C  13473  6093  8247  5858  
25 C  13653  6244  8330  5974  
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Appendix B: Synthesis of CRT100115 compound  
 
N
N
H
N H
O
N
O
BrN
O
N H
O
O
N
H
OH
O
O
O
1
2
3M eC N , H 2O
AcO H , B r2
N H 4O H , M eO H
 
 
4-acetyl pyridine was brominated to prepared α-bromo ketone 1. 2,4-dioxopiperidine 
2 was prepared from commercially available starting material in one step by 
decarboxylation. Both compounds were condensed in the presence of ammonium 
acetate to deliver the desired compound 3. NMR of compound 3 corresponded to the 
reported NMR and the purity was above the 99.5%, confirmed by LCMS.   
 
 
2-Bromo-1-pyridine-4-ylethanone (1): 
N
Br
O
 
 
4-Acetyl pyridine (1.21 g, 10 mMol) was dissolved in glacial acetic acid (20 mL). 
Bromine in chloroform (1.59 g, 10 mMol in 10 mL of chloroform) was added. After 
15 minutes a precipitate formed and the reaction was stopped after 30 minutes. The 
filtrate was collected by filtration and triturate with diethyl ether (150 mL). The 
compound (1.76g, 88 %) was used without further purification. 1H NMR (300 MHz, 
DMSO d6) δ 8.23 (2H, d, J 7.1 Hz), 7.98 (2H, d, J 7.1 Hz), 4.90 (2H, s); MS m/z 
(m+H) 200, 202. 
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2,4-Dioxopiperidine (2) 
N H
O
O  
 
Sodium 3-9methoxycarbonyl-4-oxo-1,4,5,6-tetrahydropyridin-2-olate (5.0 g, 25.9 
mMol) was portioned between 2N aqueous hydrogen chloride (50 mL) and 
dichloromethane (50 mL). The aqueous layer was extracted twice with 
dichloromethane (2 x 50 mL). The organic extract were dried over sodium sulphate, 
filtered and evaporated. The residue was suspended in acetonitrile (50 mL) and water 
(10 mL) and refluxed for 3hours. The reaction was cooled and evaporated. The 
residue was crystallised from 1:1 ethyl acetate: cyclohexane to provide the desired 
compound 2 (2.5g, 86%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.05 (s, 1H), 
3.59 (m, 2H), 3.40 (s, 2H), 2.64 (t, 2H). MS m/z (M + H) 114. 
 
 
2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one (3) 
 
N
N
H
N H
O
 
 
2-Bromo-1-pyridine-4-ylethanone 1 (1.0 g, 5.0 mMol) and 2,4-Dioxopiperidine 2 
(725 mg, 6.0 mMol) were dissolved in methanol. Ammonium acetate (770 mg, 10 
mMol) was added and the mixture was stirred at room temperature for 2 hours. The 
solvent was evaporated and the residue was purified by reverse column 
chromatography (water acetonitrile) and 250 (20 %) mg was recovered. 1H NMR  
(300 MHz, DMSO d6) δ 12.23 (bs, 1H), 8.66 (2H, d, J 7.2), 8.18 (d, 2H, J 7.2), 7.59 
(s, 1H), 3.45(m, 2H), 2.94 (m, 2H). MS m/z 214. 
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